URL,Drug
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    To reduce the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Bevyxxa (betrixaban); Portola Pharmaceuticals;
                    For the the prophylaxis of venous thromboembolism, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Byvalson (nebivolol and valsartan); Allergan;
                    For the treatment of hypertension, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals;
                    For the prevention of cardiovascular and cerebrovascular events, Approved September 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Corlanor (ivabradine); Amgen;
                    For the treatment of chronic heart failure, Approved April 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Entresto (sacubitril and valsartan); Novartis;
                    For the treatment of chronic heart failure, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Kanuma (sebelipase alfa); Alexion;
                    For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Kengreal (cangrelor) ; The Medicines Company;
                    For reducing periprocedural thrombotic events, Approved June 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Praluent (alirocumab); Sanofi Aventis;
                    For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals;
                    For the treatment of hypertension, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Repatha (evolocumab) ; Amgen;
                    For the treatment of high cholesterol, Approved August 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Savaysa (edoxaban); Daiichi Sankyo;
                    For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Uptravi (selexipag); Actelion Pharmaceuticals;
                    For the treatment of pulmonary arterial hypertension, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Epanova (omega-3-carboxylic acids); AstraZeneca;
                    For the treatment of severe hypertriglyceridemia, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Zontivity (vorapaxar); Merck;
                    For the reduction of thrombotic cardiovascular events, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Adempas (riociguat); Bayer Healthcare Pharmaceuticals;
                    For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Invokana (canagliflozin); Janssen Pharmaceuticals;
                    For the treatment of type II diabetes and to reduce the risk of cardiovascular events in type II diabetics, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Kynamro (mipomersen sodium); Genzyme;
                    For the treatment of homozygous familial hypercholesterolemia, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Liptruzet (ezetimibe and atorvastatin); Merck;
                    For the treatment of hyoerlipidemia, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Nymalize (nimodipine); Arbor Pharmaceuticals;
                    For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Opsumit (macitentan); Actelion Pharmaceuticals;
                    For the treatment of pulmonary arterial hypertension, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Varithena (polidocanol injectable foam); BTG plc;
                    For the treatment of varicose veins, November 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Eliquis (apixaban); Bristol-Myers Squibb;
                    For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Juxtapid (lomitapide); Aegerion Pharmaceuticals;
                    For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Vascepa (icosapent ethyl); Amarin Pharmaceuticals;
                    For the treatment of hypertriglyceridemia, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Brilinta (ticagrelor); AstraZeneca;
                    For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Edarbi (azilsartan medoxomil); Takeda;
                    For the treatment of hypertension, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda;
                    For the treatment of hypertension, Approved December of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of Wegenerâ€™s Granulomatosis and Microscopic Polyangiitis , Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis;
                    For the treatment of uncontrolled hypertension, Approved December 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim;
                    For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tekamlo (aliskiren + amlodipine); Novartis;
                    For the treatment of hypertension, Approved August 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo;
                    For the treatment of hypertension, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Adcirca (tadalafil); Eli Lilly;
                    For the treatment of pulmonary arterial hypertension, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
                    For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Efient (prasugrel); Eli Lilly;
                    for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Livalo (pitavastatin); Kowa Company;
                    For the treatment of primary hyperlipidemia and mixed dyslipidemia, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Multaq (dronedarone); Sanofi-aventis;
                    For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tyvaso (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Cleviprex (clevidipine); The Medicines Company;
                    For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Trilipix (fenofibric acid); Abbott Laboratories;
                    For the treatment of dyslipidemia, hypertriglyceridemia and hyperlipidemia, Approved December 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo;
                    For the treatment of hypertension, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Fenofibrate; LifeCycle Pharma;
                    For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Letairis (ambrisentan); Gilead;
                    For the treatment of pulmonary arterial hypertension, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Soliris (eculizumab); Alexion;
                    For the treatment of PNH, aHUS and generalized Myasthenia Gravis , Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tekturna (aliskiren); Novartis;
                    For the treatment of hypertension, Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Ranexa (ranolazine); CV Therapeutics;
                    For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed;
                    For the treatment of heart failure in black patients, Approved June, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Caduet (amlodipine/atorvastatin); Pfizer;
                    For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Crestor (rosuvastatin  calcium); AstraZeneca;
                    For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia, Approved August 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Levitra (vardenafil); Bayer, GlaxoSmithKline;
                    For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Altocor (lovastatin) Extended-Release Tablets; Andrx;
                    Oral tablets for the adjuctive treatment of hypercholesterolemia, Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Benicar; Daiichi Sankyo;
                    Oral tablet for the treatment of hypertension, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Imagent (perflexane lipid microspheres); Alliance Pharmaceutical;
                    Ultrasound contrast agent for improved imaging of the heart, Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Inspra (eplerenone tablets); Pharmacia & Upjohn;
                    Oral tablets for the treatment of high blood pressure., Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Plavix (clopidogrel bisulfate); Sanofi-aventis;
                    For the treatment of acute coronary syndrome, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Remodulin (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals;
                    For the treatment of cholesterol disorders, Approved December 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Diovan (valsartan); Novartis;
                    Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Natrecor (nesiritide); Scios;
                    For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Teveten (eprosartan mesylate plus hydrochlorothiazide); Unimed Pharmaceuticals;
                    Tablets for the treatment of hypertension, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tricor (fenofibrate); Abbott Laboratories;
                    For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia, Approved September 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Angiomax (bivalirudin); The Medicines Company;
                    For patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham;
                    Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Atacand (candesartan cilexetil); AstraZeneca;
                    For the treatment of hypertension, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Betapace AF Tablet; Berlex Laboratories;
                    For treatment of the irregular heartbeats in patients with atrial fibrillation, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
                    For the reduction of high blood pressure, Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company;
                    For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
                    For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
                    For the treatment of hypertension, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Nitrostat (nitroglycerin) Tablets; Parke-Davis;
                    For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Lescol (fluvastatin sodium) capsules, Rx; Novartis;
                    Treatment for  the reduction of triglycerides, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Mevacor (lovastatin) tablets; Merck;
                    Treatment for primary prevention of coronary heart disease, Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Niaspan; Kos Pharmaceuticals;
                    Niacin extended-release tablets, October 28, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Agrylin (anagrelide HCL); Roberts Pharmaceutical;
                    Treatment for Thrombocythemia, Approved December 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"CellCept; Roche;
                    Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Diovan HCT (valsartan); Novartis;
                    Treatment for hypertension, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Integrilin; COR Therapeutics, Key Pharmaceuticals;
                    Injection of eptifibatide, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Micardis (telmisartan); Boehringer Ingelheim;
                    Treatment for Hypertension, Approved November 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Rythmol; Knoll Pharmaceutical;
                    Treatment for paroxysmal atrial fibrillation, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tiazac (diltiazem hydrochloride); Forest Laboratories;
                    Treatment for chronic stable angina, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tricor (fenofibrate); Abbott Laboratories;
                    Treatment for very high triglyceride levels, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Viagra; Pfizer;
                    Treatment for impotence, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Baycol (cerivastatin sodium); Bayer;
                    Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Captopril and hydrochlorotiazide; Mylan Laboratories;
                    Treatment for hypertension, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Cardizem (R)  (Diltiazem HC1 for injection) Monvial (R); Hoechst Marion Roussel;
                    Delivery system for Monovial, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Corlopam; Neurex;
                    Treatment for severe high blood pressure, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Diovan (valsartan); Ciba Pharmaceuticals;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"DynaCirc CR; Novartis;
                    Treatment for hypertension, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"EDEX; Schwarz Pharma;
                    Treatment for erectile dysfunction, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Lescol (fluvastatin sodium); Novartis;
                    Treatment for coronary atherosclerosis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Lexxel (enalapril maleate-felodipine ER); Astra Merck;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
                    Treatment for mild-to moderate hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Normiflo; Wyeth;
                    Treatment for deep venous thrombosis, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Pentoxifylline; Faulding, Mylan Laboratories;
                    Generic equivalent of Trental, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Pindolol; Teva Pharmaceutical;
                    Generic equivalent of  Visken, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
                    Treatment for cardiac atherosclerotic events, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Posicor; Roche;
                    Treatment for hypertension and chronic stable angina pectoris, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"ReoPro; Centocor Ortho Biotech;
                    Treatment for cardiac ischemic complications, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
                    Generic equivalent of Pergonal, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Teveten (eprosartan mesylate); SmithKline Beecham;
                    Treatment for hypertension, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Verapamil; IVAX;
                    Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Warfarin Sodium tablets; Barr Laboratories;
                    Generic equivalent of Coumadin, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Zocor; Merck;
                    Treatment for high cholesterol, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Covera-HS (verapamil); GD Searle, Alza;
                    Treatment for hypertension and angina, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Lipitor (atorvastatin calcium); Pfizer;
                    For the prevention of cardiovascular disease and treatment of hyperlipidemia and dyslipidemia, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Mavik (trandolapril); Knoll Pharmaceutical;
                    Treatment for hypertension, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Muse; Vivus;
                    Treatment for impotence, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for cholesterol-lowering, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for heart disease, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"ProAmatine (midodrine); Roberts Pharmaceutical;
                    Treatment for hypotension, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Procanbid (procainamide hydrochloride extended-release tablets); Warner-Lambert;
                    Treatment for ventricular arrhythmias, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Retavase (reteplase); Boehringer Mannheim Corporation;
                    Treatment for patients suffering from heart attack, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
                    Treatment for hypertension, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Tiazac (diltiazem hydrochloride); Forest Laboratories;
                    Treatment for hypertension, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Androderm (Testosterone Transdermal System); TheraTech;
                    Treatment for primary and secondary hypogonadism, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Corvert Injection (ibutilide fumarate injection); Pharmacia & Upjohn;
                    Treatment for irregular contractions of the heart, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Prinivil or Zestril (Lisinopril); Merck, Zeneca;
                    Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/1/cardiology-vascular-diseases,"Toprol-XL (metoprolol succinate); AstraZeneca;
                    For the treatment of hypertension, angina pectoris and heart failure, Approved January 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Arestin (minocycline hydrochloride); OraPharma;
                    For treatment of adult periodontitis, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Periostat (doxycycline hyclate); CollaGenex  Pharmaceuticals;
                    Oral tablet for adjunctive treatment of adult periodontitis, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Atridox; Atrix Laboratories;
                    Treatment of chronic adult periodontitis, Approved January 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Atridox; Atrix Laboratories;
                    Treatment for periodontal disease, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Periostat (doxycycline hyclate); CollaGenex  Pharmaceuticals;
                    Treatment for periodontitis., Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"Aphthasol; Block Drug Company;
                    Treatment for canker sores, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/2/dental-and-oral-health,"DentiPatch (lidocaine transoral delivery system); Noven Pharmaceuticals;
                    Dental anesthetic patch, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Jeuveau (prabotulinumtoxinA-xvfs); Evolus;
                    For the improvement of glabellar lines, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Braftovi (encorafenib) + Mektovi (binimetinib); Array BioPharma;
                    For the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Cimzia (certolizumab pegol) ; UCB;
                    For the treatment of moderate-to-severe plaque psoriasis, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals;
                    For the treatment of plaque psoriasis , Approved March 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of Merkel cell carcinoma, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals;
                    For the treatment of cutaneous squamous cell carcinoma, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Nuzyra (omadacycline) ; Paratek Pharmaceuticals;
                    For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Qbrexza (glycopyrronium) ; Dermira;
                    For the treatment of primary axillary hyperhidrosis, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of Pemphigus Vulgaris , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Seysara (sarecycline) ; Paratek Pharmaceuticals;
                    For the treatment of moderate to severe acne vulgaris in patients 9 years of age and older., Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Bavencio (avelumab) ; EMD Serono/Pfizer;
                    For the treatment of  Merkel cell carcinoma , Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics;
                    For the treatment of acute bacterial skin and skin structure infections, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Dupixent (dupilumab); Regeneron Pharmaceuticals;
                    For the treatment of atopic dermatitis, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Eskata (hydrogen peroxide); Aclaris Therapeutics;
                    For the treatment of seborrheic keratoses, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of chronic graft-versus-host disease, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Rhofade (oxymetazoline hydrochloride); Allergan;
                    For the treatment of facial erythema associated with rosacea, Approved January 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Siliq (brodalumab); Valeant Pharmaceuticals;
                    For the treatment of plaque psoriasis , Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Tremfya (guselkumab); Janssen Biotech;
                    For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Xepi (ozenoxacin) ; Medimetriks;
                    For the treatment of impetigo, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma;
                    For the treatment of actinic keratoses, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Eucrisa (crisaborole) ointment; Pfizer;
                    For the treatment of atopic dermatitis, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Taltz (ixekizumab); Eli Lilly;
                    For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Cosentyx (secukinumab); Novartis;
                    For the treatment of plaque psoriasis, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Cotellic (cobimetinib) ; Genentech;
                    For the treatment of BRAF V600E or V600K melanoma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Enstilar (calcipotriene and betamethasone dipropionate); LEO Pharmaceuticals;
                    For the treatment of psoriasis, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Imlygic (talimogene laherparepvec) ; Amgen;
                    For the treatment of unresectable recurrent melanoma, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Kybella  (deoxycholic acid); Kythera Biopharma;
                    For the treatment of submental fat, Approved April 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Odomzo (sonidegib); Novartis;
                    For the treatment of locally advanced basal cell carcinoma, July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Dalvance (dalbavancin); Durata Therapeutics;
                    For the treatment of acute bacterial skin and skin structure infections, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals;
                    For the treatment of onychomycosis of the toenails, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Kerydin (tavaborole); Anacor;
                    For the treatment of onychomycosis of the toenails, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of unresectable or metastatic melanoma, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of unresectable or metastatic melanoma, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Orbactiv (oritavancin); The Medicines Company;
                    For the treatment of acute bacterial skin and skin structure  infections, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Otezla (apremilast); Celgene;
                    For the treatment of moderate to severe plaque psoriasis, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals;
                    For the treatment of acute bacterial skin and skin structure  infections, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Soolantra (ivermectin) cream, 1%; Galderma Labs;
                    For the treatment of inflammatory lesions of rosacea, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals;
                    For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Mekinist (trametinib); GlaxoSmithKline;
                    For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, Approved May of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Mirvaso (brimonidine); Galderma Labs;
                    For the treatment of facial erythema of rosacea, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Sitavig (acyclovir) buccal tablets; BioAlliance Pharma;
                    For the treatment of recurrent herpes labialis in adults, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Tafinlar (dabrafenib); GlaxoSmithKline;
                    For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Valchlor (mechlorethamine) gel; Ceptaris Therapeutics;
                    For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Varithena (polidocanol injectable foam); BTG plc;
                    For the treatment of varicose veins, November 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Erivedge (vismodegib); Genentech;
                    For the treatment of basal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of postherpetic neuralgia, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Picato (ingenol mebutate) gel; LEO Pharma;
                    For the treatment of actinic keratosis, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Sklice (ivermectin) lotion; Sanofi Pasteur;
                    For the treatment of head lice, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Firazyr (icatibant); Shire Pharmaceuticals;
                    For the treatment of acute attacks of hereditary angioedema, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Gralise (gabapentin); Abbott Laboratories;
                    For the treatment of postherpetic neuralgia, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"laViv (azficel-T); Fibrocell Science;
                    For the improvement of nasolabial fold wrinkles in adults, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Sylatron (peginterferon alfa-2b); Merck;
                    For the treatment of melanoma, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Yervoy (ipilimumab); Bristol-Myers Squibb;
                    For the treatment of metastatic melanoma, Approved March 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Zelboraf (vemurafenib); Roche;
                    For the treatment of  BRAF + melanoma, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Veltin (clindamycin phosphate and tretinoin); Stiefel;
                    For the treatment of acne vulgaris, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Zyclara (imiquimod); Graceway;
                    For the treatment of actinic keratoses of the face and scalp, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Stelara (ustekinumab); Janssen Biotech;
                    For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Vibativ (telavancin); Theravance;
                    For the treatment of complicated skin and skin structure infections, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Altabax (retapamulin); GlaxoSmithKline;
                    For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Extina (ketoconazole); Stiefel;
                    For the treatment of seborrheic dermatitis, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Desonate (desonide); Dow Pharm;
                    For the treatment of atopic dermatitis, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Verdeso (desonide); Connetics Corporation;
                    For the treatment of atopic dermatitis, Approved September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Tygacil (tigecycline); Wyeth;
                    For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Amevive (alefacept); Biogen IDEC;
                    For moderate to severe chronic plaque psoriasis., Approved January 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Finacea (azelaic acid) Gel, 15%; Berlex Laboratories;
                    Gel formulation for the treatment of rosacea., January 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Botox Cosmetic (botulinum toxin type A); Allergan;
                    For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Elidel; Novartis;
                    Topical cream for the treatment of atopic dermatitis, Approved December 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Estrostep (norethindrone acetate and ethinyl estradiol); Pfizer;
                    For the treatment of moderate acne vulgaris, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Finevin; Berlex Laboratories;
                    Topical cream for the treatment of mild to moderate inflammatory acne vulgaris, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Lamisil Solution, 1%; Novartis;
                    Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel); Dermik Laboratories;
                    For the topical treatment of acne vulgaris, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Chloraprep (chlorhexidine gluconate); MEDI FLEX HOSP PRODUCTS;
                    For use as a patient preoperative skin preparation, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Clindamycin phosphate topical gel; Target Research Associates;
                    For once a day treatment of acne vulgaris, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
                    For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Protopic (tacrolimus) ointment; Fujisawa Healthcare;
                    For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA); US Army Medical Research, Material Command;
                    To reduce absorption of chemical warfare agents through the skin, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Lamisil (terbinafine hydrochloride) Dermagel, 1%; Novartis;
                    Treatment for tinea pedis (athlete's foot), Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Luxiq (betamethasone valerate) Foam; Connetics Corporation;
                    Treatment for dermatoses of scalp, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Dynabac; Sanofi-aventis;
                    Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Lustra; Medicis Pharmaceutical;
                    Treatment for ultraviolet-induced skin discolorations, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"MetroLotion; Galderma Laboratories;
                    Treatment of inflammatory papules and pustules of rosacea, Approved November 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Noritate; Dermik Laboratories;
                    Treatment for rosacea, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Salagen Tablets; MGI Pharma;
                    Treatment for Sjogren's Syndrome, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Sulfamylon; Mylan Laboratories;
                    Treatment used to control bacterial infections on excised burn wounds, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Thalomid; Celgene;
                    Treatment for moderate to severe erythema nodosum leprosum (ENL), Approved July 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Avita Gel; Penederm;
                    Treatment for acne, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Bactroban Cream; SmithKline Beecham;
                    Treatment for secondarily infected traumatic skin lesions, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Clindamycin Phosphate Topical Solution USP 1%; Morton Grove Pharmaceuticals;
                    Generic equivalent of CLEOCIN Topical Solution 1%, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Dermagraft-TC; Advanced Tissue Sciences;
                    Treatment for partial-thickness and severe burns, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Klaron (sodium sulfacet amide lotion ) Lotion, 10%; Dermik Laboratories;
                    Treatment for adult acne, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for athlete's foot, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus), Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Minoxidil Topical Solution 2% for Women; Alpharma;
                    Generic equivalent of Rogaine, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol); Ortho-McNeil Pharmaceutical;
                    Treatment for acne in women seeking contraception, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Propecia; Merck;
                    Treatment for male baldness, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"REGRANEX (becaplermin) Gel; RW Johnson;
                    Treatment for diabetic foot ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Retin-A Micro (tretinoin gel) microsphere, 0.1%; Advanced Polymer Systems;
                    Treatment for acne, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Tazorac topical gel; Allergan;
                    Treatment for Psoriasis, Acne Vulgaris, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Differin (adapalene gel) Gel, 0.1%; Galderma Laboratories;
                    Treatment for acne, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Iamin; ProCyte;
                    Gel wound dressing, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Iontocaine; Iomed;
                    Needle-free anesthetic, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"IvyBlock; EnviroDerm Pharmaceuticals;
                    Treatment for poison ivy, poison oak, and poison sumac, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology,"Renova (tretinoin emollient cream); Johnson & Johnson;
                    Treatment for facial wrinkles, brown spots, and surface roughness associated with chronic sun exposure, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/22/devices,"Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline;
                    For the treatment of chronic obstructive pulmonary disease, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Jatenzo (testosterone undecanoate); Clarus Therapeutics;
                    For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Macrilen (macimorelin); Stonebridge Biopharma;
                    For the diagnosis of adult growth hormone deficiency , Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ozempic (semaglutide); Novo Nordisk;
                    For the treatment of type II diabetes, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Parsabiv (etelcalcetide); Amgen;
                    For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Qtern (dapagliflozin and saxagliptin) ; AstraZeneca;
                    For the treatment of inadequately controlled type II diabetes , Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Steglatro (ertugliflozin); Merck;
                    For the treatment of type 2 diabetes mellitus, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Adlyxin (lixisenatide); Sanofi Aventis;
                    For the treatment of type II diabetes, Approved July 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis;
                    For the treatment of inadequately controlled type II diabetes, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk;
                    For the treatment of  inadequately controlled type II diabetes, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Addyi (flibanserin); Sprout Pharmaceuticals;
                    For the treatment of premenopausal women with generalized hypoactive sexual desire disorder, Approved August 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of diabetic retinopathy in patients with diabetic macular edema, Approved March 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Natpara (parathyroid hormone) ; NPS Pharmaceuticals;
                    For the control hypocalcemia in patients with hypoparathyroidism, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Synjardy (empagliflozin and metformin hydrochloride) ; Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved August 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Tresiba (insulin degludec injection); Novo Nordisk;
                    For glycemic control in adults with diabetes mellitus, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Afrezza (insulin human) Inhalation Powder; Mannkind;
                    For the treatment of diabetes mellitus, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals;
                    For the treatment of hypogonadism, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of diabetic macular edema, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Farxiga (dapagliflozin); Bristol-Myers Squibb;
                    For the treatment of type II diabetes, January of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Jardiance (empagliflozin) ; Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Natesto, (testosterone) nasal gel; Trimel Pharmaceuticals;
                    For the treatment of deficiency or absence of endogenous testosterone, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Signifor LAR (pasireotide); Novartis;
                    For the treatment of acromegaly, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Tanzeum (albiglutide); GlaxoSmithKline;
                    For the treatment of type II diabetes mellitus, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Trulicity (dulaglutide); Eli Lilly;
                    To improve glycemic control in type II diabetics, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Vogelxo (testosterone) gel; Upsher-Smith;
                    For males with a deficiency or absence of endogenous  testosterone, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Xigduo XR (dapagliflozin + metformin hydrochloride); AstraZeneca;
                    For glycemic control in adults with type II diabetes, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Brisdelle (low-dose paroxetine mesylate); Noven Pharmaceuticals;
                    For the treatment of vasomotor symptoms of menopause, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Duavee (conjugated estrogens/bazedoxifene); Pfizer;
                    For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Invokana (canagliflozin); Janssen Pharmaceuticals;
                    For the treatment of type II diabetes and to reduce the risk of cardiovascular events in type II diabetics, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Nesina (alogliptin); Takeda;
                    For the treatment of type II diabetes mellitus, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Osphena (ospemifene); Shionogi;
                    For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Belviq (lorcaserin hydrochloride); Arena Pharmaceuticals;
                    For the chronic management of weight loss, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Bio-T-Gel (testosterone gel); Teva Pharmaceutical;
                    For the treatment of hypogonadism, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Bydureon (exenatide extended-release for injectable suspension); Amylin;
                    For the improvement of glycemic control in adults with type II diabetes mellitus, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Cometriq (cabozantinib); Exelixis;
                    For the treatment of metastatic medullary thyroid cancer, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Jentadueto (linagliptin plus metformin hydrochloride); Eli Lilly;
                    For the treatment of type II diabetes, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Korlym (mifepristone); Corcept Therapeutics;
                    For the control of hyperglycemia in adults with endogenous Cushingâ€™s syndrome, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lucentis (ranibizumab injection); Genentech;
                    For the treatment of diabetic macular edema, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Qsymia (phentermine + topiramate extended-release); Vivus;
                    For the treatment of chronic weight management, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Signifor (pasireotide diaspartate); Novartis;
                    For the treatment of Cushing's disease, Approved December of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Viokace (pancrelipase) tablets; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Afinitor (everolimus); Novartis;
                    For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Juvisync (sitagliptin and simvastatin); Merck;
                    For the treatment of type II diabetes, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Sutent (sunitinib malate); Pfizer;
                    For the treatment of pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Tradjenta (linagliptin); Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Fortesta (testosterone gel); Endo Pharmaceuticals;
                    For the treatment of hypogonadism, Approved December 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prolia (denosumab); Amgen;
                    For the treatment of osteoporosis and bone loss in men and women, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Victoza (liraglutide); Novo Nordisk;
                    For the treatment of type 2 diabetes mellitus, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Cycloset, bromocriptine mesylate; VeroScience;
                    For the treatment of type 2 diabetes mellitus, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Onglyza (saxagliptin); Bristol-Myers Squibb;
                    For the treatment of type 2 diabetes mellitus, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Accretropin (somatropin rDNA Original); Cangene;
                    For the treatment of growth failure in pediatrics, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Welchol (colesevelam hydrochloride); Daiichi Sankyo;
                    For the improvement of glycemic control in adults with type 2 diabetes mellitus, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Evamist (estradiol); Vivus;
                    For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Fenofibrate; LifeCycle Pharma;
                    For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
                    For the treatment of acromegaly, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Supprelin LA (histrelin acetate); Indevus Pharmaceuticals;
                    For the treatment of central precocious puberty, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Elestrin (estradiol gel); BioSante;
                    For the treatment of vasomotor symptoms associated with menopause, Approved December 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Januvia (sitagliptin phosphate); Merck;
                    For the treatment of type II diabetes, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda;
                    For the treatment of type 2 diabetes, Approved August of 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Byetta (exenatide); Amylin/Eli Lilly;
                    For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Increlex (mecasermin); Tercica;
                    For the treatment of growth failure due to Primary IGFD, Approved August 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Symlin (pramlintide); Amylin Pharmaceuticals;
                    For the treatment of type I and type II diabetes, Approved March 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Aldurazyme (laronidase); Genzyme;
                    For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Fabrazyme (agalsidase beta); Genzyme;
                    For the treatment of Fabry disease in adult patients, Approved April 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Somavert (pegvisomant); Pharmacia & Upjohn;
                    Injectable formulation for the treatment of acromegaly, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Avandamet (rosiglitazone maleate and metformin HCl); GlaxoSmithKline;
                    For improvement of glycemic control in type 2 diabetes patients, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Benicar; Daiichi Sankyo;
                    Oral tablet for the treatment of hypertension, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals;
                    Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Forteo (teriparatide); Eli Lilly;
                    For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Levo-T (levothyroxine sodium); Mova Pharmaceutical;
                    Indicated for the treatment of hypothyroidism and the suppression of thyroid stimulating hormone, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Metaglip (glipizide/metformin HCl); Bristol-Myers Squibb;
                    Oral tablets for the treatment of type 2 diabetes., Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Novothyrox (levothyroxine sodium); Genpharm;
                    For the treatment of hypothyroidism and suppression of thyroid-stimulating hormone, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Synthroid (levothyroxine sodium); Abbott Laboratories;
                    For replacement or supplemental therapy for hypothyroidism and pituitary thyroid stimulating hormone suppression, Approved July 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Testim; Auxilium Pharmaceuticals;
                    External cream for the treatment of male hormone deficiency., Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Campath; Berlex Laboratories;
                    Injectable treatment of B-cell chronic lymphocytic leukemia, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Diovan (valsartan); Novartis;
                    Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Femara (letrozole); Novartis;
                    First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Genotropin (somatropin) injection; Pharmacia & Upjohn;
                    For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Gleevec (imatinib mesylate); Novartis;
                    Oral therapy for the treatment of chronic myeloid leukemia, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Levoxyl; Jones Pharma;
                    Oral therapy for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone (TSH), Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Natrecor (nesiritide); Scios;
                    For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Novolog Mix 70/30; Novo Nordisk;
                    Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prozac Weekly (fluoxetine HCl); Eli Lilly;
                    For the treatment of depression, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Remeron SolTab (mirtazapine); Organon;
                    Orally disintegrating tablet for the treatment of depression, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Remicade (infliximab); Centocor Ortho Biotech;
                    For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Trelstar LA (triptorelin pamoate); Debiopharm;
                    Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Yasmin (drospirenone/ethinyl estradiol); Berlex Laboratories;
                    Oral contraceptive, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Zometa (zoledronic acid); Novartis;
                    For the treatment of hypercalcemia of malignancy, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
                    Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"AndroGel testosterone gel; Unimed Pharmaceuticals;
                    For testosterone replacement therapy in males with testosterone deficiency, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Atacand (candesartan cilexetil); AstraZeneca;
                    For the treatment of hypertension, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Cetrotide; Asta Medica;
                    For the prevention of premature ovulation in women undergoing controlled ovarian stimulation, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
                    For the reduction of high blood pressure, Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Hectorol (Doxercalciferol) Injection; Bone Care International;
                    To reduce iPTH levels in management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
                    For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
                    For the treatment of hypertension, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Mirena (levonorgestrel-releasing intrauterine system); Berlex Laboratories;
                    Hormone-releasing system for intrauterine contraception, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"NovoLog (insulin aspart); Novo Nordisk;
                    An insulin analogue for the treatment of diabetes mellitus., Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories;
                    For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
                    For the palliative treatment of advanced prostate cancer, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Viadur (leuprolide acetate implant); Alza;
                    For pain relief in men with advanced prostate cancer, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Vivelle (estradiol transdermal system); Novartis;
                    For the prevention of postmenopausal osteoporosis, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"ACTOS; Takeda;
                    Treatment for type II diabetes, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Aggrenox; Boehringer Ingelheim;
                    Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Aromasin Tablets; Pharmacia & Upjohn;
                    Exemestane Tablets, 25 mg, October 21, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Avandia (rosiglitazone maleate); SmithKline Beecham;
                    Treatment for type II diabetes mellitus, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Cernevit; Baxter Healthcare;
                    For the treatment of vitamin deficiency, Approved April 1999."
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Climara; Berlex Laboratories;
                    For the prevention of postmenopausal osteoporosis (loss of bone mass), Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Doxil (doxorubicin HCl liposome injection); Alza;
                    Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ellence; Pharmacia & Upjohn;
                    epirubicin hydrochloride, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ethyol (amifostine); US Bioscience, Alza;
                    Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Osteoporosis treatment, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Femhrt Tablets; Parke-Davis;
                    Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ortho-Prefest; Ortho-McNeil Pharmaceutical, RW Johnson;
                    17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Xenical/Orlistat Capsules; Roche;
                    Treatment for obesity management, Approved April 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Actonel; Procter & Gamble, Hoechst Marion Roussel;
                    Treatment for Paget's Disease, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Arava; Hoechst Marion Roussel;
                    Treatment for Rheumatoid Arthritis, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Celexa; Forest Laboratories;
                    Treatment for depression, Approved July 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"CellCept; Roche;
                    Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Clomipramine hydrochloride; Mylan Laboratories;
                    Generic equivalent of Anafranil, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Diovan HCT (valsartan); Novartis;
                    Treatment for hypertension, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Esclim; Fournier Research;
                    Treatment for symptoms associated to Menopause, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Estratab (.3 mg ); Solvay Pharmaceuticals;
                    Treatment for the prevention of osteoporosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glucagon; Eli Lilly;
                    Treatment for severe hypoglycemia associated with diabetes., Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glucagon; Eli Lilly;
                    Treatment for severe Hypoglycemia, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glyburide Tablets; Mylan Laboratories;
                    Treatment for Diabetes Mellitus (Type II), Approved July 1998."
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Herceptin (trastuzumab); Genentech;
                    For the treatment of metastatic breast cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Inform HER-2/neu breast cancer test; Oncor;
                    Treatment for breast cancer prediction, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Marplan Tablets; Roche;
                    Treatment of Depression, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Mircette; Organon;
                    Oral contraceptive, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prempro; Wyeth;
                    Treatment for hormone replacement therapy, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prometrium; Schering-Plough;
                    Treatment for Endometrial Hyperplasia, Approved December 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Proscar; Merck;
                    Treatment for complication relating to benign prostatic hyperplasia (BPH), Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Simulect; Novartis;
                    Treatment for acute organ transplant rejection, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Xeloda; Roche;
                    Treatment for advanced breast cancer tumors, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Zemplar; Abbott Laboratories;
                    Treatment of secondary hyperparathyroidism associated with chronic renal failure, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Baycol (cerivastatin sodium); Bayer;
                    Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Captopril and hydrochlorotiazide; Mylan Laboratories;
                    Treatment for hypertension, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Corlopam; Neurex;
                    Treatment for severe high blood pressure, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Crinone 8% (progesterone gel); Wyeth;
                    Treatment for infertile women with pregestone deficiency, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Diovan (valsartan); Ciba Pharmaceuticals;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Dostinex Tablets (cabergoline tablets); Pharmacia & Upjohn;
                    Treatment of hyperprolactinemic disorders, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"DynaCirc CR; Novartis;
                    Treatment for hypertension, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Effexor XR (venlafaxin HCI); Wyeth;
                    Treatment of depression, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Estradiol tablets; Barr Laboratories;
                    Generic equivalent of Estrace, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Estradiol tablets; Duramed Pharmaceuticals;
                    Generic equivalent of Estrace tablets, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Estrostep (norethindrone acetate and ethinyl estradiol); Warner-Lambert;
                    Treatment for oral contraception, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Etodolac; Royce Laboratories;
                    Generic equivalent of  Lodine, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Treatment for the prevention of osteoporosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Femara (letrozole); Novartis;
                    Treatment for breast cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Follistim (TM) (follitropin beta for injection); Organon;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Genotropin (somatropin) lyophilized powder; Pharmacia & Upjohn;
                    Treatment for growth hormone deficiency in adults, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Geref (sermorelin acetate for injection); Serono Laboratories;
                    Treatment for pedicatric growth disorder, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals;
                    Treatment for brain cancer, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glipizide Tablets; Duramed Pharmaceuticals;
                    Treatment for diabetes, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glyburide Tablets; Roche;
                    Treatment for blood-glucose lowering, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glyburide Tablets; Mova Pharmaceutical;
                    Generic version of Glynase PresTab, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Gonal-F (follitropin alfa for injection); Serono Laboratories;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lescol (fluvastatin sodium); Novartis;
                    Treatment for coronary atherosclerosis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lexxel (enalapril maleate-felodipine ER); Astra Merck;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"MERIDIA; Knoll Pharmaceutical;
                    Treatment for obesity, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
                    Treatment for mild-to moderate hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Norditropin  (somatropin (rDNA origin) for injection); Novo Nordisk;
                    Treatment of children who have growth failure, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Nutropin (somatropin-rDNA origin); Genentech;
                    Treatment for growth hormone deficiency, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Pindolol; Teva Pharmaceutical;
                    Generic equivalent of  Visken, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
                    Treatment for cardiac atherosclerotic events, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Posicor; Roche;
                    Treatment for hypertension and chronic stable angina pectoris, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prandin; Novo Nordisk;
                    Treatment for Type II diabetes, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prograf; Fujisawa Healthcare;
                    Treatment for the prevention of kidney transplant rejection, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"REGRANEX (becaplermin) Gel; RW Johnson;
                    Treatment for diabetic foot ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
                    Generic equivalent of Pergonal, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Skelid (tiludronate disodium); Sanofi-aventis;
                    Treatment for Pagetâ€™s disease of bone, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Testoderm TTS CIII; Alza;
                    Treatment for testosterone deficiency, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Teveten (eprosartan mesylate); SmithKline Beecham;
                    Treatment for hypertension, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Trazadone 150mg; Teva Pharmaceutical;
                    Generic equivalent of Desyrel 7, Approved  May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Trivora-21 and Trivora-28; Watson Pharmaceuticals;
                    Generic equivalents of levonorgestrel and ethinyl estradiol, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Verapamil; IVAX;
                    Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Zenapax; Roche;
                    Treatment to prevent rejection of kidney transplants, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for infants and children infected with HIV, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Aredia (pamidronate disodium for injection); Chiron;
                    Treatment for osteolytic bone metastases of breast cancer, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Arimidex (anastrozole); AstraZeneca;
                    Treatment for advanced breast cancer in postmenopausal women, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn;
                    Treatment for rheumatoid arthritis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Campostar; Pharmacia & Upjohn;
                    Treatment for metastatic colorectal cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"CEA-Scan; Immunomedics;
                    Diagnostic imaging product for colorectal cancer, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Confide; Johnson & Johnson;
                    HIV testing and counseling service, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Covera-HS (verapamil); GD Searle, Alza;
                    Treatment for hypertension and angina, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Desmopressin Acetate (DDAVP); Rhone Poulenc Rorer;
                    Treatment for central diabetes insipidus, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection); Orphan Medical;
                    Treatment of meningeal leukemia or lymphocytic lymphoma, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Estrostep (norethindrone acetate and ethinyl estradiol); Parke-Davis;
                    Treatment for birth control, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Eulexin (flutamide); Schering-Plough;
                    Treatment for prostate cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"FemPatch; Parke-Davis;
                    Treatment for menopausal symptoms, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Fertinex (urofollitropin for injection, purified); Serono Laboratories;
                    Treatment for patients undergoing infertility treatments, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for pancreatic cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Glyset (miglitol); Bayer;
                    Treatment for Type II (non-insulin-dependent) diabetes mellitus, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Humalog (insulin lispro); Eli Lilly;
                    Treatment for type I and type II diabetes, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Humatrope (somatropin [rDNA origin] for injection); Eli Lilly;
                    Treatment for Somatropin Deficiency Syndrome, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Hycamtin (topotecan hydrochloride); SmithKline Beecham;
                    Treatment for metastatic ovarian cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lithobid (Lithium Carbonate); Solvay Pharmaceuticals;
                    Treatment for manic depression, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lodine (etodolac); Wyeth;
                    Treatment for rheumatoid arthritis, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Mavik (trandolapril); Knoll Pharmaceutical;
                    Treatment for hypertension, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
                    Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Nutropin (somatropin-rDNA origin); Genentech;
                    Treatment that consists of recombinant growth hormone product, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"OxyContin (oxycodone HCl controlled-release); Purdue Pharma;
                    Treatment for pain associated with musculoskeletal conditions, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for cholesterol-lowering, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Redux (dexfenfluramine hydrochloride); Wyeth;
                    Treatment for obesity, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Remeron (Mirtazapine); Organon;
                    Treatment for depression, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Saizen; Ares-Serono;
                    Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Taxotere (Docetaxel); Rhone Poulenc Rorer;
                    Treatment for locally advanced or metastatic breast cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
                    Treatment for hypertension, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Tiazac (diltiazem hydrochloride); Forest Laboratories;
                    Treatment for hypertension, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Vivelle (estradiol transdermal system); Ciba Pharmaceuticals;
                    Treatment for moderate and severe vasomotor menopausal symptoms, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Amaryl (Glimepiride); Hoechst Marion Roussel;
                    Treatment for type II diabetes, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Androderm (Testosterone Transdermal System); TheraTech;
                    Treatment for primary and secondary hypogonadism, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Epivir (lamivudine); GlaxoSmithKline;
                    Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Ethyol (amifostine); Alza;
                    Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Fosamax (alendronate sodium); Merck;
                    Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Invirase (saquinavir); Roche;
                    Treatment for HIV/AIDS, Approved on December 7, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for mobilizing peripheral blood progenitor cells for use after transplantation., Approved on November 24, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
                    Treatment for post-menopausal osteoporosis, Approved on August 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Precose (acarbose); Bayer;
                    Treatment for non-insulin-dependent diabetes mellitus, Approved September 6, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
                    Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Prinivil or Zestril (Lisinopril); Merck, Zeneca;
                    Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology,"Western blot confirmatory device; Epitope;
                    Confirmatory test for HIV, Approved in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tosymra (sumatriptan) nasal spray; Dr. Reddy's Labs;
                    For the treatment of acute migraine in adults, Approved January 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aimovig (erenumab-aooe) ; Amgen;
                    For the preventive treatment of migraine in adults , Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ajovy (fremanezumab-vfrm); Teva Pharmaceuticals;
                    For the treatment of migraine, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xofluza (baloxavir marboxil); Shionogi;
                    For the treatment of acute uncomplicated influenza , Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ozempic (semaglutide); Novo Nordisk;
                    For the treatment of type II diabetes, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Qtern (dapagliflozin and saxagliptin) ; AstraZeneca;
                    For the treatment of inadequately controlled type II diabetes , Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Steglatro (ertugliflozin); Merck;
                    For the treatment of type 2 diabetes mellitus, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trulance (plecanatide); Synergy Pharmaceuticals;
                    For the treatment of adults with chronic idiopathic constipation, Approved January 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Byvalson (nebivolol and valsartan); Allergan;
                    For the treatment of hypertension, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Onzetra Xsail (sumatriptan nasal powder) ; Avanir;
                    For the treatment of migraine, Approved January 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis;
                    For the treatment of inadequately controlled type II diabetes, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk;
                    For the treatment of  inadequately controlled type II diabetes, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cosentyx (secukinumab); Novartis;
                    For the treatment of plaque psoriasis, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cresemba (isavuconazonium sulfate) ; Astellas;
                    For the treatment of invasive aspergillosis and invasive mucormycosis, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Enstilar (calcipotriene and betamethasone dipropionate); LEO Pharmaceuticals;
                    For the treatment of psoriasis, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kybella  (deoxycholic acid); Kythera Biopharma;
                    For the treatment of submental fat, Approved April 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Otiprio (ciprofloxacin otic suspension); Otonomy;
                    For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Savaysa (edoxaban); Daiichi Sankyo;
                    For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viberzi (eluxadoline); Actavis;
                    For the treatment of irritable bowel syndrome with diarrhea, Approved May 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of irritable bowel syndrome with diarrhea , Approved May 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Afrezza (insulin human) Inhalation Powder; Mannkind;
                    For the treatment of diabetes mellitus, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec;
                    For the treatment of hemophilia B, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline;
                    For the treatment of asthma, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals;
                    For the treatment of hypogonadism, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Belsomra (suvorexant); Merck;
                    For the treatment of insomnia, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bunavail (buprenorphine and naloxone); BioDelivery Sciences;
                    For the maintenance treatment of opioid dependence, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Contrave (naltrexone HCl and bupropion HCl) ; Takeda Pharmaceuticals U.S.A.;
                    For chronic weight management , Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dalvance (dalbavancin); Durata Therapeutics;
                    For the treatment of acute bacterial skin and skin structure infections, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dyloject (diclofenac sodium) Injection; Hospira;
                    For the management of mild, moderate or severe pain, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Entyvio (vedolizumab); Millenium Pharmaceuticals;
                    For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Farxiga (dapagliflozin); Bristol-Myers Squibb;
                    For the treatment of type II diabetes, January of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Grastek (Timothy Grass Pollen Allergen Extract); Merck;
                    For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Jardiance (empagliflozin) ; Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kerydin (tavaborole); Anacor;
                    For the treatment of onychomycosis of the toenails, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Metronidazole 1.3% Vaginal Gel; Actavis, Inc.;
                    For the treatment of bacterial vaginosis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Myalept (metreleptin for injection); Bristol-Myers Squibb;
                    For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Natesto, (testosterone) nasal gel; Trimel Pharmaceuticals;
                    For the treatment of deficiency or absence of endogenous testosterone, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Northera (droxidopa); Chelsea Therapeutics;
                    For the treatment of neurogenic orthostatic hypotension, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Otezla (apremilast); Celgene;
                    For the treatment of adults with active psoriatic arthritis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Otezla (apremilast); Celgene;
                    For the treatment of moderate to severe plaque psoriasis, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Plegridy (peginterferon beta-1a); Biogen IDEC.;
                    For the treatment of relapsing multiple sclerosis, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Qudexy XR (topiramate); Upsher-Smith Laboratories;
                    For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ragwitek (Short Ragweed Pollen Allergen Extract); Merck;
                    For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rapivab (peramivir injection); Biocryst;
                    For the treatment of acute uncomplicated influenza in adults, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Saxenda (liraglutide [rDNA origin] injection); Novo Nordisk;
                    For chronic weight management, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tanzeum (albiglutide); GlaxoSmithKline;
                    For the treatment of type II diabetes mellitus, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets; Purdue Pharma;
                    For the management of severe chronic pain, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tivorbex (indomethacin); Iroko Pharmaceuticals;
                    For the treatment of acute pain, Approved February of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trulicity (dulaglutide); Eli Lilly;
                    To improve glycemic control in type II diabetics, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release; Mallinckrodt Pharmaceuticals;
                    For the management of acute pain, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xtoro (finafloxacin otic suspension) 0.3%; Alcon;
                    For the treatment of acute otitis externa, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Actemra (ocilizumab); Genentech;
                    For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Anoro Ellipta (umeclidinium and vilanterol inhalation powder); GlaxoSmithKline;
                    For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline;
                    For the treatment of chronic obstructive pulmonary disease, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets); Duchesnay USA;
                    For the treatment of nausea and vomiting of pregnancy, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Duavee (conjugated estrogens/bazedoxifene); Pfizer;
                    For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Flublok (seasonal influenza vaccine); Protein Sciences;
                    For the active immunization against influenza virus subtypes A and type B, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ilaris (canakinumab); Novartis;
                    For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Invokana (canagliflozin); Janssen Pharmaceuticals;
                    For the treatment of type II diabetes and to reduce the risk of cardiovascular events in type II diabetics, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Liptruzet (ezetimibe and atorvastatin); Merck;
                    For the treatment of hyoerlipidemia, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nesina (alogliptin); Takeda;
                    For the treatment of type II diabetes mellitus, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Olysio (simeprevir); Janssen Therapeutics;
                    For the treatment of hepatitis C, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Osphena (ospemifene); Shionogi;
                    For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol); Teva Pharmaceutical;
                    For the prevention of conception, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sitavig (acyclovir) buccal tablets; BioAlliance Pharma;
                    For the treatment of recurrent herpes labialis in adults, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sovaldi (sofosbuvir); Gilead Sciences;
                    For the treatment of hepatitis C, December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tecfidera (dimethyl fumarate); Biogen Idec;
                    For the treatment of relapsing multiple sclerosis, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Uceris (budesonide); Santarus;
                    For the treatment of ulcerative colitis, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xiaflex (collagenase clostridium histolyticum); Auxilium;
                    For the treatment of Peyronie's disease, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene;
                    For the treatment of non-small cell lung cancer, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Afinitor (everolimus); Novartis;
                    For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Afinitor (everolimus); Novartis;
                    For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aubagio (teriflunomide); Sanofi Aventis;
                    For the treatment of multiple sclerosis, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bydureon (exenatide extended-release for injectable suspension); Amylin;
                    For the improvement of glycemic control in adults with type II diabetes mellitus, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cometriq (cabozantinib); Exelixis;
                    For the treatment of metastatic medullary thyroid cancer, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals;
                    For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc;
                    For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Erivedge (vismodegib); Genentech;
                    For the treatment of basal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Fycompa (perampanel); Eisai;
                    For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of postherpetic neuralgia, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Inlyta (axitinib); Pfizer;
                    For the treatment of advanced renal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Jentadueto (linagliptin plus metformin hydrochloride); Eli Lilly;
                    For the treatment of type II diabetes, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Jetrea (ocriplasmin); Thrombogenics;
                    For the treatment of symptomatic vitreomacular adhesion, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Korlym (mifepristone); Corcept Therapeutics;
                    For the control of hyperglycemia in adults with endogenous Cushingâ€™s syndrome, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kyprolis (carfilzomib); Onyx Pharmaceuticals;
                    For the treatment of multiple myeloma, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Linzess (linaclotide); Forest Labs and Ironwood Pharmaceuticals;
                    For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lucentis (ranibizumab injection); Genentech;
                    For the treatment of diabetic macular edema, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lyrica (pregabalin); Pfizer;
                    For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Myrbetriq (mirabegron); Astellas Pharma US, Inc;
                    For the treatment of overactive bladder, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Natazia (estradiol valerate and estradiol valerate/dienogest); Bayer;
                    For the treatment of heavy menstrual bleeding, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Neupro (Rotigotine Transdermal System); UCB;
                    For the treatment of Restless Legs Syndrome, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Omontys (peginesatide); Affymax;
                    For the treatment of anemia due to chronic kidney disease, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Oxtellar XR (oxcarbazepine extended release); Supernus Pharmaceuticals;
                    For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Perjeta (pertuzumab); Genentech;
                    For the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Picato (ingenol mebutate) gel; LEO Pharma;
                    For the treatment of actinic keratosis, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Quillivant XR (methylphenidate hydrochloride); NextWave Pharmaceuticals;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sklice (ivermectin) lotion; Sanofi Pasteur;
                    For the treatment of head lice, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Stendra (avanafil); Vivus;
                    For the treatment of erectile dysfunction, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals;
                    For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 infection, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Subsys (fentanyl sublingual spray); Insys Therapeutics;
                    For the treatment of breakthrough cancer pain, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Surfaxin (lucinactant); Discovery Laboratories;
                    For the treatment of respiratory distress syndrome in premature infants, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories;
                    For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viokace (pancrelipase) tablets; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Voraxaze (glucarpidase); BTG International;
                    For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xeljanz (tofacitinib); Pfizer;
                    For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xtandi (enzalutamide); Medivation;
                    For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zaltrap (ziv-aflibercept); Sanofi-aventis;
                    For the treatment of metastatic colorectal cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zioptan (tafluprost ophthalmic solution); Merck;
                    For the treatment of elevated intraocular pressure, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Abstral (fentanyl sublingual tablets); ProStrakan;
                    For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Afinitor (everolimus); Novartis;
                    For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Anturol (oxybutynin) Gel; Antares Pharma;
                    For the treatment of overactive bladder, Approved December 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Arcapta (indacaterol maleate inhalation powder); Novartis;
                    For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Benlysta (belimumab); Human Genome Sciences;
                    For the treatment of systemic lupus erythematosus, Approved March 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Daliresp (roflumilast); Forest Pharmaceuticals;
                    For the treatment of chronic obstructive pulmonary disease, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dificid (fidaxomicin); Optimer Pharmaceuticals;
                    For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Duexis (ibuprofen and famotidine); Horizon Pharma;
                    For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Edarbi (azilsartan medoxomil); Takeda;
                    For the treatment of hypertension, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda;
                    For the treatment of hypertension, Approved December of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Edurant (rilpivirine); Tibotec;
                    For the treatment of HIV-1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Exparel (bupivacaine liposome injectable suspension); Pacira Pharmaceuticals;
                    For postsurgical analgesia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ferriprox (deferiprone); Apotex;
                    For the treatment of transfusional iron overload due to thalassemia, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Firazyr (icatibant); Shire Pharmaceuticals;
                    For the treatment of acute attacks of hereditary angioedema, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gralise (gabapentin); Abbott Laboratories;
                    For the treatment of postherpetic neuralgia, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of restless legs syndrome, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals;
                    For the treatment of insomnia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Juvisync (sitagliptin and simvastatin); Merck;
                    For the treatment of type II diabetes, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lazanda (fentanyl citrate) nasal spray; Archimedes;
                    For the management of breakthrough cancer pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Makena (hydroxyprogesterone caproate injection); Hologic;
                    For the prevention of risk of preterm birth, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nulojix (belatacept); Bristol-Myers Squibb;
                    For the prevention of organ rejection following kidney transplant, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Onfi (clobazam); Lundbeck;
                    For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Oxecta (oxycodone HCl); Pfizer;
                    For the management of acute and chronic moderate to severe pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Potiga (ezogabine); Valeant Pharmaceuticals;
                    For the treatment of partial-onset seizures, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sutent (sunitinib malate); Pfizer;
                    For the treatment of pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sylatron (peginterferon alfa-2b); Merck;
                    For the treatment of melanoma, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tradjenta (linagliptin); Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vandetanib (vandetanib); AstraZeneca;
                    For the treatment of thyroid cancer, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viibryd (vilazodone hydrochloride); Clinical Data;
                    For the treatment of major depressive disorder, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xalkori (crizotinib); Pfizer;
                    For the treatment of ALK+ non-small cell lung cancer, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Yervoy (ipilimumab); Bristol-Myers Squibb;
                    For the treatment of metastatic melanoma, Approved March 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zelboraf (vemurafenib); Roche;
                    For the treatment of  BRAF + melanoma, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zytiga (abiraterone acetate); Centocor Ortho Biotech;
                    For the treatment of prostate cancer, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Actemra (tocilizumab); Genentech;
                    For the treatment of rheumatoid arthritis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ampyra (dalfampridine); Acorda;
                    For the improvement of walking in patients with multiple sclerosis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis;
                    For the treatment of uncontrolled hypertension, Approved December 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Botox (onabotulinumtoxinA); Allergan;
                    For the treatment of chronic migraine, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Botox (onabotulinumtoxinA); Allergan;
                    For the treatment of upper limb spasticity, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Butrans (buprenorphine) Transdermal System; Purdue Pharma;
                    moderate to severe chronic pain, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cuvposa (glycopyrrolate); Shionogi;
                    For the treatment of chronic severe drooling in pediatrics with neurologic conditions, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dulera (mometasone furoate + formoterol fumarate dihydrate); Merck;
                    For the treatment of asthma, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Egrifta (tesamorelin for injection); Theratechnologies;
                    For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Exalgo (hydromorphone hydrochloride) extended release; Alza;
                    For the management of moderate to severe pain, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gilenya (fingolimod); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved September 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Halaven (eribulin mesylate); Eisai;
                    For the treatment of metastatic breast cancer, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Herceptin (trastuzumab); Genentech;
                    For the treatment of gastric cancer, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Jalyn (dutasteride + tamsulosin); GlaxoSmithKline;
                    For the treatment of benign prostatic hyperplasia, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Jevtana (cabazitaxel); sanofi aventis;
                    For the treatment of prostate cancer, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kapvay (clonidine hydrochloride); Shionogi;
                    For the treatment of attention deficit hyperactivity disorder, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Krystexxa (pegloticase); Savient Pharma;
                    For the treatment of chronic gout (hyperuricemia), Approved September 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Oleptro (trazodone hydrochloride); Labopharm;
                    For the treatment of major depressive disorder, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim;
                    For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prolia (denosumab); Amgen;
                    For the treatment of osteoporosis and bone loss in men and women, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Provenge (sipuleucel-T); Dendreon;
                    For the treatment of hormone refractory prostate cancer, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Silenor (doxepin); Somaxon Pharma;
                    For the treatment of insomnia, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sprix (ketorolac tromethamine); Roxro Pharma;
                    For the treatment of moderate to severe pain, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tekamlo (aliskiren + amlodipine); Novartis;
                    For the treatment of hypertension, Approved August 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo;
                    For the treatment of hypertension, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Veltin (clindamycin phosphate and tretinoin); Stiefel;
                    For the treatment of acne vulgaris, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Victoza (liraglutide); Novo Nordisk;
                    For the treatment of type 2 diabetes mellitus, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vimovo (naproxen + esomeprazole); AstraZeneca;
                    For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the prevention of relapse to opioid dependence, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zymaxid (gatifloxacin ophthalmic solution); Allergan;
                    For the treatment of bacterial conjunctivitis, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Adcirca (tadalafil); Eli Lilly;
                    For the treatment of pulmonary arterial hypertension, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Afinitor (everolimus); Novartis;
                    For the treatment of renal cell carcinoma, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avastin (bevacizumab); Genentech;
                    For the treatment of renal cell carcinoma, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals;
                    For the treatment of itching associated with allergic conjunctivitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals;
                    For the treatment of migraine attacks, Approved June of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
                    For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of rheumatoid arthritis, Approved May of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cycloset, bromocriptine mesylate; VeroScience;
                    For the treatment of type 2 diabetes mellitus, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Embeda (morphine sulfate and naltrexone hydrochloride); King Pharmaceuticals;
                    For the treatment of moderate to severe pain, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Extavia (Interferon beta-l b); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Intuniv (guanfacine extended-release); Shire Pharmaceuticals;
                    For the treatment of ADHD in children and adolescents, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Metozolv ODT (metoclopramide hydrochloride); Salix Pharmaceuticals;
                    For the treatment of gastroesophageal reflux and diabetic gastroparesis, Approved September of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Onglyza (saxagliptin); Bristol-Myers Squibb;
                    For the treatment of type 2 diabetes mellitus, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Onsolis (fentanyl buccal); BioDelivery Sciences;
                    For the management of breakthrough cancer pain, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pennsaid (diclofenac sodium topical solution); Nuvo Research;
                    For the treatment of osteoarthritis of the knee, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sabril (vigabatrin); Lundbeck;
                    For the treatment of infantile spasms and complex partial seizures, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Saphris (asenapine); Schering-Plough;
                    For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Simponi (golimumab); Centocor Ortho Biotech;
                    For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Stelara (ustekinumab); Janssen Biotech;
                    For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tyvaso (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vibativ (telavancin); Theravance;
                    For the treatment of complicated skin and skin structure infections, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of renal cell carcinoma, Approved October of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zipsor (diclofenac potassium); Xanodyne Pharmaceuticals;
                    For the treatment of mild to moderate acute pain, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Alvesco (ciclesonide); Nycomed;
                    For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the treatment of HIV, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Banzel (rufinamide); Elan Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of Crohnâ€™s disease, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cleviprex (clevidipine); The Medicines Company;
                    For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Degarelix (degarelix for injection); Ferring Pharmaceuticals;
                    For the treatment of prostate cancer, Approved December of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Intelence (etravirine); Tibotec;
                    For the treatment of HIV-1, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Stavzor (valproic acid delayed release); Banner Pharmacaps;
                    For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tysabri (natalizumab); Biogen IDEC;
                    For the maintenance treatment of moderate to severe Crohnâ€™s disease, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vimpat (lacosamide); Schwarz Pharma;
                    For the treatment of partial-onset seizures in adults with epilepsy, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Welchol (colesevelam hydrochloride); Daiichi Sankyo;
                    For the improvement of glycemic control in adults with type 2 diabetes mellitus, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
                    For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo;
                    For the treatment of hypertension, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Doribax (doripenem); Johnson & Johnson;
                    For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Evamist (estradiol); Vivus;
                    For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Evista (raloxifene hydrochloride); Eli Lilly;
                    For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Exelon (rivastigmine tartrate); Novartis;
                    For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Hycamtin (topotecan hydrochloride); GlaxoSmithKline;
                    For the treatment of small cell lung cancer, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Isentress (raltegravir); Merck;
                    For the treatment of HIV-1, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ixempra (ixabepilone); Bristol-Myers Squibb;
                    For the treatment of breast cancer, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Letairis (ambrisentan); Gilead;
                    For the treatment of pulmonary arterial hypertension, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Neupro (rotigotine); Schwarz Pharma;
                    For the treatment of Parkinson's disease, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Reclast (zoledronic acid); Novartis;
                    For the treatment of postmenopausal osteoporosis, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Renvela (sevelamer carbonate); Genzyme;
                    For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Selzentry (maraviroc); Pfizer;
                    For the treatment of CCR5-tropic HIV-1, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tekturna (aliskiren); Novartis;
                    For the treatment of hypertension, Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Torisel (temsirolimus); Wyeth;
                    For the treatment of renal cell carcinoma, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tykerb (lapatinib); GlaxoSmithKline;
                    For the treatment of breast cancer, Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vyvanse (Lisdexamfetamine Dimesylate); New River;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Desonate (desonide); Dow Pharm;
                    For the treatment of atopic dermatitis, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Elestrin (estradiol gel); BioSante;
                    For the treatment of vasomotor symptoms associated with menopause, Approved December 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Eraxis (anidulafungin); Pfizer;
                    For the treatment of fungal infections, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Januvia (sitagliptin phosphate); Merck;
                    For the treatment of type II diabetes, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Noxafil (posaconazole); Schering-Plough;
                    For the treatment of fungal infections, Approved in September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prezista (darunavir); Tibotec;
                    For the treatment of treatment-resistant HIV infections, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ranexa (ranolazine); CV Therapeutics;
                    For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vectibix (panitumumab); Amgen;
                    For the treatment of colorectal cancer, Approved September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Verdeso (desonide); Connetics Corporation;
                    For the treatment of atopic dermatitis, Approved September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the treatment of alcohol dependence, Approved April 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda;
                    For the treatment of type 2 diabetes, Approved August of 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the adjunctive treatment of HIV-1 infections, Approved June, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed;
                    For the treatment of heart failure in black patients, Approved June, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Boniva (ibandronate); Roche / GlaxoSmithKline;
                    For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Byetta (exenatide); Amylin/Eli Lilly;
                    For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nexavar (sorafenib); Bayer/Onyx;
                    For the Treatment of Renal Cell Carcinoma, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Orencia (abatacept); Bristol-Myers Squibb;
                    For the Treatment of Rheumatoid Arthritis, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Symlin (pramlintide); Amylin Pharmaceuticals;
                    For the treatment of type I and type II diabetes, Approved March 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec;
                    For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Apokyn (apomorphine hydrochloride); Mylan Laboratories;
                    For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinsonâ€™s disease, Approved April, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avastin (bevacizumab); Genentech;
                    For the treatment of metastatic carcinoma of the colon or rectum, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Caduet (amlodipine/atorvastatin); Pfizer;
                    For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Campral (acamprosate calcium); Forest Laboratories;
                    For the treatment of alcohol dependence and the maintenance of alcohol abstinence, Approved August, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cymbalta (duloxetine); Eli Lilly;
                    For the treatment of major depressive disorder, Approved August 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Erbitux (cetuximab); Imclone, Bristol-Myers Squibb;
                    For the treatment of EGFR-expressing, metastatic colorectal cancer, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"EstroGel (estradiol gel 0.06%); Solvay Pharmaceuticals;
                    For the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, Approved April 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lyrica (pregabalin); Pfizer;
                    For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, Approved December 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Spiriva HandiHaler (tiotropium bromide); Boehringer Ingelheim;
                    For the treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tarceva (erlotinib, OSI 774); Genentech, OSI Pharmaceuticals;
                    For the treatment of advanced refractory metastatic non-small cell lung cancer, Approved November, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vioxx (rofecoxib); Merck;
                    For the treatment of rheumatoid arthritis, Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Amevive (alefacept); Biogen IDEC;
                    For moderate to severe chronic plaque psoriasis., Approved January 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cialis (tadalafil); Eli Lilly;
                    Oral agent for the treatment for erectile dysfunction, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Finacea (azelaic acid) Gel, 15%; Berlex Laboratories;
                    Gel formulation for the treatment of rosacea., January 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Fuzeon (enfuvirtide); Trimeris, Roche;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Iressa (gefitinib); AstraZeneca;
                    For the second-line treatment of non-small-cell lung cancer, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Levitra (vardenafil); Bayer, GlaxoSmithKline;
                    For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lexiva (fosamprenavir calcium); GlaxoSmithKline;
                    For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Namenda (memantine HCl); Forest Laboratories;
                    For the treatment of moderate to severe dementia of the Alzheimerâ€™s type., Approved October 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals;
                    For treatment of advanced prostate cancer, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Premarin (conjugated estrogens); Wyeth;
                    For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis;
                    For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xolair (omalizumab); Genentech;
                    For the treatment of asthma, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aciphex (rabeprazole sodium); Elan Pharmaceuticals;
                    For the treatment of symptomatic gastroesophageal reflux disease, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Alora; Watson Pharmaceuticals;
                    Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avandamet (rosiglitazone maleate and metformin HCl); GlaxoSmithKline;
                    For improvement of glycemic control in type 2 diabetes patients, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avinza (morphine sulfate); Elan Pharmaceuticals;
                    Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Benicar; Daiichi Sankyo;
                    Oral tablet for the treatment of hypertension, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Botox Cosmetic (botulinum toxin type A); Allergan;
                    For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals;
                    Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Eligard (leuprolide acetate); Atrix Laboratories;
                    For the palliative treatment of advanced prostate cancer, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Enbrel (etanercept); Immunex;
                    For the treatment of psoriatic arthritis, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Faslodex (fulvestrant); AstraZeneca;
                    For the treatment of hormone receptor positive metastatic breast cancer, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Forteo (teriparatide); Eli Lilly;
                    For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Humira (adalimumab); Abbott Laboratories;
                    For the treatment of moderately to severely active rheumatoid arthritis, Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Inspra (eplerenone tablets); Pharmacia & Upjohn;
                    Oral tablets for the treatment of high blood pressure., Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lexapro (escitalopram oxalate); Forest Laboratories;
                    An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder, Approved August 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Metaglip (glipizide/metformin HCl); Bristol-Myers Squibb;
                    Oral tablets for the treatment of type 2 diabetes., Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Paxil CR (paroxetine hydrochloride); GlaxoSmithKline;
                    Oral tablet for the treatment of depression and panic disorder, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Qvar (beclomethasone dipropionate); Ivax;
                    For the treatment of asthma, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rebif (interferon beta-1a); Serono Laboratories;
                    Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Relpax (eletriptan hydrobromide); Pfizer;
                    For the acute treatment of migraine headaches, Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Remicade (infliximab); Centocor Ortho Biotech;
                    Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Remodulin (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ritalin LA (methylphenidate HCl); Novartis;
                    Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Strattera (atomoxetine HCl); Eli Lilly;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sustiva; Bristol-Myers Squibb;
                    Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vfend (voriconazole); Pfizer;
                    For the treatment of fungal infections, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zelnorm (tegaserod maleate) Tablets; Novartis;
                    For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation, Approved July 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Adderall XR; Shire Pharmaceuticals;
                    Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals;
                    For the treatment of cholesterol disorders, Approved December 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avelox I.V. (moxifloxacin hydrochloride); Bayer;
                    For adults with susceptible strains of bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Axert (almotriptan malate) tablets; Pharmacia & Upjohn;
                    For the treatment of migraine attacks, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bayer Extra Strength Asprin; Bayer;
                    Oral treatment for mild to moderate migraine pain, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bextra; Pharmacia, Pfizer;
                    Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cancidas; Merck;
                    For the treatment of invasive aspergillosis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Diovan (valsartan); Novartis;
                    Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"DuoNeb (albuterol sulfate and ipratropium bromide); Dey Laboratories;
                    For the treatment of bronchospasm associated with COPD, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dutasteride; GlaxoSmithKline;
                    For the treatment of symptomatic benign prostatic hyperplasia, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Elidel; Novartis;
                    Topical cream for the treatment of atopic dermatitis, Approved December 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Entocort EC (budesonide); AstraZeneca;
                    Capsules for the treatment of mild-to-moderate, active Crohn's disease, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Estrostep (norethindrone acetate and ethinyl estradiol); Pfizer;
                    For the treatment of moderate acne vulgaris, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Femara (letrozole); Novartis;
                    First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Finevin; Berlex Laboratories;
                    Topical cream for the treatment of mild to moderate inflammatory acne vulgaris, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Focalin (dexmethylphenidate HCl); Celgene;
                    For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Foradil Aerolizer (formoterol fumarate inhalation powder); Novartis;
                    Bronchodilator for COPD, asthma and bronchospasm, Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Frova (frovatriptan succinate); Elan Pharmaceuticals;
                    Tablets for the acute treatment of migraine attacks, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kineret; Amgen;
                    Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lamisil Solution, 1%; Novartis;
                    Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lumigan (bimatoprost ophthalmic solution); Allergan;
                    For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Metadate CD; Celltech Pharmaceuticals;
                    Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nexium (esomeprazole magnesium); AstraZeneca;
                    For the eradication of Helicobacter pylori, the healing of erosive esophagitis, and the treatment of symptomatic GERD, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Novolog Mix 70/30; Novo Nordisk;
                    Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Protonix (pantoprazole sodium) Intravenous Formulation; Wyeth;
                    For the short-term treatment of gastroesophageal reflux disease, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prozac Weekly (fluoxetine HCl); Eli Lilly;
                    For the treatment of depression, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Remeron SolTab (mirtazapine); Organon;
                    Orally disintegrating tablet for the treatment of depression, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Remicade (infliximab); Centocor Ortho Biotech;
                    For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Reminyl (galantamine hydrobromide); Janssen Pharmaceuticals;
                    For the treatment of mild to moderate dementia of the Alzheimer's type, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Spectracef; TAP Pharmaceuticals;
                    Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Supartz; Smith & Nephew Orthopaedics;
                    Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tavist (clemastine fumarate); Novartis;
                    Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Teveten (eprosartan mesylate plus hydrochlorothiazide); Unimed Pharmaceuticals;
                    Tablets for the treatment of hypertension, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tracleer (bosentan); Actelion;
                    For the treatment of pulmonary arterial hypertension, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Travatan (travoprost ophthalmic solution); Alcon;
                    For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trelstar LA (triptorelin pamoate); Debiopharm;
                    Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tricor (fenofibrate); Abbott Laboratories;
                    For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia, Approved September 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ultracet (acetaminophen and tramadol HCl); Ortho-McNeil Pharmaceutical;
                    For the short-term management of acute pain, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Valcyte (valganciclovir HCl); Roche;
                    For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ventolin HFA (albuterol sulfate inhalation aerosol); GlaxoSmithKline;
                    For the treatment or prevention of bronchospasm, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viread (tenofovir disoproxil fumarate); Gilead;
                    Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zomig (zolmitriptan); AstraZeneca;
                    Orally disintegrating tablet for the treatment of acute migraine in adults, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
                    Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Atacand (candesartan cilexetil); AstraZeneca;
                    For the treatment of hypertension, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel); Dermik Laboratories;
                    For the topical treatment of acne vulgaris, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Betaxon; Alcon;
                    For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories;
                    For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Children's Motrin Cold; McNeil Consumer Products;
                    For temporary relief of the common cold, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Clindamycin phosphate topical gel; Target Research Associates;
                    For once a day treatment of acne vulgaris, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Colazal (balsalazide disodium); Salix Pharmaceuticals;
                    Mild to moderately active ulcerative colitis, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Concerta; Alza;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Depakote ER (divalproex sodium); Abbott Laboratories;
                    For the prophylaxis (prevention) of migraine headaches in adults, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
                    For the reduction of high blood pressure, Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Exelon (rivastigmine tartrate); Novartis;
                    Indicated for the treatment of mild to moderate dementia of the Alzheimer's type, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kaletra Capsules and Oral Solution; Abbott Laboratories;
                    For the treatment of HIV-1 infection, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
                    For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
                    For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough;
                    For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lotronex (alosetron HCL) Tablets; GlaxoSmithKline;
                    Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
                    For the treatment of hypertension, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Mobic (meloxicam) Tablets; Boehringer Ingelheim;
                    For relief of the signs and symptoms of osteoarthritis, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    Treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    For the treatment of partial seizures in pediatric patients three years of age and older, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nitrostat (nitroglycerin) Tablets; Parke-Davis;
                    For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Novantrone (mitoxantrone hydrochloride); Immunex;
                    For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"NovoLog (insulin aspart); Novo Nordisk;
                    An insulin analogue for the treatment of diabetes mellitus., Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories;
                    For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pepcid Complete; Merck;
                    For use in the relief of heartburn associated with acid indigestion and sour stomach, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth;
                    For treatment of erosive esophagitis, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Protopic (tacrolimus) ointment; Fujisawa Healthcare;
                    For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Renagel (sevelamer hydrochloride); Genzyme;
                    For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rescula (unoprostone isopropyl ophthalmic solution) 0.15%; Ciba Vision;
                    For the treatment of open-angle glaucoma or ocular hypertension, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
                    For the palliative treatment of advanced prostate cancer, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trileptal (oxcarbazepine) Tablets; Novartis;
                    Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline;
                    For the treatment of HIV-1 infection, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Venofer (iron sucrose injection); Luitpold Pharmaceuticals;
                    For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viadur (leuprolide acetate implant); Alza;
                    For pain relief in men with advanced prostate cancer, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vivelle (estradiol transdermal system); Novartis;
                    For the prevention of postmenopausal osteoporosis, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zonegran (zonisamide) Capsules; Dainippon Pharmaceutical;
                    Adjunctive therapy for treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Accolate; AstraZeneca;
                    zafirlukast, 10 mg and 20 mg tablets., Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aggrenox; Boehringer Ingelheim;
                    Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aromasin Tablets; Pharmacia & Upjohn;
                    Exemestane Tablets, 25 mg, October 21, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Comtan; Novartis;
                    200mg entacapone tablets, October 19, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ellence; Pharmacia & Upjohn;
                    epirubicin hydrochloride, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Osteoporosis treatment, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Femhrt Tablets; Parke-Davis;
                    Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Keppra; UCB;
                    Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ortho-Prefest; Ortho-McNeil Pharmaceutical, RW Johnson;
                    17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Synercid I.V.; Rhone Poulenc Rorer;
                    quinupristin and dalfopristin for injection, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Amerge; GlaxoSmithKline;
                    Treatment for acute migraine, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Arava; Hoechst Marion Roussel;
                    Treatment for Rheumatoid Arthritis, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Celexa; Forest Laboratories;
                    Treatment for depression, Approved July 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cimetidine Hydrochloride Oral Solution; Pharmaceutical Formulations;
                    Generic equivalent of Tagamet HB 200, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Clomipramine hydrochloride; Mylan Laboratories;
                    Generic equivalent of Anafranil, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Clonazepam; Watson Pharmaceuticals;
                    Generic equivalent of Klonopin, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cosopt; Merck;
                    Treatment for glaucoma or ocular hypertension, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Diovan HCT (valsartan); Novartis;
                    Treatment for hypertension, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Esclim; Fournier Research;
                    Treatment for symptoms associated to Menopause, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Estratab (.3 mg ); Solvay Pharmaceuticals;
                    Treatment for the prevention of osteoporosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Etodolac; Faulding;
                    Generic equivalent of Lodine 500 mg tablets, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Excedrin Migraine; Bristol-Myers Squibb;
                    Treatment for mild to moderate migraine pain, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for Lung Cancer, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Glucagon; Eli Lilly;
                    Treatment for severe hypoglycemia associated with diabetes., Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Glyburide Tablets; Mylan Laboratories;
                    Treatment for Diabetes Mellitus (Type II), Approved July 1998."
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Herceptin (trastuzumab); Genentech;
                    For the treatment of metastatic breast cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Inform HER-2/neu breast cancer test; Oncor;
                    Treatment for breast cancer prediction, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lamictal Chewable Dispersible Tablets; GlaxoSmithKline;
                    Treatment for Epilepsy, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lodine XL (etodolac); Wyeth;
                    Treatment for arthritis, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
                    Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Marplan Tablets; Roche;
                    Treatment of Depression, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Maxalt; Merck;
                    Acute treatment of migraine headache, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Naltrexone Hydrochloride Tablets; Barr Laboratories;
                    Generic equivalent of Revia, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Noritate; Dermik Laboratories;
                    Treatment for rosacea, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Photofrin; QLT;
                    Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prempro; Wyeth;
                    Treatment for hormone replacement therapy, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"PREVACID(R) (lansopraxole); TAP Pharmaceuticals;
                    Treatment of heartburn associated with GERD, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prilosec (omeprazole); Astra Merck;
                    Treatment for heartburn, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Proleukin; Chiron;
                    Treatment for metastatic melanoma, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prometrium; Solvay Pharmaceuticals;
                    Treatment for amenorrhea (abnormal cessation of menses), Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rocephin; Roche;
                    Treatment for pediatric otitis media, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Singulair; Merck;
                    Treatment for asthma, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Sulfamylon; Mylan Laboratories;
                    Treatment used to control bacterial infections on excised burn wounds, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Synagis; MedImmune;
                    Treatment for the prevention of serious lower respiratory tract disease in infants, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tasmar; Roche;
                    Treatment for Parkinson's Disease, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tiazac (diltiazem hydrochloride); Forest Laboratories;
                    Treatment for chronic stable angina, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viagra; Pfizer;
                    Treatment for impotence, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vitravene Injection; Isis Pharmaceuticals;
                    Treatment for CMV in AIDS patients, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Xeloda; Roche;
                    Treatment for advanced breast cancer tumors, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zantac 75 Efferdose; GlaxoSmithKline;
                    Treatment for heartburn, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine," INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham;
                    Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aphthasol; Block Drug Company;
                    Treatment for canker sores, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Arthrotec; Searle;
                    Treatment for arthritis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Asacol (mesalamine); Procter & Gamble;
                    Treatment of ulcerative colitis, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avita Gel; Penederm;
                    Treatment for acne, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bactroban Cream; SmithKline Beecham;
                    Treatment for secondarily infected traumatic skin lesions, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Bromfenac; Duract, Wyeth-Ayerst Laboratories;
                    Management of acute pain, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Captopril and hydrochlorotiazide; Mylan Laboratories;
                    Treatment for hypertension, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Carbatrol; Elan Pharmaceuticals;
                    Treatment for epileptic seizures and trigeminal neuralgia, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ceftin (cefuroxime axetil); GlaxoSmithKline;
                    Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cimetadine Hydrochloride Oral Solution 300mg/5ml; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tagamet Oral Solution, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cimetidine Hydrochloride Oral Solution; Hi-Tech Pharmacal;
                    Generic equivalent of Tagamet Oral Solution, 300 mg/5 ml, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cipro (ciprofloxacin HCl); Bayer;
                    Treatment for acute sinusitis, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Clindamycin Phosphate Topical Solution USP 1%; Morton Grove Pharmaceuticals;
                    Generic equivalent of CLEOCIN Topical Solution 1%, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Combivir; GlaxoSmithKline;
                    Treatment for AIDS and HIV Infection, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Copaxone; Teva Pharmaceutical;
                    Treatment for relapsing-remitting multiple sclerosis, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Corlopam; Neurex;
                    Treatment for severe high blood pressure, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Dermagraft-TC; Advanced Tissue Sciences;
                    Treatment for partial-thickness and severe burns, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Diovan (valsartan); Ciba Pharmaceuticals;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"DynaCirc CR; Novartis;
                    Treatment for hypertension, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"EDEX; Schwarz Pharma;
                    Treatment for erectile dysfunction, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Effexor XR (venlafaxin HCI); Wyeth;
                    Treatment of depression, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Estradiol tablets; Barr Laboratories;
                    Generic equivalent of Estrace, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Estradiol tablets; Duramed Pharmaceuticals;
                    Generic equivalent of Estrace tablets, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Etodolac; Royce Laboratories;
                    Generic equivalent of Lodine, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Etodolac; Royce Laboratories;
                    Generic equivalent of  Lodine, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Treatment for the prevention of osteoporosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Femara (letrozole); Novartis;
                    Treatment for breast cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"FEMSTAT One; Roche;
                    Treatment for vaginal yeast infections, Approved Februrary 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"FLOMAX; Boehringer Ingelheim;
                    Treatment for benign prostatic hypertrophy (BPH), Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Flovent Rotadisk; GlaxoSmithKline;
                    Treatment of asthma in patients four and older, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Floxin otic; Daiichi Sankyo;
                    Treatment for otitis media, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Follistim (TM) (follitropin beta for injection); Organon;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Fortovase; Roche;
                    Treatment for HIV infection, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals;
                    Treatment for brain cancer, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Glipizide Tablets; Duramed Pharmaceuticals;
                    Treatment for diabetes, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gonal-F (follitropin alfa for injection); Serono Laboratories;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Imitrex (sumatriptan) injection and tablets; GlaxoSmithKline;
                    Treatment for migraine headaches, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Imitrex (sumatriptan) nasal spray; GlaxoSmithKline;
                    Treatment for migraine, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Interstim Continence Control Therapy; Medtronic;
                    Treatment for incontinence, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Klaron (sodium sulfacet amide lotion ) Lotion, 10%; Dermik Laboratories;
                    Treatment for adult acne, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lescol (fluvastatin sodium); Novartis;
                    Treatment for coronary atherosclerosis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lexxel (enalapril maleate-felodipine ER); Astra Merck;
                    Treatment for hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals;
                    Treatment for prostate cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"LUVOX  (fluvoxamine maleate); Solvay Pharmaceuticals, Pharmacia & Upjohn;
                    Treatment for obsessive compulsive disorder (OCD) in children and adolescents, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for athlete's foot, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Metaprotereol Sulfate Inhalation Solution, 5%; Morton Grove Pharmaceuticals;
                    Generic equivalent of Alupentr Inhalation Solution, 5%, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
                    Treatment for mild-to moderate hypertension, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Migranal; Novartis;
                    Treatment for migraine headaches, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Minoxidil Topical Solution 2% for Women; Alpharma;
                    Generic equivalent of Rogaine, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Mirapex; Pharmacia & Upjohn, Boehringer Ingelheim;
                    Treatment for Parkinsonâ€™s Disease, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"NORCO tablets (Hydrocodone Bitartrate/Acetaminophen 10 mg/325 mg); Watson Pharmaceuticals;
                    Treatment for moderate to moderately severe pain, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Norvir (ritonavir); Abbott Laboratories;
                    Treatment for HIV infection, Approved March 1996/March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol); Ortho-McNeil Pharmaceutical;
                    Treatment for acne in women seeking contraception, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pindolol; Teva Pharmaceutical;
                    Generic equivalent of  Visken, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
                    Treatment for cardiac atherosclerotic events, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Posicor; Roche;
                    Treatment for hypertension and chronic stable angina pectoris, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pramipexole; Pharmacia & Upjohn;
                    Treatment for Parkinson's Disease, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prandin; Novo Nordisk;
                    Treatment for Type II diabetes, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prevpac; TAP Pharmaceuticals;
                    Treatment for duodenal ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Propecia; Merck;
                    Treatment for male baldness, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Quadramet (Samarium Sm 153 Lexidronam Injection); DuPont Merck Pharmaceutical Company;
                    Treatment for pain associated with bone cancer, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ranitidine Capsules; Geneva Pharmaceuticals;
                    Generic equivalent of Zantac GELdose, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ranitidine Tablets; Apotex;
                    Generic equivalent of Zantac, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Raxar (grepafloxacin); GlaxoSmithKline;
                    Treatment for chronic bronchitis, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"REGRANEX (becaplermin) Gel; RW Johnson;
                    Treatment for diabetic foot ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
                    Generic equivalent of Pergonal, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Requip (ropinirole hydrochloride); SmithKline Beecham;
                    Treatment for Parkinson's Disease, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn;
                    Treatment for HIV-1 infection, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Retin-A Micro (tretinoin gel) microsphere, 0.1%; Advanced Polymer Systems;
                    Treatment for acne, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Selegiline tablets; Teva Pharmaceutical;
                    Generic equivalent of Eldepryl tablets, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Serevent; GlaxoSmithKline;
                    Treatment of asthma, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"SPORANOX (itraconazole); Janssen Pharmaceuticals;
                    Treatment for oral thrush, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Synvisc, Synvisc-One (Hylan GF 20); Genzyme;
                    For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tazorac topical gel; Allergan;
                    Treatment for Psoriasis, Acne Vulgaris, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Teveten (eprosartan mesylate); SmithKline Beecham;
                    Treatment for hypertension, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for mild to moderate asthma, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for mild-to-moderate bronchial asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tolmetin Sodium; Teva Pharmaceutical;
                    Treatment for arthritis, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Topamax (topiramate); Ortho-McNeil Pharmaceutical;
                    Treatment for partial onset seizures, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trazadone 150mg; Teva Pharmaceutical;
                    Generic equivalent of Desyrel 7, Approved  May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Trovan; Pfizer;
                    Treatment for bacterial infections, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vanceril 84 mcg Double Strength (beclomethasone dipropionate, 84 mcg) Inhalation Aerosol; Schering-Plough;
                    Treatment for asthma, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Verapamil; IVAX;
                    Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals;
                    Treatment for HIV infection in adults and children, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zagam (sparfloxacin) tablets; Rhone Poulenc Rorer;
                    Treatment for community-acquired pneumonia (CAP) and chronic bronchitis, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for infants and children infected with HIV, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zoloft (sertraline HCl); Pfizer;
                    Treatment for panic disorder, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zoloft (sertraline HCl); Pfizer;
                    Treatment of panic disorder in children ages 6-17, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zomig (zolmitriptan); AstraZeneca;
                    Treatment for migraine, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zyflo (Zileuton); Abbott Laboratories;
                    Treatment for asthma in patients 12 years and older, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Accolate; AstraZeneca;
                    Treatment for asthma, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Adderall (mixed salts of a single-entity amphetamine); Richwood Pharmaceutical;
                    Treatment for attention-deficit/hyperactivity disorder, Supplemental NDA Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Alphagan (brimonidine); Allergan;
                    Treatment for open-angle glaucoma and ocular hypertension, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Anexsia; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Apthasol (Amlexanox); Access Pharmaceuticals;
                    Treatment for canker sores, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Aredia (pamidronate disodium for injection); Chiron;
                    Treatment for osteolytic bone metastases of breast cancer, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"ARICEPT (donepezil hydrochloride); Eisai;
                    Treatment for Alzheimer's Disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Arimidex (anastrozole); AstraZeneca;
                    Treatment for advanced breast cancer in postmenopausal women, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Atrovent (ipratropium bromide); Boehringer Ingelheim;
                    Treatment for runny nose due to allergies and the common cold, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Augmentin (amoxicillin/clavulanate); SmithKline Beecham;
                    Treatment for infections involving drug-resistant bacteria, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Axid AR (nizatidine; Whitehall-Robins Healthcare;
                    Over-the-counter anti-ulcer treatment, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Azmacort (triamcinolone acetonide) Inhalation Aerosol; Rhone Poulenc Rorer;
                    Treatment for asthma, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn;
                    Treatment for rheumatoid arthritis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Campostar; Pharmacia & Upjohn;
                    Treatment for metastatic colorectal cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Carrington patch; Carrington Laboratories;
                    Treatment for canker sores, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"CEA-Scan; Immunomedics;
                    Diagnostic imaging product for colorectal cancer, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Children's Advil (pediatric ibuprofen); Whitehall-Robins Healthcare;
                    Treatment of fever and minor aches and pains, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Claritin Syrup (loratadine); Schering-Plough;
                    Treatment for children with seasonal allergies, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Confide; Johnson & Johnson;
                    HIV testing and counseling service, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Crixivan (Indinavir sulfate); Merck;
                    Treatment for HIV infection, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"DentiPatch (lidocaine transoral delivery system); Noven Pharmaceuticals;
                    Dental anesthetic patch, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for epilepsy, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for migraine headaches, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Differin (adapalene gel) Gel, 0.1%; Galderma Laboratories;
                    Treatment for acne, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Elmiron (pentosan polysulfate sodium); IVAX;
                    Treatment for interstitial cystitis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Eulexin (flutamide); Schering-Plough;
                    Treatment for prostate cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"FemPatch; Parke-Davis;
                    Treatment for menopausal symptoms, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Feridex I.V.; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of liver lesions, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Fertinex (urofollitropin for injection, purified); Serono Laboratories;
                    Treatment for patients undergoing infertility treatments, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer;
                    Treatment for mastocytosis, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"GastroMARK; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of the gastrointestinal tract, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for pancreatic cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Glyset (miglitol); Bayer;
                    Treatment for Type II (non-insulin-dependent) diabetes mellitus, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Humalog (insulin lispro); Eli Lilly;
                    Treatment for type I and type II diabetes, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Hycamtin (topotecan hydrochloride); SmithKline Beecham;
                    Treatment for metastatic ovarian cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Kadian; Purepac Pharmaceutical;
                    Treatment for chronic moderate to severe pain, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals;
                    Treatment for nail fungal infections, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for the replenishment of white blood cells, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lithobid (Lithium Carbonate); Solvay Pharmaceuticals;
                    Treatment for manic depression, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lodine (etodolac); Wyeth;
                    Treatment for rheumatoid arthritis, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Mavik (trandolapril); Knoll Pharmaceutical;
                    Treatment for hypertension, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Monistat 3 (miconazole nitrate); Johnson & Johnson;
                    Over the counter treatment for vaginal yeast infections, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Monurol; Forest Laboratories;
                    Treatment for uncomplicated urinary tract infection, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Muse; Vivus;
                    Treatment for impotence, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
                    Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ocuflox (ofloxacin opthalmic solution) 0.3%; Allergan;
                    Treatment for corneal ulcers, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"OcuHist; Pfizer;
                    Over-the-counter antihistamine eye drop, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Oral Cytovene; Roche;
                    Treatment for the prevention of cytomegalovirus (CMV), Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"OxyContin (oxycodone HCl controlled-release); Purdue Pharma;
                    Treatment for pain associated with musculoskeletal conditions, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Paxil (paroxetine hydrochloride); SmithKline Beecham;
                    Treatment for panic disorder, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Photodynamic Therapy; Sanofi-aventis;
                    Photodynamic therapy device for the treatment of esophageal cancer, Approved January, 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for heart disease, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for cholesterol-lowering, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prilosec (omeprazole); Astra Merck;
                    Treatment for heartburn, gastroesophageal reflux disease (GERD), Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prilosec (omeprazole); Astra Merck;
                    Treatment for gastric ulcers, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prilosec (omeprazole)/Biaxin (clarithromycin) Combination Therapy; Astra Merck, Abbott Laboratories;
                    Treatment for duodenal ulcers, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"ProAmatine (midodrine); Roberts Pharmaceutical;
                    Treatment for hypotension, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Procanbid (procainamide hydrochloride extended-release tablets); Warner-Lambert;
                    Treatment for ventricular arrhythmias, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Remeron (Mirtazapine); Organon;
                    Treatment for depression, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
                    Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Retavase (reteplase); Boehringer Mannheim Corporation;
                    Treatment for patients suffering from heart attack, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tavist (clemastine fumarate); Sandoz Pharmaceuticals;
                    Treatment for cold symptoms, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Taxotere (Docetaxel); Rhone Poulenc Rorer;
                    Treatment for locally advanced or metastatic breast cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
                    Treatment for hypertension, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tegretol (carbamazepine); Ciba Pharmaceuticals;
                    Treatment for young children with epilepsy, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tegretol XR (carbamazepine); Ciba-Geigy;
                    Anti-epileptic treatment, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Tiazac (diltiazem hydrochloride); Forest Laboratories;
                    Treatment for hypertension, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"UltraJect; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Videx (didanosine); Bristol-Myers Squibb;
                    Treatment of HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Viramune (nevirapine); Boehringer Ingelheim;
                    Treatment for HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vistide (cidofovir); Gilead;
                    Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vitrasert Implant; Chiron;
                    Drug delivery system for the treatment of cytomegalovirus, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Vivelle (estradiol transdermal system); Ciba Pharmaceuticals;
                    Treatment for moderate and severe vasomotor menopausal symptoms, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Amaryl (Glimepiride); Hoechst Marion Roussel;
                    Treatment for type II diabetes, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Avonex (Interferon Beta 1-A); Biogen IDEC;
                    Treatment for multiple sclerosis, Recommended for Approval in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Caverject (alprostadil); Upjohn;
                    Treatment for impotence, Approved on July 6, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Cedax (ceftibuten); Schering-Plough;
                    Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Clarithromycin (Biaxin); Abbott Laboratories;
                    Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Epivir (lamivudine); GlaxoSmithKline;
                    Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Ethyol (amifostine); Alza;
                    Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Femstat 3 (butoconazole nitrate 2%); Procter & Gamble, Roche;
                    Over the counter treatment for vaginal yeast infections, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Fosamax (alendronate sodium); Merck;
                    Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Intron A (Interferon alfa-2b, recombinant); Schering-Plough;
                    An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Invirase (saquinavir); Roche;
                    Treatment for HIV/AIDS, Approved on December 7, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
                    Treatment for post-menopausal osteoporosis, Approved on August 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Precose (acarbose); Bayer;
                    Treatment for non-insulin-dependent diabetes mellitus, Approved September 6, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
                    Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Prinivil or Zestril (Lisinopril); Merck, Zeneca;
                    Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Self-examination breast pad; Inventive Products;
                    Self-examination breast pad, Approved on December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Toprol-XL (metoprolol succinate); AstraZeneca;
                    For the treatment of hypertension, angina pectoris and heart failure, Approved January 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Western blot confirmatory device; Epitope;
                    Confirmatory test for HIV, Approved in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/23/family-medicine,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Aemcolo (rifamycin); Aries Pharmaceuticals;
                    For the treatment of traveler's diarrhea, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications;
                    For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Motegrity (prucalopride) ; Shire Pharmaceuticals;
                    For the treatment of chronic idiopathic constipation, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of MSI-H or dMMR metastatic colorectal cancer , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Xerava (eravacycline) ; Tetraphase Pharmaceuticals;
                    For the treatment of complicated intra-abdominal infections , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of PD-L1 expressing gastric or gastroesophageal junction adenocarcinoma, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Symproic (naldemedine); Shionogi;
                    For the treatment of opioid-induced constipation, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Trulance (plecanatide); Synergy Pharmaceuticals;
                    For the treatment of adults with chronic idiopathic constipation, Approved January 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Xermelo (telotristat ethyl); Lexicon Pharmaceuticals;
                    For the treatment of carcinoid syndrome diarrhea, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zinplava (bezlotoxumab); Merck;
                    For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Avycaz  (ceftazidime-avibactam); Actavis;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cholbam (cholic acid); Asklepion Pharmaceuticals;
                    For the treatment of bile acid synthesis and peroxisomal disorders, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Lonsurf (trifluridine and tipiracil); Taiho Oncology;
                    For the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Onivyde (irinotecan liposome injection); Merrimack;
                    For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Varubi (rolapitant); Tesaro;
                    For the prevention of delayed nausea and vomiting associated with chemotherapy, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Viberzi (eluxadoline); Actavis;
                    For the treatment of irritable bowel syndrome with diarrhea, Approved May 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of irritable bowel syndrome with diarrhea , Approved May 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Akynzeo (netupitant and palonosetron); Helsinn;
                    For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cyramza (ramucirumab); Eli Lilly;
                    For the treatment of gastric cancer, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Entyvio (vedolizumab); Millenium Pharmaceuticals;
                    For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Movantik (naloxegol); AstraZeneca;
                    For the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Simponi (golimumab); Janssen Biotech;
                    For the treatment of ulcerative colitis, Aproved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Stivarga (regorafenib); Bayer;
                    For the treatment of gastrointestinal stromal tumor, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Uceris (budesonide); Santarus;
                    For the treatment of ulcerative colitis, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Gattex (teduglutide); NPS Pharmaceuticals;
                    For the treatment of short bowel syndrome, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Linzess (linaclotide); Forest Labs and Ironwood Pharmaceuticals;
                    For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Mytesi (crofelemer); Napo Pharmaceuticals;
                    For the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals;
                    For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Viokace (pancrelipase) tablets; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Xtandi (enzalutamide); Medivation;
                    For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zaltrap (ziv-aflibercept); Sanofi-aventis;
                    For the treatment of metastatic colorectal cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Afinitor (everolimus); Novartis;
                    For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Dificid (fidaxomicin); Optimer Pharmaceuticals;
                    For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Duexis (ibuprofen and famotidine); Horizon Pharma;
                    For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Incivek (telaprevir); Vertex Pharmaceuticals;
                    For the treatment of genotype 1 chronic hepatitis C, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Rectiv (nitroglycerin) ointment 0.4%; ProStrakan;
                    For the treatment of chronic anal fissure, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Sutent (sunitinib malate); Pfizer;
                    For the treatment of pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Victrelis (boceprevir); Merck;
                    For the treatment of chronic hepatitis C genotype 1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Herceptin (trastuzumab); Genentech;
                    For the treatment of gastric cancer, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Pancreaze (pancrelipase); Johnson & Johnson;
                    For the treatment of exocrine pancreatic insufficiency, Approved April of 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Vimovo (naproxen + esomeprazole); AstraZeneca;
                    For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals;
                    For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Metozolv ODT (metoclopramide hydrochloride); Salix Pharmaceuticals;
                    For the treatment of gastroesophageal reflux and diabetic gastroparesis, Approved September of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Stelara (ustekinumab); Janssen Biotech;
                    For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zenpep (pancrelipase); Eurand;
                    For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of Crohnâ€™s disease, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Entereg (alvimopan); GlaxoSmithKline;
                    For the treatment of postoperative ileus, Approved May 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Rotarix (Rotavirus Vaccine, Live, Oral); GlaxoSmithKline;
                    For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Sancuso (granisetron); ProStrakan;
                    For the treatment of chemotherapy-induced nausea and vomiting, Approved September 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Tysabri (natalizumab); Biogen IDEC;
                    For the maintenance treatment of moderate to severe Crohnâ€™s disease, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Amitiza (lubiprostone); Sucampo/Takeda;
                    For the treatment of chronic idiopathic constipation, Approved January 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Tygacil (tigecycline); Wyeth;
                    For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Avastin (bevacizumab); Genentech;
                    For the treatment of metastatic carcinoma of the colon or rectum, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Erbitux (cetuximab); Imclone, Bristol-Myers Squibb;
                    For the treatment of EGFR-expressing, metastatic colorectal cancer, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Aloxi (palonosetron); MGI Pharma, Helsinn Healthcare;
                    For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, Approved August 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Emend (aprepitant); Merck;
                    For the treatment of nausea and vomiting associated with chemotherapy, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Oxytrol (oxybutynin transdermal system); Watson Pharmaceuticals;
                    For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency., Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Aciphex (rabeprazole sodium); Elan Pharmaceuticals;
                    For the treatment of symptomatic gastroesophageal reflux disease, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Alinia (nitazoxanide); Romark Laboratories;
                    For the treatment Diarrhea caused by Cryptosporidium and Giardia in children., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); Sanofi-aventis;
                    For the treatment of colon or rectum carcinomas, Approved August 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Gleevec (imatinib mesylate); Novartis;
                    For the treatment of gastrointestinal stromal tumors (GISTs), Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Hepsera (adefovir dipivoxil); Gilead;
                    For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Orfadin (nitisinone); Orphan Pharmaceuticals;
                    Capsules for the treatment of hereditary tyrosinemia type I, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Pegasys (peginterferon alfa-2a); Roche;
                    For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Protonix (pantoprazole sodium) Delayed Release Tablets; Wyeth;
                    Oral tablets for the treatment of gastroesophageal and pathological hypersecretory conditions, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"SecreFlo (secretin); Repligen;
                    To aid in the diagnosis of pancreatic dysfunction and gastrinoma, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zelnorm (tegaserod maleate) Tablets; Novartis;
                    For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation, Approved July 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Canasa (mesalamine); Axcan;
                    For the treatment of active ulcerative proctitis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Entocort EC (budesonide); AstraZeneca;
                    Capsules for the treatment of mild-to-moderate, active Crohn's disease, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Nexium (esomeprazole magnesium); AstraZeneca;
                    For the eradication of Helicobacter pylori, the healing of erosive esophagitis, and the treatment of symptomatic GERD, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Protonix (pantoprazole sodium) Intravenous Formulation; Wyeth;
                    For the short-term treatment of gastroesophageal reflux disease, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Rebetol (ribavirin); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Twinrix; GlaxoSmithKline;
                    For the prevention of hepatitis A and B, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Colazal (balsalazide disodium); Salix Pharmaceuticals;
                    Mild to moderately active ulcerative colitis, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Lotronex (alosetron HCL) Tablets; GlaxoSmithKline;
                    Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Pepcid Complete; Merck;
                    For use in the relief of heartburn associated with acid indigestion and sour stomach, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth;
                    For treatment of erosive esophagitis, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Visicol Tablet; Inkine Pharmaceutical;
                    For cleansing of the bowel as a preparation for colonoscopy, in adults 18 years of age and older, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prevpac; TAP Pharmaceuticals;
                    Treatment for eradication of H. pylori, Approved February 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cimetidine Hydrochloride Oral Solution; Pharmaceutical Formulations;
                    Generic equivalent of Tagamet HB 200, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"PREVACID(R) (lansopraxole); TAP Pharmaceuticals;
                    Treatment of heartburn associated with GERD, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prilosec (omeprazole); Astra Merck;
                    Treatment for heartburn, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Zantac 75 Efferdose; GlaxoSmithKline;
                    Treatment for heartburn, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Asacol (mesalamine); Procter & Gamble;
                    Treatment of ulcerative colitis, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cimetadine Hydrochloride Oral Solution 300mg/5ml; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tagamet Oral Solution, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cimetidine Hydrochloride Oral Solution; Hi-Tech Pharmacal;
                    Generic equivalent of Tagamet Oral Solution, 300 mg/5 ml, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prevpac; TAP Pharmaceuticals;
                    Treatment for duodenal ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prochloroperazine; Duramed Pharmaceuticals;
                    Generic equivalent of Compazine, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Ranitidine Capsules; Geneva Pharmaceuticals;
                    Generic equivalent of Zantac GELdose, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Ranitidine Tablets; Apotex;
                    Generic equivalent of Zantac, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Urso; Axcan;
                    Treatment for primary biliary cirrhosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Axid AR (nizatidine; Whitehall-Robins Healthcare;
                    Over-the-counter anti-ulcer treatment, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Cipro (ciprofloxacin) I.V. and Cipro (ciprofloxacin HCI) tablets; Bayer;
                    Treatment for complicated intra-abdominal infections, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"GastroMARK; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of the gastrointestinal tract, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Merrem I.V. (meropenem); AstraZeneca;
                    Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prilosec (omeprazole); Astra Merck;
                    Treatment for heartburn, gastroesophageal reflux disease (GERD), Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prilosec (omeprazole); Astra Merck;
                    Treatment for gastric ulcers, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Prilosec (omeprazole)/Biaxin (clarithromycin) Combination Therapy; Astra Merck, Abbott Laboratories;
                    Treatment for duodenal ulcers, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Seprafilm; Genzyme;
                    Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/5/gastroenterology,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk;
                    For the treatment of hemophilia A, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Crysvita (burosumab-twza) ; Ultragenyx;
                    For the treatment of X-linked hypophosphatemia, Approved April 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Galafold (migalastat); Amicus Therapeutics;
                    For the treatment of Fabry Disease, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Onpattro (patisiran); Alnylam Pharmaceuticals;
                    For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Revcovi (elapegademase-lvlr); Leadiant Biosciences;
                    For the treatment of adenosine deaminase severe combined immune deficiency, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Takhzyro (lanadelumab-flyo) ; Shire Pharmaceuticals;
                    For the prevention of hereditary angioedema attacks, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Tegsedi (inotersen); Ionis Pharmaceuticals;
                     For the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease," Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring;
                    For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Brineura (cerliponase alfa); BioMarin;
                    For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Mepsevii (vestronidase alfa-vjbk) ; Ultragenyx;
                    For the treatment of Mucopolysaccharidosis VII , Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Spinraza (nusinersen); Biogen;
                    For the treatment of spinal muscular atrophy, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kanuma (sebelipase alfa); Alexion;
                    For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Strensiq (asfotase alfa); Alexion;
                    For the treatment of hypophosphatasia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Xuriden (uridine triacetate); Wellstat Therapeutics;
                    For the treatment of hereditary orotic aciduria, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec;
                    For the treatment of hemophilia B, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Cerdelga (eliglustat); Genzyme;
                    For the treatment of certain adult patients with Gaucher disease type 1, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Qudexy XR (topiramate); Upsher-Smith Laboratories;
                    For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Vimizim (elosulfase alfa); BioMarin;
                    For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kineret, anakinra; Swedish Orphan Biovitrum;
                    For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kynamro (mipomersen sodium); Genzyme;
                    For the treatment of homozygous familial hypercholesterolemia, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics;
                    For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk;
                    For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Fycompa (perampanel); Eisai;
                    For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Juxtapid (lomitapide); Aegerion Pharmaceuticals;
                    For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kalydeco (ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis with the G551D mutation in the CFTR gene, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Oxtellar XR (oxcarbazepine extended release); Supernus Pharmaceuticals;
                    For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Ferriprox (deferiprone); Apotex;
                    For the treatment of transfusional iron overload due to thalassemia, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Onfi (clobazam); Lundbeck;
                    For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Potiga (ezogabine); Valeant Pharmaceuticals;
                    For the treatment of partial-onset seizures, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Cayston (aztreonam for inhalation solution); Gilead;
                    For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Vpriv (velaglucerase alfa for injection); Shire Pharmaceuticals;
                    For the treatment of type 1 Gaucher disease, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Berinert (C1 Esterase Inhibitor (Human)); CSL Behring;
                    For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kalbitor (ecallantide); Dyax;
                    For the treatment of hereditary angioedema, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Sabril (vigabatrin); Lundbeck;
                    For the treatment of infantile spasms and complex partial seizures, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Saphris (asenapine); Schering-Plough;
                    For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Zenpep (pancrelipase); Eurand;
                    For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Banzel (rufinamide); Elan Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Stavzor (valproic acid delayed release); Banner Pharmacaps;
                    For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Vimpat (lacosamide); Schwarz Pharma;
                    For the treatment of partial-onset seizures in adults with epilepsy, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Kogenate FS (Antihemophilic Factor Recombinant); Bayer;
                    For the treatment of hemophilia A, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    Treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Trileptal (oxcarbazepine) Tablets; Novartis;
                    Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Zonegran (zonisamide) Capsules; Dainippon Pharmaceutical;
                    Adjunctive therapy for treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Keppra; UCB;
                    Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Clonazepam; Watson Pharmaceuticals;
                    Generic equivalent of Klonopin, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Lamictal Chewable Dispersible Tablets; GlaxoSmithKline;
                    Treatment for Epilepsy, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"BeneFIX (coagulation Factor IX (recombinant)); Genetics Institute;
                    Treatment for hemophilia B, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Carbatrol; Elan Pharmaceuticals;
                    Treatment for epileptic seizures and trigeminal neuralgia, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Galzin (zinc acetate); Teva Pharmaceutical;
                    Treatment for Wilsonâ€™s disease, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Tobi; PathoGenesis;
                    Treatment for cystic fibrosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Topamax (topiramate); Ortho-McNeil Pharmaceutical;
                    Treatment for partial onset seizures, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"AlphaNine SD Coagulation Factor IX (Human); Alpha Therapeutic Corporation;
                    Treatment for the prevention and control of bleeding in subjects with hemophilia, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for epilepsy, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis patients with advanced disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Saizen; Ares-Serono;
                    Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Tegretol (carbamazepine); Ciba Pharmaceuticals;
                    Treatment for young children with epilepsy, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/34/genetic-disease,"Tegretol XR (carbamazepine); Ciba-Geigy;
                    Anti-epileptic treatment, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/21/healthy-volunteers,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/21/healthy-volunteers,"Flublok (seasonal influenza vaccine); Protein Sciences;
                    For the active immunization against influenza virus subtypes A and type B, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Cablivi (caplacizumab-yhdp); Ablynx;
                    For the treatment of acquired thrombotic thrombocytopenic purpura, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk;
                    For the treatment of hemophilia A, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola Pharmaceuticals;
                    for the reversal of factor Xa inhibitors, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Asparlas (calaspargase pegol-mknl ); Servier;
                    For the treatment of acute lymphoblastic leukemia in pediatrics and young adults, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Copiktra (duvelisib); Verastem;
                    For the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or follicular lymphoma, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Daurismo (glasdegib); Pfizer;
                    For the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Doptelet (avatrombopag) ; AkaRx;
                    For the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Elzonris (tagraxofusp-erzs); Stemline Therapeutics;
                    For the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatrics, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Jivi (antihemophilic factor [recombinant] PEGylated-aucl); Bayer;
                    For hemophilia A, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of primary mediastinal B-cell lymphoma, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Leukine (sargramostim); Partner Therapeutics;
                    For hematopoietic syndrome of acute radiation syndrome, Approved March 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Lokelma (sodium zirconium cyclosilicate); AstraZeneca;
                    For the treatment of hyperkalemia, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Lumoxiti (moxetumomab pasudotox-tdf); AstraZeneca;
                    For the treatment of  relapsed or refractory hairy cell leukemia, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Mulpleta (lusutrombopag); Shionogi;
                    For the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Palynziq (pegvaliase-pqpz) ; BioMarin;
                    For the treatment of phenylketonuria, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Poteligeo (mogamulizumab-kpkc); Kyowa Kirin;
                    For the treatment of mycosis fungoides or SÃ©zary syndrome , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals;
                    For the treatment of chronic immune thrombocytopenia, Approved April 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Tibsovo (ivosidenib); Agios Pharmaceuticals;
                    For the treatment of acute myeloid leukemia with a susceptible IDH1 mutation, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Ultomiris (ravulizumab-cwvz); Alexion Pharmaceuticals;
                    For the treatment of paroxysmal nocturnal hemoglobinuria , Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Xospata (gilteritinib) ; Astellas;
                    For the treatment of acute myeloid leukemia with a FLT3 mutation, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Aliqopa (copanlisib); Bayer;
                    For the treatment of follicular lymphoma , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Besponsa (inotuzumab ozogamicin); Pfizer;
                    For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Calquence (acalabrutinib); Acerta Pharmaceuticals;
                    For the treatment of mantle cell lymphoma , Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Endari (L-glutamine oral powder); Emmaus Life Sciences;
                    For the treatment of sickle cell disease , Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Giapreza (angiotensin II) ; La Jolla Pharmaceuticals;
                    For the treatment of septic shock, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Hemlibra (emicizumab-kxwh); Genentech;
                    For the prevention or reduction of bleeding episodes in patients with or without FVIII inhibitors, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"IDHIFA (enasidenib); Celgene;
                    For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of marginal zone lymphoma, Approved January 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of classical Hodgkin Lymphoma, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kymriah (tisagenlecleucel); Novartis;
                    For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk;
                    For the treatment of  hemophilia B, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Rydapt (midostaurin); Novartis;
                    For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma;
                    For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals;
                    For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring;
                    For the treatment of hemophillia A, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring;
                    For the treatment of hemophilia B, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ;
                    For the treatment of hemophillia A, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of classical Hodgkin lymphoma, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Venclexta (venetoclax); AbbVie;
                    For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Darzalex (daratumumab); Janssen Biotech;
                    For the treatment of multiple myeloma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Farydak (panobinostat); Novartis;
                    For the treatment of multiple myeloma, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of WaldenstrÃ¶mâ€™s macroglobulinemia, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Natpara (parathyroid hormone) ; NPS Pharmaceuticals;
                    For the control hypocalcemia in patients with hypoparathyroidism, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Nuwiq (recombinant Factor VIII); Octapharma;
                    For the prophylaxis and treatment of hemophilia A, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Praxbind (idarucizumab); Boehringer Ingelheim;
                    For the reversal of the anticoagulant effects of dabigatran, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Veltassa (patiromer); Relypsa;
                    For the treatment of hyperkalemia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec;
                    For the treatment of hemophilia B, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Beleodaq (belinostat); Spectrum Pharmaceuticals;
                    For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Blincyto (blinatumomab); Amgen;
                    For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion  Protein] ; Biogen IDEC.;
                    For the treatment of hemophillia A, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]; Baxter;
                    For the treatment of acquired hemophilia A, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Ruconest (C1 esterase inhibitor [recombinant]); Pharming Group;
                    For the treatment of hereditary  angioedema, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Sylvant (siltuximab); Janssen Biotech;
                    For the treatment of multicentric Castlemanâ€™s disease, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Zontivity (vorapaxar); Merck;
                    For the reduction of thrombotic cardiovascular events, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Zydelig (idelalisib); Gilead;
                    For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Gazyva (obinutuzumab); Genentech;
                    For the treatment of previously untreated chronic lymphocytic leukemia, Approved October of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of mantle cell lymphoma, Approved November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Injectafer (ferric carboxymaltose injection); Luitpold Pharmaceuticals;
                    For the treatment of iron deficiency anemia, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kcentra (Prothrombin Complex Concentrate); CSL Behring;
                    For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Nymalize (nimodipine); Arbor Pharmaceuticals;
                    For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Pomalyst (pomalidomide); Celgene;
                    For the treatment of relapsed and refractory multiple myeloma, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics;
                    For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Revlimid (lenalidomide); Celgene;
                    For the treatment of mantle cell lymphoma, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Rixubis (Coagulation Factor IX (Recombinant)]; Baxter International;
                    For the routine prophylaxis and control of hemophilia B, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk;
                    For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Valchlor (mechlorethamine) gel; Ceptaris Therapeutics;
                    For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Bosulif (bosutinib); Pfizer;
                    For the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Iclusig (ponatinib); Ariad Pharmaceuticals;
                    For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kyprolis (carfilzomib); Onyx Pharmaceuticals;
                    For the treatment of multiple myeloma, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics;
                    For the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Neutroval (tbo-filgrastim); Teva Pharmaceutical;
                    For the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Omontys (peginesatide); Affymax;
                    For the treatment of anemia due to chronic kidney disease, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Synribo (omacetaxine mepesuccinate); Teva Pharmaceutical;
                    For the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Adcetris (brentuximab vedotin); Seattle Genetics;
                    For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, Approved August 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Erwinaze (asparaginase Erwinia chrysanthemi); Eusa Pharma;
                    For the treatment of acute lymphoblastic leukemia, Approved November of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Ferriprox (deferiprone); Apotex;
                    For the treatment of transfusional iron overload due to thalassemia, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Jakafi (ruxolitinib); Incyte;
                    For the treatment of myelofibrosis, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Xarelto (rivaroxaban); Janssen Pharmaceuticals;
                    For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of chronic lymphocytic leukemia, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Vpriv (velaglucerase alfa for injection); Shire Pharmaceuticals;
                    For the treatment of type 1 Gaucher disease, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Arzerra (ofatumumab); GlaxoSmithKline;
                    For the treatment of chronic lymphocytic leukemia, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
                    For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Efient (prasugrel); Eli Lilly;
                    for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Elitek (rasburicase); sanofi-aventis;
                    For the management of plasma uric acid levels in adults with malignancies, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Feraheme (ferumoxytol); AMAG;
                    For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Folotyn (pralatrexate injection); Allos Therapeutics;
                    For the treatment of peripheral T-cell lymphoma, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Istodax (romidepsin); Gloucester Pharmaceuticals;
                    For the treatment of cutaneous T-cell lymphoma, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Samsca (tolvaptan); Otsuka;
                    For the treatment of hyponatremia, Approved May of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human); Octapharma;
                    For the treatment of von Willebrand disease, Approved December of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Mozobil (plerixafor injection); Genzyme;
                    For the treatment of non-Hodgkinâ€™s lymphoma and multiple myeloma, Approved December 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Nplate (romiplostim); Amgen;
                    For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Promacta (eltrombopag); GlaxoSmithKline;
                    For the treatment of thrombocytopenia, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kuvan (sapropterin dihydrochloride); BioMarin Pharmaceuticals;
                    For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria, Approved December 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Mircera (methoxy polyethylene glycol-epoetin beta); Roche;
                    For the treatment of anemia associated with chronic renal failure, Approved November 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Soliris (eculizumab); Alexion;
                    For the treatment of PNH, aHUS and generalized Myasthenia Gravis , Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Dacogen (decitabine); MGI Pharma;
                    For the treatment of both treatment-naÃ¯ve and -experienced Myelodysplastic Syndromes, Approved May 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Revlimid (lenalidomide); Celgene;
                    For the treatment of low- and intermediate-1-risk myelodysplastic syndromes, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Vidaza (azacitidine); Pharmion Corporation;
                    For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias, Approved May 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Bexxar; Corixa;
                    For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved  June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Levitra (vardenafil); Bayer, GlaxoSmithKline;
                    For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
                    For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Neulasta; Amgen;
                    Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Arixtra; Organon, Sanofi-Synthelabo;
                    Injectable solution for the prevention of deep vein thrombosis, Approved December 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham;
                    Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company;
                    For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Kogenate FS (Antihemophilic Factor Recombinant); Bayer;
                    For the treatment of hemophilia A, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Renagel (sevelamer hydrochloride); Genzyme;
                    For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Venofer (iron sucrose injection); Luitpold Pharmaceuticals;
                    For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Aggrenox; Boehringer Ingelheim;
                    Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Busulflex; Orphan Medical;
                    For use in combination for the treatment of leukemia, Approved February 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Ferrlecit; R&D; Laboratories;
                    For the treatment of iron deficiency anemia., Approved February 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Fragmin; Pharmacia & Upjohn;
                    Treatment of prophylaxis of deep vein thrombosis (DVT), Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
                    Treatment for acute deep vein thrombosis, Approved January 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Actonel; Procter & Gamble, Hoechst Marion Roussel;
                    Treatment for Paget's Disease, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Droxia; Bristol-Myers Squibb;
                    Treatment for sickle-cell anemia, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Glucagon; Eli Lilly;
                    Treatment for severe Hypoglycemia, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
                    Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Neupogen; Amgen;
                    Treatment for slow white blood cell recovery following chemotherapy, Approval April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Refludan; Hoechst Marion Roussel;
                    Treatment of heparin-induced thrombocytopenia type II, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Agrylin (anagrelide HCL); Roberts Pharmaceutical;
                    Treatment for thrombocythemia, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"BeneFIX (coagulation Factor IX (recombinant)); Genetics Institute;
                    Treatment for hemophilia B, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Glyburide Tablets; Roche;
                    Treatment for blood-glucose lowering, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Glyburide Tablets; Mova Pharmaceutical;
                    Generic version of Glynase PresTab, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
                    Treatment for deep vein thrombosis, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Neumega; Genetics Institute;
                    Treatment for thrombocytopenia, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Rituxan (rituximab) ; Biogen IDEC, Genentech;
                    For the treatment of Non-Hodgkin's lymphoma, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"AlphaNine SD Coagulation Factor IX (Human); Alpha Therapeutic Corporation;
                    Treatment for the prevention and control of bleeding in subjects with hemophilia, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer;
                    Treatment for mastocytosis, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for the replenishment of white blood cells, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Pravachol (pravastatin sodium); Bristol-Myers Squibb;
                    Treatment for cholesterol-lowering, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Egaten (triclabendazole); Novartis;
                    For the treatment of fascioliasis (liver fluke infestation), Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Keytruda (pembrolizumab); Merck;
                    For the treatment of hepatocellular carcinoma, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Lenvima (lenvatinib); Eisai;
                    For the treatment of unresectable hepatocellular carcinoma, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Mulpleta (lusutrombopag); Shionogi;
                    For the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax;
                    For the prevention of hepatitis B virus infection, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Mavyret (glecaprevir and pibrentasvir) ; AbbVie;
                    For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of hepatocellular carcinoma , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead;
                    For the treatment of hepatitis C, Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Defitelio (defibrotide sodium); Jazz Pharmaceuticals;
                    For the treatment of hepatic veno-occlusive disease  with renal or pulmonary dysfunction following HSCT, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Ocaliva (obeticholic acid); Intercept Pharmaceuticals;
                    For the treatment of primary biliary cholangitis, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Vemlidy (tenofovir alafenamide); Gilead Sciences;
                    For the treatment of chronic hepatitis B , Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Zepatier (elbasvir and grazoprevir); Merck;
                    For the treatment of  chronic HCV genotypes 1 or 4 , Approved January 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Cholbam (cholic acid); Asklepion Pharmaceuticals;
                    For the treatment of bile acid synthesis and peroxisomal disorders, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Daklinza (daclatasvir) ; Bristol-Myers Squibb;
                    For the treatment of chronic HCV genotype 3, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Technivie, (ombitasvir, paritaprevir and ritonavir); Abbvie;
                    For the treatment of chronic HCV genotype 4, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Olysio (simeprevir); Janssen Therapeutics;
                    For the treatment of hepatitis C, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Sovaldi (sofosbuvir); Gilead Sciences;
                    For the treatment of hepatitis C, December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Inlyta (axitinib); Pfizer;
                    For the treatment of advanced renal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Kalydeco (ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis with the G551D mutation in the CFTR gene, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Viokace (pancrelipase) tablets; Aptalis Pharma;
                    For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Duexis (ibuprofen and famotidine); Horizon Pharma;
                    For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Incivek (telaprevir); Vertex Pharmaceuticals;
                    For the treatment of genotype 1 chronic hepatitis C, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Victrelis (boceprevir); Merck;
                    For the treatment of chronic hepatitis C genotype 1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Cayston (aztreonam for inhalation solution); Gilead;
                    For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Afinitor (everolimus); Novartis;
                    For the treatment of renal cell carcinoma, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Avastin (bevacizumab); Genentech;
                    For the treatment of renal cell carcinoma, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of renal cell carcinoma, Approved October of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Zenpep (pancrelipase); Eurand;
                    For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Viread (tenofovir disoproxil fumarate); Gilead;
                    For the treatment of hepatitis B, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Torisel (temsirolimus); Wyeth;
                    For the treatment of renal cell carcinoma, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Tyzeka (telbivudine); Idenix Pharma;
                    For the treatment of hepatitis B virus, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Baraclude (entecavir); Bristol-Myers Squibb;
                    For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Nexavar (sorafenib); Bayer/Onyx;
                    For the Treatment of Renal Cell Carcinoma, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli, Approved May 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Hepsera (adefovir dipivoxil); Gilead;
                    For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Pediarix Vaccine; GlaxoSmithKline;
                    For the prevention of diphtheria, tetanus, pertussi, polio and  hepatitis  B in children 6 weeks to 7 years old., Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Pegasys (peginterferon alfa-2a); Roche;
                    For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Protonix (pantoprazole sodium) Delayed Release Tablets; Wyeth;
                    Oral tablets for the treatment of gastroesophageal and pathological hypersecretory conditions, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Peg-Intron (peginterferon alfa-2b); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Rebetol (ribavirin); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Twinrix; GlaxoSmithKline;
                    For the prevention of hepatitis A and B, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"REBETRON (TM) Combination Therapy; Schering-Plough;
                    Treatment for Chronic Hepatitis C, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Cimetadine Hydrochloride Oral Solution 300mg/5ml; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tagamet Oral Solution, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Galzin (zinc acetate); Teva Pharmaceutical;
                    Treatment for Wilsonâ€™s disease, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"INFERGEN (interferon alfacon-1); Amgen;
                    Treatment for chronic hepatitis C virus, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Intron A (interferon alfa-2b, recombinant); Schering-Plough;
                    Treatment for hepatitis C, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Tobi; PathoGenesis;
                    Treatment for cystic fibrosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Feridex I.V.; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of liver lesions, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Havrix; SmithKline Beecham;
                    Treatment for hepatitis A, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Prilosec (omeprazole); Astra Merck;
                    Treatment for gastric ulcers, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis patients with advanced disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/24/hepatology-liver-pancreatic-gall-bladder,"Zithromax (azithromycin); Pfizer;
                    Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Asceniv (Immune Globulin Intravenous, Human â€“ slra 10% Liquid); ADMA Biologics;
                    For the treatment of Primary Humoral Immunodeficiency Disease , Approved April 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Gamifant (emapalumab-lzsg); NovImmune;
                    For the treatment of primary hemophagocytic lymphohistiocytosis, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals;
                    For the treatment of plaque psoriasis , Approved March 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Revcovi (elapegademase-lvlr); Leadiant Biosciences;
                    For the treatment of adenosine deaminase severe combined immune deficiency, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of Pemphigus Vulgaris , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Takhzyro (lanadelumab-flyo) ; Shire Pharmaceuticals;
                    For the prevention of hereditary angioedema attacks, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals;
                    For the treatment of chronic immune thrombocytopenia, Approved April 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ultomiris (ravulizumab-cwvz); Alexion Pharmaceuticals;
                    For the treatment of paroxysmal nocturnal hemoglobinuria , Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Xofluza (baloxavir marboxil); Shionogi;
                    For the treatment of acute uncomplicated influenza , Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Yupelri (revefenacin); Theravance Biopharma;
                    For the maintenance treatment of chronic obstructive pulmonary disease, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology," Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring;
                    For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Actemra (tocilizumab) injection; Genentech;
                    For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ocrevus (ocrelizumab); Genentech;
                    For the treatment of multiple sclerosis, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tremfya (guselkumab); Janssen Biotech;
                    For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead;
                    For the treatment of hepatitis C, Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zerviate (cetirizine ophthalmic solution 0.24%); NicOx;
                    For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring;
                    For the treatment of hemophillia A, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Descovy (emtricitabine and tenofovir alafenamide); Gilead;
                    For the treatment of HIV-1 infection, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences;
                    For the treatment of hepatitis C, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences;
                    For the treatment of HIV-1 as initial therapy, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Taltz (ixekizumab); Eli Lilly;
                    For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
                    For active immunization against Cholera, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cosentyx (secukinumab); Novartis;
                    For the treatment of plaque psoriasis, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Envarsus XR (tacrolimus extended-release); Veloxis;
                    For the prophylaxis of organ rejection in kidney transplant patients , Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Evotaz (atazanavir and cobicistat) ; Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide); Gilead Sciences;
                    For the treatment of HIV-1 infection, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Orkambi (lumacaftor and ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Prezcobix (darunavir and cobicistat); Janssen;
                    For the treatment of HIV-1 infection, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Entyvio (vedolizumab); Millenium Pharmaceuticals;
                    For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Grastek (Timothy Grass Pollen Allergen Extract); Merck;
                    For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant  Human Hyaluronidase]; Baxter;
                    For the treatment of Primary Immunodeficiency, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Incruse Ellipta (umeclidinium inhalation powder); GlaxoSmithKline;
                    For the treatment of chronic obstructive pulmonary disease, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Myalept (metreleptin for injection); Bristol-Myers Squibb;
                    For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Otezla (apremilast); Celgene;
                    For the treatment of adults with active psoriatic arthritis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Otezla (apremilast); Celgene;
                    For the treatment of moderate to severe plaque psoriasis, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Plegridy (peginterferon beta-1a); Biogen IDEC.;
                    For the treatment of relapsing multiple sclerosis, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ragwitek (Short Ragweed Pollen Allergen Extract); Merck;
                    For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Sylvant (siltuximab); Janssen Biotech;
                    For the treatment of multicentric Castlemanâ€™s disease, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Triumeq (abacavir, dolutegravir, and lamivudine); ViiV HealthCare;
                    For the treatment of HIV-1, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active psoriatic arthritis, Approved September 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active ankylosing spondylitis , Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Flublok (seasonal influenza vaccine); Protein Sciences;
                    For the active immunization against influenza virus subtypes A and type B, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Kineret, anakinra; Swedish Orphan Biovitrum;
                    For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Simponi (golimumab); Janssen Biotech;
                    For the treatment of ulcerative colitis, Aproved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Sitavig (acyclovir) buccal tablets; BioAlliance Pharma;
                    For the treatment of recurrent herpes labialis in adults, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tecfidera (dimethyl fumarate); Biogen Idec;
                    For the treatment of relapsing multiple sclerosis, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tivicay (dolutegravir); ViiV HealthCare;
                    For the treatment of HIV-1 in adults and children over 12 years of age, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"VariZIG, Varicella Zoster Immune Globulin (Human); Cangene;
                    For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Flucelvax, Influenza Virus Vaccine; Novartis;
                    For the treatment of influenza virus subtypes A and type B, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of postherpetic neuralgia, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Mytesi (crofelemer); Napo Pharmaceuticals;
                    For the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 infection, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories;
                    For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Arcapta (indacaterol maleate inhalation powder); Novartis;
                    For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Benlysta (belimumab); Human Genome Sciences;
                    For the treatment of systemic lupus erythematosus, Approved March 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Daliresp (roflumilast); Forest Pharmaceuticals;
                    For the treatment of chronic obstructive pulmonary disease, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Dificid (fidaxomicin); Optimer Pharmaceuticals;
                    For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Edurant (rilpivirine); Tibotec;
                    For the treatment of HIV-1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Firazyr (icatibant); Shire Pharmaceuticals;
                    For the treatment of acute attacks of hereditary angioedema, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Gralise (gabapentin); Abbott Laboratories;
                    For the treatment of postherpetic neuralgia, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Incivek (telaprevir); Vertex Pharmaceuticals;
                    For the treatment of genotype 1 chronic hepatitis C, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Nulojix (belatacept); Bristol-Myers Squibb;
                    For the prevention of organ rejection following kidney transplant, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of Wegenerâ€™s Granulomatosis and Microscopic Polyangiitis , Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Victrelis (boceprevir); Merck;
                    For the treatment of chronic hepatitis C genotype 1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cayston (aztreonam for inhalation solution); Gilead;
                    For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Egrifta (tesamorelin for injection); Theratechnologies;
                    For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Menveo (meningitis vaccine); Novartis;
                    For the active immunization to prevent invasive meningococcal disease, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Oravig (miconazole); Strativa Pharmaceuticals;
                    oropharyngeal candidiasis, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine); Wyeth;
                    For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zortress (everolimus); Novartis;
                    For the prevention of organ rejection following kidney transplant, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zymaxid (gatifloxacin ophthalmic solution); Allergan;
                    For the treatment of bacterial conjunctivitis, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals;
                    For the treatment of itching associated with allergic conjunctivitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Berinert (C1 Esterase Inhibitor (Human)); CSL Behring;
                    For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb;
                    For the treatment of bacterial conjunctivitis, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
                    For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline;
                    For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ilaris (canakinumab); Novartis;
                    For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Valneva;
                    For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Kalbitor (ecallantide); Dyax;
                    For the treatment of hereditary angioedema, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Qutenza (capsaicin); NeurogesX;
                    For the treatment of neuropathic pain associated with postherpetic neuralgia, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vibativ (telavancin); Theravance;
                    For the treatment of complicated skin and skin structure infections, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics;
                    For the treatment of acute herpetic keratitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the treatment of HIV, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cinryze (C1 Inhibitor (Human)); Lev Pharmaceuticals;
                    For the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Intelence (etravirine); Tibotec;
                    For the treatment of HIV-1, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals;
                    For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rotarix (Rotavirus Vaccine, Live, Oral); GlaxoSmithKline;
                    For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tysabri (natalizumab); Biogen IDEC;
                    For the maintenance treatment of moderate to severe Crohnâ€™s disease, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Viread (tenofovir disoproxil fumarate); Gilead;
                    For the treatment of hepatitis B, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Altabax (retapamulin); GlaxoSmithKline;
                    For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"AzaSite (azithromycin); InSite Vision;
                    For the treatment of bacterial conjunctivitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Doribax (doripenem); Johnson & Johnson;
                    For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Extina (ketoconazole); Stiefel;
                    For the treatment of seborrheic dermatitis, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Isentress (raltegravir); Merck;
                    For the treatment of HIV-1, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Selzentry (maraviroc); Pfizer;
                    For the treatment of CCR5-tropic HIV-1, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Veramyst (fluticasone furoate); GlaxoSmithKline;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Eraxis (anidulafungin); Pfizer;
                    For the treatment of fungal infections, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck;
                    For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Noxafil (posaconazole); Schering-Plough;
                    For the treatment of fungal infections, Approved in September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Prezista (darunavir); Tibotec;
                    For the treatment of treatment-resistant HIV infections, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rotateq (rotavirus vaccine, live oral pentavalent); Merck;
                    For the prevention of gastroenteritis associated with rotavirus infections in infants, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tyzeka (telbivudine); Idenix Pharma;
                    For the treatment of hepatitis B virus, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Veregen (kunecatechins); Medigene;
                    For the treatment of external genital and perianal warts, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the adjunctive treatment of HIV-1 infections, Approved June, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Baraclude (entecavir); Bristol-Myers Squibb;
                    For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tygacil (tigecycline); Wyeth;
                    For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Ketek (telithromycin); Sanofi-aventis;
                    For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia., Approved April 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli, Approved May 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Amevive (alefacept); Biogen IDEC;
                    For moderate to severe chronic plaque psoriasis., Approved January 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"FluMist ( Influenza Virus Vaccine); MedImmune;
                    For the prevention of disease caused by influenza A and B viruses, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Fuzeon (enfuvirtide); Trimeris, Roche;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Lexiva (fosamprenavir calcium); GlaxoSmithKline;
                    For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Alinia (nitazoxanide); Romark Laboratories;
                    For the treatment Diarrhea caused by Cryptosporidium and Giardia in children., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Clarinex; Schering-Plough;
                    Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Daptacel; Sanofi Pasteur;
                    Pediatric vaccine for immunization against diptheria, tetanus and pertussis, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Fluzone Preservative-free; Sanofi Pasteur;
                    Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Hepsera (adefovir dipivoxil); Gilead;
                    For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Pediarix Vaccine; GlaxoSmithKline;
                    For the prevention of diphtheria, tetanus, pertussi, polio and  hepatitis  B in children 6 weeks to 7 years old., Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Pegasys (peginterferon alfa-2a); Roche;
                    For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Restasis (cyclosporine ophthalmic emulsion); Allergan;
                    For the treatment of low tear production., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Sustiva; Bristol-Myers Squibb;
                    Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vfend (voriconazole); Pfizer;
                    For the treatment of fungal infections, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Avelox I.V. (moxifloxacin hydrochloride); Bayer;
                    For adults with susceptible strains of bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cancidas; Merck;
                    For the treatment of invasive aspergillosis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Peg-Intron (peginterferon alfa-2b); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rebetol (ribavirin); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Spectracef; TAP Pharmaceuticals;
                    Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Twinrix; GlaxoSmithKline;
                    For the prevention of hepatitis A and B, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Valcyte (valganciclovir HCl); Roche;
                    For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Viread (tenofovir disoproxil fumarate); Gilead;
                    Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Xigris (drotrecogin alfa [activated]); Eli Lilly;
                    For the treatment of severe sepsis, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Abreva (docosanol); Avanir Pharmaceuticals;
                    For the treatment of herpes simplex, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories;
                    For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Children's Motrin Cold; McNeil Consumer Products;
                    For temporary relief of the common cold, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Evoxac; SnowBrand Pharmaceuticals;
                    For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome, Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Kaletra Capsules and Oral Solution; Abbott Laboratories;
                    For the treatment of HIV-1 infection, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
                    For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough;
                    For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Malarone (atovaquone; proguanil hydrochloride) Tablet; GlaxoSmithKline;
                    For the treatment and prevention of Plasmodium falciparum malaria, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rapamune (sirolimus) Tablets; Wyeth;
                    For treatment of kidney rejection, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rid Mousse; Soltec Research;
                    For the treatment of head, pubic (crab), and body lice, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
                    For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Trivagizole 3 (clotrimazole) Vaginal Cream; Taro Pharmaceuticals;
                    For the treatment of vaginal yeast infections, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline;
                    For the treatment of HIV-1 infection, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Agenerase  (amprenavir); GlaxoSmithKline;
                    For the treatment of HIV-1 infection., Approved April 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
                    Treatment for bacterial vaginosis, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Famvir (famciclovir); SmithKline Beecham;
                    Treatment for Herpes Simplex Infections in HIV-infected patients, Approved January 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Norvir (ritonavir); Abbott Laboratories;
                    Treatment for HIV infection, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Panretin Gel; Ligand Pharmaceuticals;
                    Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma., Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rapamune (sirolimus) oral solution; Wyeth;
                    Oral solution of sirolimus, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Relenza; GlaxoSmithKline;
                    Treatment for uncomplicated acute illness due to influenza virus, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Synercid I.V.; Rhone Poulenc Rorer;
                    quinupristin and dalfopristin for injection, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Tamiflu  capsule; Roche;
                    Oseltamivir phosphate capsule, October 27, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vistide (cidofovir); Gilead;
                    For the treatment of cytomegalovirus (CMV) retinitis, Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Allegra-D; Hoechst Marion Roussel;
                    Treatment for nasal congestion due to seasonal allergy, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"CellCept; Roche;
                    Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Clemastine fumarate syrup; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tavist Syrup, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
                    Treatment for bacterial vaginosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Dynabac; Sanofi-aventis;
                    Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"REBETRON (TM) Combination Therapy; Schering-Plough;
                    Treatment for Chronic Hepatitis C, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Simulect; Novartis;
                    Treatment for acute organ transplant rejection, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Timentin; SmithKline Beecham;
                    Treatment for wide range of infections in children, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Viroptic; King Pharmaceuticals;
                    Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology," INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham;
                    Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Acyclovir Capsules; Teva Pharmaceutical;
                    Generic equivalent of Zovirax, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Aldara (imiquimod); 3M Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Aphthasol; Block Drug Company;
                    Treatment for canker sores, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Combivir; GlaxoSmithKline;
                    Treatment for AIDS and HIV Infection, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Famvir (famciclovir); SmithKline Beecham;
                    Treatment for genital herpes, Approved September 17, 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Flagyl ER; Searle;
                    Treatment for bacterial vaginosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Flonase Nasal Spray; GlaxoSmithKline;
                    Treatment for seasonal and perennial allergic rhinitis, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Fortovase; Roche;
                    Treatment for HIV infection, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"INFERGEN (interferon alfacon-1); Amgen;
                    Treatment for chronic hepatitis C virus, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Intron A (interferon alfa-2b, recombinant); Schering-Plough;
                    Treatment for hepatitis C, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Norvir (ritonavir); Abbott Laboratories;
                    Treatment for HIV infection, Approved March 1996/March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn;
                    Treatment for HIV-1 infection, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"SPORANOX (itraconazole); Janssen Pharmaceuticals;
                    Treatment for oral thrush, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Stromectol (ivermectin); Merck;
                    Treatment for nondisseminated intestinal threadworm, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Taxol; Bristol-Myers Squibb;
                    Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Trovan; Pfizer;
                    Treatment for bacterial infections, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals;
                    Treatment for HIV infection in adults and children, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for infants and children infected with HIV, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Apthasol (Amlexanox); Access Pharmaceuticals;
                    Treatment for canker sores, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Carrington patch; Carrington Laboratories;
                    Treatment for canker sores, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Confide; Johnson & Johnson;
                    HIV testing and counseling service, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Crixivan (Indinavir sulfate); Merck;
                    Treatment for HIV infection, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer;
                    Treatment for mastocytosis, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Havrix; SmithKline Beecham;
                    Treatment for hepatitis A, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals;
                    Treatment for nail fungal infections, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for the replenishment of white blood cells, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Oral Cytovene; Roche;
                    Treatment for the prevention of cytomegalovirus (CMV), Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
                    Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Videx (didanosine); Bristol-Myers Squibb;
                    Treatment of HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Viramune (nevirapine); Boehringer Ingelheim;
                    Treatment for HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vistide (cidofovir); Gilead;
                    Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Vitrasert Implant; Chiron;
                    Drug delivery system for the treatment of cytomegalovirus, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zithromax (azithromycin); Pfizer;
                    Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Cedax (ceftibuten); Schering-Plough;
                    Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Clarithromycin (Biaxin); Abbott Laboratories;
                    Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Epivir (lamivudine); GlaxoSmithKline;
                    Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Intron A (Interferon alfa-2b, recombinant); Schering-Plough;
                    An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Invirase (saquinavir); Roche;
                    Treatment for HIV/AIDS, Approved on December 7, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Valtrex (valacyclovir HCl); GlaxoSmithKline;
                    Treatment for recurrent genital herpes, Approved  December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Western blot confirmatory device; Epitope;
                    Confirmatory test for HIV, Approved in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/7/immunology,"Zyrtec (cetirizine HCl); Pfizer;
                    Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Egaten (triclabendazole); Novartis;
                    For the treatment of fascioliasis (liver fluke infestation), Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Aemcolo (rifamycin); Aries Pharmaceuticals;
                    For the treatment of traveler's diarrhea, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Gilead;
                    For the treatment of HIV-1 infection in adults, Approved February 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) ; Merck;
                    For the treatment of HIV-1 infection, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Krintafel (tafenoquine) ; GlaxoSmithKline;
                    For the prevention of malaria relapse in patients receiving appropriate antimalarial therapy , Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Moxidectin; Medicines Development for Global Health;
                    For the treatment of onchocerciasis (river blindness) , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Nuzyra (omadacycline) ; Paratek Pharmaceuticals;
                    For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Pifeltro (doravirine) ; Merck;
                    For the treatment of HIV-1 infection, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide); Janssen Therapeutics;
                    For the treatment of HIV-1 infection, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tpoxx (tecovirimat); Siga Technologies;
                    For the treatment of smallpox , Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Trogarzo (ibalizumab-uiyk); TaiMed Biologics;
                    For the treatment of multidrug resistant HIV-1 infection, Approved March 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vaxelis (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b); Merck;
                    For the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xerava (eravacycline) ; Tetraphase Pharmaceuticals;
                    For the treatment of complicated intra-abdominal infections , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xofluza (baloxavir marboxil); Shionogi;
                    For the treatment of acute uncomplicated influenza , Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zemdri (plazomicin); Achaogen;
                    For the treatment of complicated urinary tract infections , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics;
                    For the treatment of acute bacterial skin and skin structure infections, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Benznidazole; Chemo Group;
                    For the treatment of Chagas disease , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Giapreza (angiotensin II) ; La Jolla Pharmaceuticals;
                    For the treatment of septic shock, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax;
                    For the prevention of hepatitis B virus infection, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of chronic graft-versus-host disease, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Juluca (dolutegravir and rilpivirine); ViiV Healthcare;
                    For the treatment of HIV-1 infection in adults, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"KedRab [Rabies Immune Globulin (Human)]; Kedrion Biopharma ;
                    For the post-exposure prophylaxis of rabies infection, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Mavyret (glecaprevir and pibrentasvir) ; AbbVie;
                    For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Prevymis (letermovir) ; Merck;
                    For the prevention of cytomegalovirus following allogenic hematopoietic stem cell transplant, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline;
                    For the prevention of herpes zoster (shingles), Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Solosec (secnidazole) ; Symbiomix Therapeutics;
                    For the treatment of bacterial vaginosis , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vabomere (meropenem and vaborbactam); The Medicines Company;
                    For the treatment of complicated urinary tract infections , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xepi (ozenoxacin) ; Medimetriks;
                    For the treatment of impetigo, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Anthim (obiltoxaximab); Elusys Therapeutics;
                    For the treatment of inhalational anthrax , Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Descovy (emtricitabine and tenofovir alafenamide); Gilead;
                    For the treatment of HIV-1 infection, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences;
                    For the treatment of hepatitis C, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences;
                    For the treatment of HIV-1 as initial therapy, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Syndros (dronabinol oral solution); Insys Therapeutics;
                    For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
                    For active immunization against Cholera, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vemlidy (tenofovir alafenamide); Gilead Sciences;
                    For the treatment of chronic hepatitis B , Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zepatier (elbasvir and grazoprevir); Merck;
                    For the treatment of  chronic HCV genotypes 1 or 4 , Approved January 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zinplava (bezlotoxumab); Merck;
                    For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Avycaz  (ceftazidime-avibactam); Actavis;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Bexsero (Meningococcal Group B Vaccine); Novartis;
                    For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Cresemba (isavuconazonium sulfate) ; Astellas;
                    For the treatment of invasive aspergillosis and invasive mucormycosis, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Daklinza (daclatasvir) ; Bristol-Myers Squibb;
                    For the treatment of chronic HCV genotype 3, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Evotaz (atazanavir and cobicistat) ; Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Fluad (trivalent influenza vaccine); Seqirus;
                    For the prevention of influenza A and B, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide); Gilead Sciences;
                    For the treatment of HIV-1 infection, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Prezcobix (darunavir and cobicistat); Janssen;
                    For the treatment of HIV-1 infection, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Technivie, (ombitasvir, paritaprevir and ritonavir); Abbvie;
                    For the treatment of chronic HCV genotype 4, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Dalvance (dalbavancin); Durata Therapeutics;
                    For the treatment of acute bacterial skin and skin structure infections, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Harvoni (ledipasvir and sofosbuvir); Gilead;
                    For the treatment of hepatitis C, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Impavido (miltefosine); Knight Therapeutics;
                    For the treatment of visceral, cutaneous and mucosal leishmaniasis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals;
                    For the treatment of onychomycosis of the toenails, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Kerydin (tavaborole); Anacor;
                    For the treatment of onychomycosis of the toenails, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Metronidazole 1.3% Vaginal Gel; Actavis, Inc.;
                    For the treatment of bacterial vaginosis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Orbactiv (oritavancin); The Medicines Company;
                    For the treatment of acute bacterial skin and skin structure  infections, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Rapivab (peramivir injection); Biocryst;
                    For the treatment of acute uncomplicated influenza in adults, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals;
                    For the treatment of acute bacterial skin and skin structure  infections, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Triumeq (abacavir, dolutegravir, and lamivudine); ViiV HealthCare;
                    For the treatment of HIV-1, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets; Abbvie;
                    For the treatment of  genotype 1 chronic hepatitis C virus, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xtoro (finafloxacin otic suspension) 0.3%; Alcon;
                    For the treatment of acute otitis externa, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Flublok (seasonal influenza vaccine); Protein Sciences;
                    For the active immunization against influenza virus subtypes A and type B, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals;
                    For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Olysio (simeprevir); Janssen Therapeutics;
                    For the treatment of hepatitis C, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sitavig (acyclovir) buccal tablets; BioAlliance Pharma;
                    For the treatment of recurrent herpes labialis in adults, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sovaldi (sofosbuvir); Gilead Sciences;
                    For the treatment of hepatitis C, December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"VariZIG, Varicella Zoster Immune Globulin (Human); Cangene;
                    For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vibativ (telavancin); Theravance;
                    For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Abthrax (raxibacumab); GlaxoSmithKline;
                    For the treatment and prevention of anthrax, Approved December of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Afinitor (everolimus); Novartis;
                    For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals;
                    For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc;
                    For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Flucelvax, Influenza Virus Vaccine; Novartis;
                    For the treatment of influenza virus subtypes A and type B, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Jetrea (ocriplasmin); Thrombogenics;
                    For the treatment of symptomatic vitreomacular adhesion, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Linzess (linaclotide); Forest Labs and Ironwood Pharmaceuticals;
                    For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Mytesi (crofelemer); Napo Pharmaceuticals;
                    For the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sirturo (bedaquiline); Janssen Therapeutics;
                    For the treatment of multi-drug resistant tuberculosis, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sklice (ivermectin) lotion; Sanofi Pasteur;
                    For the treatment of head lice, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 infection, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories;
                    For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Afinitor (everolimus); Novartis;
                    For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead;
                    For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Dificid (fidaxomicin); Optimer Pharmaceuticals;
                    For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Edurant (rilpivirine); Tibotec;
                    For the treatment of HIV-1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Firazyr (icatibant); Shire Pharmaceuticals;
                    For the treatment of acute attacks of hereditary angioedema, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Gralise (gabapentin); Abbott Laboratories;
                    For the treatment of postherpetic neuralgia, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Incivek (telaprevir); Vertex Pharmaceuticals;
                    For the treatment of genotype 1 chronic hepatitis C, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Victrelis (boceprevir); Merck;
                    For the treatment of chronic hepatitis C genotype 1, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Egrifta (tesamorelin for injection); Theratechnologies;
                    For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Menveo (meningitis vaccine); Novartis;
                    For the active immunization to prevent invasive meningococcal disease, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zymaxid (gatifloxacin ophthalmic solution); Allergan;
                    For the treatment of bacterial conjunctivitis, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Afinitor (everolimus); Novartis;
                    For the treatment of renal cell carcinoma, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals;
                    For the treatment of itching associated with allergic conjunctivitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Coartem (artemether/lumefantrine); Novartis;
                    For the treatment of malaria infections due to Plasmodium falciparum, Approved April 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline;
                    For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Valneva;
                    For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vibativ (telavancin); Theravance;
                    For the treatment of complicated skin and skin structure infections, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the treatment of HIV, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Intelence (etravirine); Tibotec;
                    For the treatment of HIV-1, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Patanase (olopatadine hydrochloride); Alcon;
                    For the treatment of seasonal allergic rhinitis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Viread (tenofovir disoproxil fumarate); Gilead;
                    For the treatment of hepatitis B, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Isentress (raltegravir); Merck;
                    For the treatment of HIV-1, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Selzentry (maraviroc); Pfizer;
                    For the treatment of CCR5-tropic HIV-1, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Veramyst (fluticasone furoate); GlaxoSmithKline;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Eraxis (anidulafungin); Pfizer;
                    For the treatment of fungal infections, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Noxafil (posaconazole); Schering-Plough;
                    For the treatment of fungal infections, Approved in September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Prezista (darunavir); Tibotec;
                    For the treatment of treatment-resistant HIV infections, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tyzeka (telbivudine); Idenix Pharma;
                    For the treatment of hepatitis B virus, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Veregen (kunecatechins); Medigene;
                    For the treatment of external genital and perianal warts, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the adjunctive treatment of HIV-1 infections, Approved June, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Baraclude (entecavir); Bristol-Myers Squibb;
                    For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tindamax, tinidazole; Presutti Laboratories;
                    For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis, Approved May, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"FluMist ( Influenza Virus Vaccine); MedImmune;
                    For the prevention of disease caused by influenza A and B viruses, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Fuzeon (enfuvirtide); Trimeris, Roche;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lexiva (fosamprenavir calcium); GlaxoSmithKline;
                    For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
                    For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Botox Cosmetic (botulinum toxin type A); Allergan;
                    For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Clarinex; Schering-Plough;
                    Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Hepsera (adefovir dipivoxil); Gilead;
                    For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Pediarix Vaccine; GlaxoSmithKline;
                    For the prevention of diphtheria, tetanus, pertussi, polio and  hepatitis  B in children 6 weeks to 7 years old., Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Pegasys (peginterferon alfa-2a); Roche;
                    For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Sustiva; Bristol-Myers Squibb;
                    Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vfend (voriconazole); Pfizer;
                    For the treatment of fungal infections, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zelnorm (tegaserod maleate) Tablets; Novartis;
                    For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation, Approved July 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Avelox I.V. (moxifloxacin hydrochloride); Bayer;
                    For adults with susceptible strains of bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Cancidas; Merck;
                    For the treatment of invasive aspergillosis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lamisil Solution, 1%; Novartis;
                    Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"NasalCrom Nasal Spray; Pharmacia & Upjohn;
                    Over-the-counter nasal spray for treatment of all nasal allergy symptoms, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Peg-Intron (peginterferon alfa-2b); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Rebetol (ribavirin); Schering-Plough;
                    For the treatment of chronic hepatitis C, Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Spectracef; TAP Pharmaceuticals;
                    Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tavist (clemastine fumarate); Novartis;
                    Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Twinrix; GlaxoSmithKline;
                    For the prevention of hepatitis A and B, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Valcyte (valganciclovir HCl); Roche;
                    For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Viread (tenofovir disoproxil fumarate); Gilead;
                    Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Xigris (drotrecogin alfa [activated]); Eli Lilly;
                    For the treatment of severe sepsis, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Abreva (docosanol); Avanir Pharmaceuticals;
                    For the treatment of herpes simplex, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Children's Motrin Cold; McNeil Consumer Products;
                    For temporary relief of the common cold, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Kaletra Capsules and Oral Solution; Abbott Laboratories;
                    For the treatment of HIV-1 infection, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
                    For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough;
                    For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lotronex (alosetron HCL) Tablets; GlaxoSmithKline;
                    Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
                    For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline;
                    For the treatment of HIV-1 infection, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Nasonex Nasal Spray; Schering-Plough;
                    Treatment of seasonal allergic rhinitis, Approved January 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Rhinocort Aqua Nasal Spray; AstraZeneca;
                    A nasal spray containing budesonide, Approved October 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Synercid I.V.; Rhone Poulenc Rorer;
                    quinupristin and dalfopristin for injection, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tamiflu  capsule; Roche;
                    Oseltamivir phosphate capsule, October 27, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Allegra-D; Hoechst Marion Roussel;
                    Treatment for nasal congestion due to seasonal allergy, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Clemastine fumarate syrup; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tavist Syrup, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"REBETRON (TM) Combination Therapy; Schering-Plough;
                    Treatment for Chronic Hepatitis C, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Synagis; MedImmune;
                    Treatment for the prevention of serious lower respiratory tract disease in infants, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Viroptic; King Pharmaceuticals;
                    Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Aldara (imiquimod); 3M Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Bactroban Cream; SmithKline Beecham;
                    Treatment for secondarily infected traumatic skin lesions, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Ceftin (cefuroxime axetil); GlaxoSmithKline;
                    Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet); Schering-Plough;
                    Treatment for seasonal allergy symptoms, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Combivir; GlaxoSmithKline;
                    Treatment for AIDS and HIV Infection, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Famvir (famciclovir); SmithKline Beecham;
                    Treatment for genital herpes, Approved September 17, 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Flonase Nasal Spray; GlaxoSmithKline;
                    Treatment for seasonal and perennial allergic rhinitis, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Floxin otic; Daiichi Sankyo;
                    Treatment for otitis media, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Fortovase; Roche;
                    Treatment for HIV infection, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"INFERGEN (interferon alfacon-1); Amgen;
                    Treatment for chronic hepatitis C virus, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Intron A (interferon alfa-2b, recombinant); Schering-Plough;
                    Treatment for hepatitis C, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for athlete's foot, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus), Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Norvir (ritonavir); Abbott Laboratories;
                    Treatment for HIV infection, Approved March 1996/March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn;
                    Treatment for HIV-1 infection, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Taxol; Bristol-Myers Squibb;
                    Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Timentin; SmithKline Beecham;
                    Treatment for septicemia, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Trovan; Pfizer;
                    Treatment for bacterial infections, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals;
                    Treatment for HIV infection in adults and children, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for infants and children infected with HIV, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"AK-Con-A (naphazoline ophthalmic); Akorn;
                    Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Albenza (albendazole); SmithKline Beecham;
                    Treatment for parasitic infections caused by worms, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Allegra (fexofenadine hydrochloride); Hoechst Marion Roussel;
                    Treatment for seasonal allergy symptoms, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Astelin nasal spray; Wallace Laboratories;
                    Treatment for seasonal allergic rhinitis, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Atrovent (ipratropium bromide); Boehringer Ingelheim;
                    Treatment for runny nose due to allergies and the common cold, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Augmentin (amoxicillin/clavulanate); SmithKline Beecham;
                    Treatment for infections involving drug-resistant bacteria, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Children's Advil (pediatric ibuprofen); Whitehall-Robins Healthcare;
                    Treatment of fever and minor aches and pains, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Confide; Johnson & Johnson;
                    HIV testing and counseling service, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Crixivan (Indinavir sulfate); Merck;
                    Treatment for HIV infection, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Elmiron (pentosan polysulfate sodium); IVAX;
                    Treatment for interstitial cystitis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Havrix; SmithKline Beecham;
                    Treatment for hepatitis A, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"IvyBlock; EnviroDerm Pharmaceuticals;
                    Treatment for poison ivy, poison oak, and poison sumac, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals;
                    Treatment for nail fungal infections, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for the replenishment of white blood cells, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Merrem I.V. (meropenem); AstraZeneca;
                    Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Nasacort AQ (triamcinolone acetonide) Nasal Spray; Rhone Poulenc Rorer;
                    Treatment for allergic rhinitis, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"OcuHist; Pfizer;
                    Over-the-counter antihistamine eye drop, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
                    Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Tavist (clemastine fumarate); Sandoz Pharmaceuticals;
                    Treatment for cold symptoms, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Vancenase AQ 84 mcg Double Strength; Schering-Plough;
                    Treatment for allergic and non-allergic rhinitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Videx (didanosine); Bristol-Myers Squibb;
                    Treatment of HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Viramune (nevirapine); Boehringer Ingelheim;
                    Treatment for HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zithromax (azithromycin); Pfizer;
                    Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Cedax (ceftibuten); Schering-Plough;
                    Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Clarithromycin (Biaxin); Abbott Laboratories;
                    Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Epivir (lamivudine); GlaxoSmithKline;
                    Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Invirase (saquinavir); Roche;
                    Treatment for HIV/AIDS, Approved on December 7, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Valtrex (valacyclovir HCl); GlaxoSmithKline;
                    Treatment for recurrent genital herpes, Approved  December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Western blot confirmatory device; Epitope;
                    Confirmatory test for HIV, Approved in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases,"Zyrtec (cetirizine HCl); Pfizer;
                    Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/26/internal-medicine,"Tegsedi (inotersen); Ionis Pharmaceuticals;
                     For the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/26/internal-medicine,"Duzallo (lesinurad and allopurinol) ; Ardea Biosciences;
                    For the treatment of hyperuricemia associated with gout , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/26/internal-medicine,"Cerdelga (eliglustat); Genzyme;
                    For the treatment of certain adult patients with Gaucher disease type 1, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Mavenclad (cladribine) ; Merck;
                    For the treatment of relapsing multiple sclerosis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Mayzent (siponimod); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Crysvita (burosumab-twza) ; Ultragenyx;
                    For the treatment of X-linked hypophosphatemia, Approved April 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Firdapse  (amifampridine) ; Catalyst Pharmaceuticals;
                    For the treatment of Lambert-Eaton myasthenic syndrome , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Olumiant (baricitinib); Eli Lilly;
                    For the treatment of moderate to severe rheumatoid arthritis with inadequete response to TNF antagonist therapies, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Brineura (cerliponase alfa); BioMarin;
                    For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Duzallo (lesinurad and allopurinol) ; Ardea Biosciences;
                    For the treatment of hyperuricemia associated with gout , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Emflaza (deflazacort); Marathon Pharmaceuticals;
                    For the treatment of Duchenne muscular dystrophy, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Kevzara (sarilumab); Sanofi ;
                    For the treatment of active rheumatoid arthritis, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Ocrevus (ocrelizumab); Genentech;
                    For the treatment of multiple sclerosis, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Tymlos (abaloparatide) ; Radius Health;
                    For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics;
                    For the treatment of osteoarthritis knee pain, Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Exondys 51 (eteplirsen); Sarepta Therapeutics;
                    For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Spinraza (nusinersen); Biogen;
                    For the treatment of spinal muscular atrophy, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Zinbryta (daclizumab) ; Biogen;
                    For the treatment of relapsing multiple sclerosis, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Vivlodex (meloxicam) ; Iroko Pharmaceuticals;
                    For the management of osteoarthritis pain, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Lemtrada (alemtuzumab); Genzyme;
                    For the treatment of relapsing multiple sclerosis, Approved November 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Otezla (apremilast); Celgene;
                    For the treatment of adults with active psoriatic arthritis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Plegridy (peginterferon beta-1a); Biogen IDEC.;
                    For the treatment of relapsing multiple sclerosis, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets; Purdue Pharma;
                    For the management of severe chronic pain, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Vimizim (elosulfase alfa); BioMarin;
                    For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Actemra (ocilizumab); Genentech;
                    For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active psoriatic arthritis, Approved September 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active ankylosing spondylitis , Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Duavee (conjugated estrogens/bazedoxifene); Pfizer;
                    For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Ilaris (canakinumab); Novartis;
                    For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Tecfidera (dimethyl fumarate); Biogen Idec;
                    For the treatment of relapsing multiple sclerosis, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Aubagio (teriflunomide); Sanofi Aventis;
                    For the treatment of multiple sclerosis, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Elelyso (taliglucerase alfa); Pfizer;
                    For the treatment of Gaucher disease, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Lyrica (pregabalin); Pfizer;
                    For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Myrbetriq (mirabegron); Astellas Pharma US, Inc;
                    For the treatment of overactive bladder, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Neupro (Rotigotine Transdermal System); UCB;
                    For the treatment of Restless Legs Syndrome, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Stendra (avanafil); Vivus;
                    For the treatment of erectile dysfunction, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of soft tissue sarcoma, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Xeljanz (tofacitinib); Pfizer;
                    For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Actemra (tocilizumab); Genentech;
                    For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Duexis (ibuprofen and famotidine); Horizon Pharma;
                    For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Actemra (tocilizumab); Genentech;
                    For the treatment of rheumatoid arthritis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Ampyra (dalfampridine); Acorda;
                    For the improvement of walking in patients with multiple sclerosis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Botox (onabotulinumtoxinA); Allergan;
                    For the treatment of upper limb spasticity, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Gilenya (fingolimod); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved September 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Krystexxa (pegloticase); Savient Pharma;
                    For the treatment of chronic gout (hyperuricemia), Approved September 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Prolia (denosumab); Amgen;
                    For the treatment of osteoporosis and bone loss in men and women, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Vimovo (naproxen + esomeprazole); AstraZeneca;
                    For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Xeomin (incobotulinumtoxinA); Merz Pharmaceutical;
                    For the treatment of cervical dystonia and blepharospasm, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Xgeva (denosumab); Amgen;
                    For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Xiaflex (collagenase clostridium histolyticum); Auxilium Pharmaceuticals;
                    For the treatment of Dupuytrenâ€™s contracture, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of rheumatoid arthritis, Approved May of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Colcrys (colchicine); Mutual Pharmaceuticals;
                    For gout flares and familial Mediterranean fever, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Extavia (Interferon beta-l b); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Pennsaid (diclofenac sodium topical solution); Nuvo Research;
                    For the treatment of osteoarthritis of the knee, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Sabril (vigabatrin); Lundbeck;
                    For the treatment of infantile spasms and complex partial seizures, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Savella (milnacipran hydrochloride); Forest Laboratories;
                    For the treatment of fibromyalgia, Approved January 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Simponi (golimumab); Centocor Ortho Biotech;
                    For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Orencia (abatacept); Bristol-Myers Squibb;
                    For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Xenazine (tetrabenazine); Prestwick Pharma;
                    For the treatment of chorea due to Huntington's disease, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
                    For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Evista (raloxifene hydrochloride); Eli Lilly;
                    For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Reclast (zoledronic acid); Novartis;
                    For the treatment of Paget's disease, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Reclast (zoledronic acid); Novartis;
                    For the treatment of postmenopausal osteoporosis, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Soliris (eculizumab); Alexion;
                    For the treatment of PNH, aHUS and generalized Myasthenia Gravis , Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
                    For the treatment of acromegaly, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of moderately-to severely-active rheumatoid arthritis, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Boniva (ibandronate); Roche / GlaxoSmithKline;
                    For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Naglazyme (galsulfase); BioMarin Pharmaceuticals;
                    For the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), Approved May 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Vioxx (rofecoxib); Merck;
                    For the treatment of rheumatoid arthritis, Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Aldurazyme (laronidase); Genzyme;
                    For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Premarin (conjugated estrogens); Wyeth;
                    For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Somavert (pegvisomant); Pharmacia & Upjohn;
                    Injectable formulation for the treatment of acromegaly, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Velcade (bortezomib); Millennium Pharmaceuticals;
                    Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Alora; Watson Pharmaceuticals;
                    Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Avinza (morphine sulfate); Elan Pharmaceuticals;
                    Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Forteo (teriparatide); Eli Lilly;
                    For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Remicade (infliximab); Centocor Ortho Biotech;
                    Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Testim; Auxilium Pharmaceuticals;
                    External cream for the treatment of male hormone deficiency., Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Vivelle-Dot (estradiol transdermal system); Novartis;
                    For the prevention of post-menopausal osteoporosis, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Genotropin (somatropin) injection; Pharmacia & Upjohn;
                    For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Kineret; Amgen;
                    Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Supartz; Smith & Nephew Orthopaedics;
                    Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
                    Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Mobic (meloxicam) Tablets; Boehringer Ingelheim;
                    For relief of the signs and symptoms of osteoarthritis, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Myobloc; Elan Pharmaceuticals;
                    Injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Osteoporosis treatment, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Femhrt Tablets; Parke-Davis;
                    Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Actonel; Procter & Gamble, Hoechst Marion Roussel;
                    Treatment for Paget's Disease, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Estratab (.3 mg ); Solvay Pharmaceuticals;
                    Treatment for the prevention of osteoporosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Etodolac; Faulding;
                    Generic equivalent of Lodine 500 mg tablets, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Lodine XL (etodolac); Wyeth;
                    Treatment for arthritis, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
                    Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Arthrotec; Searle;
                    Treatment for arthritis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Atracurium Besylate Injection; Faulding;
                    Generic equivalent of Tracrium, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Estradiol tablets; Barr Laboratories;
                    Generic equivalent of Estrace, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Etodolac; Royce Laboratories;
                    Generic equivalent of Lodine, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Treatment for the prevention of osteoporosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Ketoprofen; Schein Pharmaceutical;
                    Generic equivalent or Oruvail, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Skelid (tiludronate disodium); Sanofi-aventis;
                    Treatment for Pagetâ€™s disease of bone, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Synvisc, Synvisc-One (Hylan GF 20); Genzyme;
                    For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Tolmetin Sodium; Teva Pharmaceutical;
                    Treatment for arthritis, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Kadian; Purepac Pharmaceutical;
                    Treatment for chronic moderate to severe pain, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
                    Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"OxyContin (oxycodone HCl controlled-release); Purdue Pharma;
                    Treatment for pain associated with musculoskeletal conditions, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Saizen; Ares-Serono;
                    Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Seprafilm; Genzyme;
                    Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Zanaflex (tizanidine hydrochloride); Elan Pharmaceuticals;
                    Treatment for muscle spasticity, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Fosamax (alendronate sodium); Merck;
                    Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
                    Treatment for post-menopausal osteoporosis, Approved on August 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/8/musculoskeletal,"Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
                    Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Jynarque (tolvaptan); Otsuka America;
                    For the treatment of autosomal dominant polycystic kidney disease, Approved April 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Parsabiv (etelcalcetide); Amgen;
                    For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Cabometyx (cabozantinib); Exelixis;
                    For the treatment of advanced renal cell carcinoma, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Lenvima (lenvatinib); Eisai;
                    For the treatment of advanced renal cell carcinoma, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Rayaldee (calcifediol) ; Opko Health;
                    For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Envarsus XR (tacrolimus extended-release); Veloxis;
                    For the prophylaxis of organ rejection in kidney transplant patients , Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of advanced renal cell carcinoma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Zurampic (lesinurad); AstraZeneca;
                    For the treatment of hyperuricemia associated with gout , Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Auryxia (Ferric citrate); Keryx Biopharma;
                    For the treatment of hyperphosphatemia in patients with chronic kidney disease, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Harvoni (ledipasvir and sofosbuvir); Gilead;
                    For the treatment of hepatitis C, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets; Abbvie;
                    For the treatment of  genotype 1 chronic hepatitis C virus, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Injectafer (ferric carboxymaltose injection); Luitpold Pharmaceuticals;
                    For the treatment of iron deficiency anemia, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Procysbi (cysteamine bitartrate); Raptor Pharmaceuticals;
                    For the management of nephropathic cystinosis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Afinitor (everolimus); Novartis;
                    For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Inlyta (axitinib); Pfizer;
                    For the treatment of advanced renal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Myrbetriq (mirabegron); Astellas Pharma US, Inc;
                    For the treatment of overactive bladder, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Omontys (peginesatide); Affymax;
                    For the treatment of anemia due to chronic kidney disease, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Stendra (avanafil); Vivus;
                    For the treatment of erectile dysfunction, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals;
                    For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Voraxaze (glucarpidase); BTG International;
                    For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Anturol (oxybutynin) Gel; Antares Pharma;
                    For the treatment of overactive bladder, Approved December 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Nulojix (belatacept); Bristol-Myers Squibb;
                    For the prevention of organ rejection following kidney transplant, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Carbaglu (carglumic acid); Recordati;
                    For the treatment of hyperammonemia, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Jalyn (dutasteride + tamsulosin); GlaxoSmithKline;
                    For the treatment of benign prostatic hyperplasia, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Jevtana (cabazitaxel); sanofi aventis;
                    For the treatment of prostate cancer, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Provenge (sipuleucel-T); Dendreon;
                    For the treatment of hormone refractory prostate cancer, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of hepatic encephalopathy, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Zortress (everolimus); Novartis;
                    For the prevention of organ rejection following kidney transplant, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Afinitor (everolimus); Novartis;
                    For the treatment of renal cell carcinoma, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Avastin (bevacizumab); Genentech;
                    For the treatment of renal cell carcinoma, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Feraheme (ferumoxytol); AMAG;
                    For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Gelnique (oxybutynin chloride); Watson Pharmaceuticals;
                    For the treatment of overactive bladder, Approved January 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of renal cell carcinoma, Approved October of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Degarelix (degarelix for injection); Ferring Pharmaceuticals;
                    For the treatment of prostate cancer, Approved December of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Toviaz (fesoterodine fumarate); Pfizer;
                    For the treatment of overactive bladder, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Doribax (doripenem); Johnson & Johnson;
                    For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Mircera (methoxy polyethylene glycol-epoetin beta); Roche;
                    For the treatment of anemia associated with chronic renal failure, Approved November 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Renvela (sevelamer carbonate); Genzyme;
                    For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Soliris (eculizumab); Alexion;
                    For the treatment of PNH, aHUS and generalized Myasthenia Gravis , Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Torisel (temsirolimus); Wyeth;
                    For the treatment of renal cell carcinoma, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Vaprisol (conivaptan); Astellas Pharma US, Inc;
                    For the treatment of euvolemic hyponatremia, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Fosrenol, lanthanum carbonate; Shire Pharmaceuticals;
                    For the treatment of hyperphosphatemia related to kidney dysfunction, Approved October, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Sanctura (trospium chloride); Indevus Pharmaceuticals;
                    For the treatment of overactive bladder with symptoms of urge urinary incontinence, Approved May, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Sensipar (cinacalcet); Amgen;
                    For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients, Approved March 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Vesicare (solifenacin succinate); Yamanouchi, GlaxoSmithKline;
                    For the treatment of overactive bladder with symptoms of urge urinary incontinence, Approved November, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Fabrazyme (agalsidase beta); Genzyme;
                    For the treatment of Fabry disease in adult patients, Approved April 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Oxytrol (oxybutynin transdermal system); Watson Pharmaceuticals;
                    For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency., Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis;
                    For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Eligard (leuprolide acetate); Atrix Laboratories;
                    For the palliative treatment of advanced prostate cancer, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Mesnex; Bristol-Myers Squibb, Baxter Healthcare;
                    Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex (ifosfamide), Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Dutasteride; GlaxoSmithKline;
                    For the treatment of symptomatic benign prostatic hyperplasia, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"PhosLo; Braintree Laboratories;
                    Oral capsules and gelcaps for the control of hyperphosphatemia in end stage renal failure, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Trelstar LA (triptorelin pamoate); Debiopharm;
                    Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Detrol LA (tolterodine tartrate); Pharmacia & Upjohn;
                    For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Hectorol (Doxercalciferol) Injection; Bone Care International;
                    To reduce iPTH levels in management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Rapamune (sirolimus) Tablets; Wyeth;
                    For treatment of kidney rejection, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Renagel (sevelamer hydrochloride); GelTex Pharmaceuticals;
                    For the reduction of serum phosphorus in patients with end-stage renal disease (ESRD), Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Renagel (sevelamer hydrochloride); Genzyme;
                    For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
                    For the palliative treatment of advanced prostate cancer, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Venofer (iron sucrose injection); Luitpold Pharmaceuticals;
                    For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Viadur (leuprolide acetate implant); Alza;
                    For pain relief in men with advanced prostate cancer, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Ditropan XL (oxybutynin chloride); Alza;
                    Treatment for overactive bladder, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Levaquin; RW Johnson;
                    Treatment for urinary tract infection, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Tequin; Bristol-Myers Squibb;
                    Tequin (Injectable and Tablet), December, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Detrol (tolterodine tartrate); Pharmacia & Upjohn;
                    Treatment for an overactive bladder, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Ditropan XL (oxybutynin chloride); Alza;
                    Treatment for and Overactive Bladder, Approved December 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Proscar; Merck;
                    Treatment for complication relating to benign prostatic hyperplasia (BPH), Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"RenaGelRenagel (sevelamer hydrochloride); GelTex Pharmaceuticals;
                    Treatment for Renal Disease, Approved November 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Simulect; Novartis;
                    Treatment for acute organ transplant rejection, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Zemplar; Abbott Laboratories;
                    Treatment of secondary hyperparathyroidism associated with chronic renal failure, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"EDEX; Schwarz Pharma;
                    Treatment for erectile dysfunction, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"FLOMAX; Boehringer Ingelheim;
                    Treatment for benign prostatic hypertrophy (BPH), Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Interstim Continence Control Therapy; Medtronic;
                    Treatment for incontinence, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Prograf; Fujisawa Healthcare;
                    Treatment for the prevention of kidney transplant rejection, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Zenapax; Roche;
                    Treatment to prevent rejection of kidney transplants, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Cipro (ciprofloxacin HCl); Bayer;
                    Treatment for cystitis, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Elmiron (pentosan polysulfate sodium); IVAX;
                    Treatment for interstitial cystitis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Eulexin (flutamide); Schering-Plough;
                    Treatment for prostate cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for pancreatic cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Monurol; Forest Laboratories;
                    Treatment for uncomplicated urinary tract infection, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Seprafilm; Genzyme;
                    Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/9/nephrology,"Caverject (alprostadil); Upjohn;
                    Treatment for impotence, Approved on July 6, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Mavenclad (cladribine) ; Merck;
                    For the treatment of relapsing multiple sclerosis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Mayzent (siponimod); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Spravato (esketamine) nasal spray; Janssen Pharmaceuticals;
                    For the treatment of treatment-resistant depression in adults, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Sunosi (solriamfetol) ; Jazz Pharmaceuticals;
                    For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tosymra (sumatriptan) nasal spray; Dr. Reddy's Labs;
                    For the treatment of acute migraine in adults, Approved January 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Aimovig (erenumab-aooe) ; Amgen;
                    For the preventive treatment of migraine in adults , Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Ajovy (fremanezumab-vfrm); Teva Pharmaceuticals;
                    For the treatment of migraine, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Diacomit (stiripentol) ; Biocodex;
                    For the treatment of seizures associated with Dravet syndrome, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Dsuvia (sufentanil) ; AcelRx Pharma;
                    For the management of acute pain, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Emgality (galcanezumab-gnlm) ; Eli Lilly;
                    For the preventive treatment of migraine in adults , Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Epidiolex (cannabidiol); GW Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Firdapse  (amifampridine) ; Catalyst Pharmaceuticals;
                    For the treatment of Lambert-Eaton myasthenic syndrome , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Onpattro (patisiran); Alnylam Pharmaceuticals;
                    For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tegsedi (inotersen); Ionis Pharmaceuticals;
                     For the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Austedo (deutetrabenazine) ; Teva Pharmaceuticals;
                    For the treatment of chorea associated with Huntingtonâ€™s disease and tardive dyskinesia , Initial approval April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Brineura (cerliponase alfa); BioMarin;
                    For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Gocovri (amantadine) ; Adamas Pharmaceuticals;
                    For the treatment of Parkinson's disease dyskinesia, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Ingrezza (valbenazine); Neurocrine Biosciences;
                    For the treatment of tardive dyskinesia, Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Radicava (edaravone); Mitsubishi Tanabe Pharma;
                    For the treatment of amyotrophic lateral sclerosis , Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Xadago (safinamide); Newron Pharmaceuticals;
                    For the treatment of Parkinson's disease, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Briviact (brivaracetam); UCB;
                    For the treatment of partial onset seizures related to epilepsy, Approved February 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Carnexiv (carbamazepine); Lundbeck;
                     replacement therapy when oral administration is not feasible, in adults with seizures, Approved October 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Exondys 51 (eteplirsen); Sarepta Therapeutics;
                    For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nuplazid (pimavanserin); Acadia Pharmaceuticals;
                    For the treatment of hallucinations and delusions associated with Parkinsonâ€™s disease, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nuplazid (pimavanserin); Acadia Pharmaceuticals;
                    For the treatment of hallucinations and delusions associated with Parkinsonâ€™s disease psychosis, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Onzetra Xsail (sumatriptan nasal powder) ; Avanir;
                    For the treatment of migraine, Approved January 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Spinraza (nusinersen); Biogen;
                    For the treatment of spinal muscular atrophy, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Troxyca ER (oxycodone + naltrexone); Pfizer;
                    For the management of severe pain, Approved August 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zinbryta (daclizumab) ; Biogen;
                    For the treatment of relapsing multiple sclerosis, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Aristada (aripiprazole lauroxil) extended-release injectable; Alkermes;
                    For the treatment of schizophrenia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Belbuca (buprenorphine) ; Endo Pharmaceuticals;
                    For the management of severe pain, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Duopa (carbidopa and levodopa) enteral suspension ; Abbvie;
                    For the treatment of motor fluctuations in patients with advanced Parkinson's disease, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Rytary (carbidopa and levodopa) extended-release capsules; Impax Labs;
                    For the treatment of Parkinson's disease, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vivlodex (meloxicam) ; Iroko Pharmaceuticals;
                    For the management of osteoarthritis pain, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vraylar (cariprazine); Allergan;
                    For the treatment of schizophrenia and bipolar disorder, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Belsomra (suvorexant); Merck;
                    For the treatment of insomnia, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Dyloject (diclofenac sodium) Injection; Hospira;
                    For the management of mild, moderate or severe pain, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Hetlioz (tasimelteon); Vanda Pharmaceuticals;
                    For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lemtrada (alemtuzumab); Genzyme;
                    For the treatment of relapsing multiple sclerosis, Approved November 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Movantik (naloxegol); AstraZeneca;
                    For the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride); Forest Laboratories;
                    For the treatment of moderate to severe dementia of the Alzheimer's type, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Northera (droxidopa); Chelsea Therapeutics;
                    For the treatment of neurogenic orthostatic hypotension, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Plegridy (peginterferon beta-1a); Biogen IDEC.;
                    For the treatment of relapsing multiple sclerosis, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Qudexy XR (topiramate); Upsher-Smith Laboratories;
                    For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets; Purdue Pharma;
                    For the management of severe chronic pain, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tivorbex (indomethacin); Iroko Pharmaceuticals;
                    For the treatment of acute pain, Approved February of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release; Mallinckrodt Pharmaceuticals;
                    For the management of acute pain, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Aptiom (eslicarbazepine acetate); Sunovion Pharmaceuticals;
                    For the adjunctive treatment of partial-onset seizures, Approved November 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Fetzima (levomilnacipran); Forest Laboratories;
                    For the treatment of major depressive disorder, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nymalize (nimodipine); Arbor Pharmaceuticals;
                    For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Trokendi XR (topiramate); Supernus Pharmaceuticals;
                    For the treatment of partial onset, tonic-clonic and Lennox-Gastaut Syndrome seizures, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules; Zogenix;
                    For the management of severe pain, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zubsolv (buprenorphine and naloxone); Orexo AB;
                    For the maintenance treatment of opioid dependence, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Eliquis (apixaban); Bristol-Myers Squibb;
                    For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Fycompa (perampanel); Eisai;
                    For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of postherpetic neuralgia, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lyrica (pregabalin); Pfizer;
                    For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Neupro (Rotigotine Transdermal System); UCB;
                    For the treatment of Restless Legs Syndrome, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Oxtellar XR (oxcarbazepine extended release); Supernus Pharmaceuticals;
                    For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Quillivant XR (methylphenidate hydrochloride); NextWave Pharmaceuticals;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Subsys (fentanyl sublingual spray); Insys Therapeutics;
                    For the treatment of breakthrough cancer pain, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Abstral (fentanyl sublingual tablets); ProStrakan;
                    For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Exparel (bupivacaine liposome injectable suspension); Pacira Pharmaceuticals;
                    For postsurgical analgesia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Gralise (gabapentin); Abbott Laboratories;
                    For the treatment of postherpetic neuralgia, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of restless legs syndrome, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals;
                    For the treatment of insomnia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lazanda (fentanyl citrate) nasal spray; Archimedes;
                    For the management of breakthrough cancer pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Onfi (clobazam); Lundbeck;
                    For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Oxecta (oxycodone HCl); Pfizer;
                    For the management of acute and chronic moderate to severe pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Potiga (ezogabine); Valeant Pharmaceuticals;
                    For the treatment of partial-onset seizures, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Viibryd (vilazodone hydrochloride); Clinical Data;
                    For the treatment of major depressive disorder, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Ampyra (dalfampridine); Acorda;
                    For the improvement of walking in patients with multiple sclerosis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Botox (onabotulinumtoxinA); Allergan;
                    For the treatment of upper limb spasticity, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Botox (onabotulinumtoxinA); Allergan;
                    For the treatment of chronic migraine, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Butrans (buprenorphine) Transdermal System; Purdue Pharma;
                    moderate to severe chronic pain, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Carbaglu (carglumic acid); Recordati;
                    For the treatment of hyperammonemia, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Cuvposa (glycopyrrolate); Shionogi;
                    For the treatment of chronic severe drooling in pediatrics with neurologic conditions, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Exalgo (hydromorphone hydrochloride) extended release; Alza;
                    For the management of moderate to severe pain, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Kapvay (clonidine hydrochloride); Shionogi;
                    For the treatment of attention deficit hyperactivity disorder, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nuedexta (dextromethorphan hydrobromide and quinidine sulfate); Avanir Pharmaceuticals;
                    For the treatment of pseudobulbar affect, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Silenor (doxepin); Somaxon Pharma;
                    For the treatment of insomnia, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Sprix (ketorolac tromethamine); Roxro Pharma;
                    For the treatment of moderate to severe pain, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the prevention of relapse to opioid dependence, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vpriv (velaglucerase alfa for injection); Shire Pharmaceuticals;
                    For the treatment of type 1 Gaucher disease, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Xifaxan (rifaximin); Salix Pharmaceuticals;
                    For the treatment of hepatic encephalopathy, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals;
                    For the treatment of migraine attacks, Approved June of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Edluar (zolpidem tartrate); Orexo;
                    For the treatment of insomnia, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Embeda (morphine sulfate and naltrexone hydrochloride); King Pharmaceuticals;
                    For the treatment of moderate to severe pain, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Extavia (Interferon beta-l b); Novartis;
                    For the treatment of relapsing multiple sclerosis, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Intuniv (guanfacine extended-release); Shire Pharmaceuticals;
                    For the treatment of ADHD in children and adolescents, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Onsolis (fentanyl buccal); BioDelivery Sciences;
                    For the management of breakthrough cancer pain, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Qutenza (capsaicin); NeurogesX;
                    For the treatment of neuropathic pain associated with postherpetic neuralgia, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Sabril (vigabatrin); Lundbeck;
                    For the treatment of infantile spasms and complex partial seizures, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zipsor (diclofenac potassium); Xanodyne Pharmaceuticals;
                    For the treatment of mild to moderate acute pain, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Banzel (rufinamide); Elan Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Durezol (difluprednate); Sirion Therapeutics;
                    For the treatment of inflammation and pain associated with ocular surgery, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lusedra (fospropofol disodium); Elan Pharmaceuticals;
                    A sedative-hypnotic agent indicated for monitored anesthesia care sedation, Approved December of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nucynta (tapentadol); Ortho-McNeil Pharmaceutical;
                    moderate to severe acute pain, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Stavzor (valproic acid delayed release); Banner Pharmacaps;
                    For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vimpat (lacosamide); Schwarz Pharma;
                    For the treatment of partial-onset seizures in adults with epilepsy, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Xenazine (tetrabenazine); Prestwick Pharma;
                    For the treatment of chorea due to Huntington's disease, Approved August 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
                    For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Exelon (rivastigmine tartrate); Novartis;
                    For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Neupro (rotigotine); Schwarz Pharma;
                    For the treatment of Parkinson's disease, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Nuvigil (armodafinil); Cephalon;
                    For the treatment of excessive sleepiness, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Soliris (eculizumab); Alexion;
                    For the treatment of PNH, aHUS and generalized Myasthenia Gravis , Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vyvanse (Lisdexamfetamine Dimesylate); New River;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zingo (lidocaine hydrochloride monohydrate); Powder Pharmaceuticals;
                    For local analgesia prior to venipuncture or peripheral intravenous cannulation, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Invega (paliperidone); Janssen Pharmaceuticals;
                    For the treatment of schizophrenia, Approved December 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the treatment of alcohol dependence, Approved April 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Rozerem (ramelteon); Takeda;
                    For the treatment of sleep-onset insomnia, Approved July, 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec;
                    For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Apokyn (apomorphine hydrochloride); Mylan Laboratories;
                    For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinsonâ€™s disease, Approved April, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lunesta (eszopiclone); Sepracor;
                    For the treatment of insomnia and sleep maintenance, Approved December 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lyrica (pregabalin); Pfizer;
                    For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, Approved December 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Cialis (tadalafil); Eli Lilly;
                    Oral agent for the treatment for erectile dysfunction, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Levitra (vardenafil); Bayer, GlaxoSmithKline;
                    For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Namenda (memantine HCl); Forest Laboratories;
                    For the treatment of moderate to severe dementia of the Alzheimerâ€™s type., Approved October 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Avinza (morphine sulfate); Elan Pharmaceuticals;
                    Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Neurontin (gabapentin); Pfizer;
                    Oral treatment for the management of post-herpetic neuralgia (PHN), Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Rebif (interferon beta-1a); Serono Laboratories;
                    Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis, Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Relpax (eletriptan hydrobromide); Pfizer;
                    For the acute treatment of migraine headaches, Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Strattera (atomoxetine HCl); Eli Lilly;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Xyrem (sodium oxybate); Orphan Medical;
                    For the treatment of cataplexy, a sudden loss of muscle tone, associated with narcolepsy, Approved July 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Axert (almotriptan malate) tablets; Pharmacia & Upjohn;
                    For the treatment of migraine attacks, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Bayer Extra Strength Asprin; Bayer;
                    Oral treatment for mild to moderate migraine pain, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Focalin (dexmethylphenidate HCl); Celgene;
                    For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Frova (frovatriptan succinate); Elan Pharmaceuticals;
                    Tablets for the acute treatment of migraine attacks, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Metadate CD; Celltech Pharmaceuticals;
                    Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Reminyl (galantamine hydrobromide); Janssen Pharmaceuticals;
                    For the treatment of mild to moderate dementia of the Alzheimer's type, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Ultracet (acetaminophen and tramadol HCl); Ortho-McNeil Pharmaceutical;
                    For the short-term management of acute pain, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zomig (zolmitriptan); AstraZeneca;
                    Orally disintegrating tablet for the treatment of acute migraine in adults, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Depakote ER (divalproex sodium); Abbott Laboratories;
                    For the prophylaxis (prevention) of migraine headaches in adults, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Exelon (rivastigmine tartrate); Novartis;
                    Indicated for the treatment of mild to moderate dementia of the Alzheimer's type, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Myobloc; Elan Pharmaceuticals;
                    Injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    For the treatment of partial seizures in pediatric patients three years of age and older, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    Treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Novantrone (mitoxantrone hydrochloride); Immunex;
                    For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Trileptal (oxcarbazepine) Tablets; Novartis;
                    Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zonegran (zonisamide) Capsules; Dainippon Pharmaceutical;
                    Adjunctive therapy for treatment of partial seizures in adults with epilepsy, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Aggrenox; Boehringer Ingelheim;
                    Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Cenestin; Duramed Pharmaceuticals;
                    Treatment for symptoms associated with menopause, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Comtan; Novartis;
                    200mg entacapone tablets, October 19, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Keppra; UCB;
                    Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy, Approved November 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lamictal (lamotrigine) Chewable Dispersible Tablets; GlaxoSmithKline;
                    Treatment for epileptic seizures, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lidoderm Patch (lidocaine patch 5% ); Hind Health Care;
                    Treatment of pain in post-herpetic neuralgia, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Sonata; American Home Products;
                    Treatment fo insomnia, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Topamax (topiramate); Ortho-McNeil Pharmaceutical;
                    Treatment for epilepsy in pediatric patients, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Amerge; GlaxoSmithKline;
                    Treatment for acute migraine, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Clonazepam; Watson Pharmaceuticals;
                    Generic equivalent of Klonopin, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Cylert; Abbott Laboratories;
                    Treatment for Attention Deficit Disorder, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Excedrin Migraine; Bristol-Myers Squibb;
                    Treatment for mild to moderate migraine pain, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Lamictal Chewable Dispersible Tablets; GlaxoSmithKline;
                    Treatment for Epilepsy, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Maxalt; Merck;
                    Acute treatment of migraine headache, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Naltrexone Hydrochloride Tablets; Barr Laboratories;
                    Generic equivalent of Revia, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Oxycodone and Aspirin; Watson Pharmaceuticals;
                    Generic equivalent of Percodan, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tasmar; Roche;
                    Treatment for Parkinson's Disease, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Bromfenac; Duract, Wyeth-Ayerst Laboratories;
                    Management of acute pain, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Carbatrol; Elan Pharmaceuticals;
                    Treatment for epileptic seizures and trigeminal neuralgia, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Copaxone; Teva Pharmaceutical;
                    Treatment for relapsing-remitting multiple sclerosis, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Galzin (zinc acetate); Teva Pharmaceutical;
                    Treatment for Wilsonâ€™s disease, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Imitrex (sumatriptan) injection and tablets; GlaxoSmithKline;
                    Treatment for migraine headaches, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Imitrex (sumatriptan) nasal spray; GlaxoSmithKline;
                    Treatment for migraine, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Migranal; Novartis;
                    Treatment for migraine headaches, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Mirapex; Pharmacia & Upjohn, Boehringer Ingelheim;
                    Treatment for Parkinsonâ€™s Disease, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"NORCO tablets (Hydrocodone Bitartrate/Acetaminophen 10 mg/325 mg); Watson Pharmaceuticals;
                    Treatment for moderate to moderately severe pain, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Oxycodone with Acetaminophen 5mg/325mg; Watson Pharmaceuticals;
                    Generic equivalent of Percocet and Tylox, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Pramipexole; Pharmacia & Upjohn;
                    Treatment for Parkinson's Disease, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Quadramet (Samarium Sm 153 Lexidronam Injection); DuPont Merck Pharmaceutical Company;
                    Treatment for pain associated with bone cancer, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Requip (ropinirole hydrochloride); SmithKline Beecham;
                    Treatment for Parkinson's Disease, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Selegiline tablets; Teva Pharmaceutical;
                    Generic equivalent of Eldepryl tablets, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Topamax (topiramate); Ortho-McNeil Pharmaceutical;
                    Treatment for partial onset seizures, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"VERSED (midazolam HCI); Roche;
                    Treatment for sedating children who must undergo painful surgery, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zomig (zolmitriptan); AstraZeneca;
                    Treatment for migraine, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Anexsia; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"ARICEPT (donepezil hydrochloride); Eisai;
                    Treatment for Alzheimer's Disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for epilepsy, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for migraine headaches, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Iontocaine; Iomed;
                    Needle-free anesthetic, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Kadian; Purepac Pharmaceutical;
                    Treatment for chronic moderate to severe pain, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Merrem I.V. (meropenem); AstraZeneca;
                    Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Redux (dexfenfluramine hydrochloride); Wyeth;
                    Treatment for obesity, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tegretol (carbamazepine); Ciba Pharmaceuticals;
                    Treatment for young children with epilepsy, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Tegretol XR (carbamazepine); Ciba-Geigy;
                    Anti-epileptic treatment, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"UltraJect; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Zanaflex (tizanidine hydrochloride); Elan Pharmaceuticals;
                    Treatment for muscle spasticity, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Avonex (Interferon Beta 1-A); Biogen IDEC;
                    Treatment for multiple sclerosis, Recommended for Approval in December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology,"Rilutek (riluzole); Rhone Poulenc Rorer;
                    Treatment for amyotrophic lateral sclerosis (ALS), Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Contrave (naltrexone HCl and bupropion HCl) ; Takeda Pharmaceuticals U.S.A.;
                    For chronic weight management , Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Jardiance (empagliflozin) ; Boehringer Ingelheim;
                    For the treatment of type II diabetes, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Saxenda (liraglutide [rDNA origin] injection); Novo Nordisk;
                    For chronic weight management, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Tanzeum (albiglutide); GlaxoSmithKline;
                    For the treatment of type II diabetes mellitus, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Trulicity (dulaglutide); Eli Lilly;
                    To improve glycemic control in type II diabetics, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Nesina (alogliptin); Takeda;
                    For the treatment of type II diabetes mellitus, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Belviq (lorcaserin hydrochloride); Arena Pharmaceuticals;
                    For the chronic management of weight loss, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Bydureon (exenatide extended-release for injectable suspension); Amylin;
                    For the improvement of glycemic control in adults with type II diabetes mellitus, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Qsymia (phentermine + topiramate extended-release); Vivus;
                    For the treatment of chronic weight management, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"MERIDIA; Knoll Pharmaceutical;
                    Treatment for obesity, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/27/nutrition-and-weight-loss,"Redux (dexfenfluramine hydrochloride); Wyeth;
                    Treatment for obesity, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme;
                    For the treatment of HER2-overexpressing breast cancer, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Tecentriq (atezolizumab); Genentech/Roche;
                    For the treatment of triple negative breast cancer, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Zulresso (brexanolone); Sage Therapeutics;
                    For the treatment of postpartum depression, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Annovera (segesterone acetate andethinylestradiolvaginal system) ; TherapeuticsMD;
                    For the prevention of pregnancy, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Bijuva (estradiol and progesterone) ; TherapeuticsMD;
                    For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Imvexxy (estradiol vaginal inserts) ; TherapeuticsMD;
                    For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Keytruda (pembrolizumab); Merck;
                    For the treatment of recurrent or metastatic cervical cancer , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Orilissa (elagolix) ; AbbVie;
                    For the management of moderate to severe pain associated with endometriosis, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Talzenna (talazoparib); Pfizer;
                    For the treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Kisqali (ribociclib); Novartis;
                    For the treatment of breast cancer, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Solosec (secnidazole) ; Symbiomix Therapeutics;
                    For the treatment of bacterial vaginosis , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Tymlos (abaloparatide) ; Radius Health;
                    For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Verzenio (abemaciclib); Eli Lilly;
                    For the treatment of HR+, HER2- breast cancer, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Zejula (niraparib); Tesaro;
                    For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Intrarosa (prasterone vaginal insert); Endoceutics;
                    For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Rubraca (rucaparib); Clovis Oncology;
                    For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Addyi (flibanserin); Sprout Pharmaceuticals;
                    For the treatment of premenopausal women with generalized hypoactive sexual desire disorder, Approved August 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ibrance (palbociclib); Pfizer;
                    For the treatment of HR-positive, HER2-negative breast cancer, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Avastin (bevacizumab); Genentech;
                    For the treatment of persistent, recurrent, or metastatic cervical cancer, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Avastin (bevacizumab); Genentech;
                    For the treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved November 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Lynparza (olaparib); AstraZeneca;
                    For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Metronidazole 1.3% Vaginal Gel; Actavis, Inc.;
                    For the treatment of bacterial vaginosis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Brisdelle (low-dose paroxetine mesylate); Noven Pharmaceuticals;
                    For the treatment of vasomotor symptoms of menopause, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets); Duchesnay USA;
                    For the treatment of nausea and vomiting of pregnancy, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Duavee (conjugated estrogens/bazedoxifene); Pfizer;
                    For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Kadcyla (ado-trastuzumab emtansine); Genentech;
                    For the treatment of HER2-positive metastatic breast cancer, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate); Warner Chilcott;
                    For the prevention of pregnancy, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Osphena (ospemifene); Shionogi;
                    For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol); Teva Pharmaceutical;
                    For the prevention of conception, Approved April 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Afinitor (everolimus); Novartis;
                    For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Natazia (estradiol valerate and estradiol valerate/dienogest); Bayer;
                    For the treatment of heavy menstrual bleeding, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Perjeta (pertuzumab); Genentech;
                    For the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Makena (hydroxyprogesterone caproate injection); Hologic;
                    For the prevention of risk of preterm birth, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"ella (ulipristal acetate); HRA Pharma;
                    For the emergency prevention of contraception, Approved August 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Halaven (eribulin mesylate); Eisai;
                    For the treatment of metastatic breast cancer, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Natazia (estradiol valerate + dienogest); Bayer;
                    For the prevention of contraception, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Prolia (denosumab); Amgen;
                    For the treatment of osteoporosis and bone loss in men and women, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
                    For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Lysteda (tranexamic acid); Xanodyne Pharmaceuticals;
                    For the treatment of heavy menstrual bleeding, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Evamist (estradiol); Vivus;
                    For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Evista (raloxifene hydrochloride); Eli Lilly;
                    For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Reclast (zoledronic acid); Novartis;
                    For the treatment of postmenopausal osteoporosis, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Elestrin (estradiol gel); BioSante;
                    For the treatment of vasomotor symptoms associated with menopause, Approved December 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"EstroGel (estradiol gel 0.06%); Solvay Pharmaceuticals;
                    For the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, Approved April 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Premarin (conjugated estrogens); Wyeth;
                    For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Seasonale, Lo Seasonale, Seasonique (ethinylestradiol + levonorgestrel); Duramed Pharmaceuticals;
                    For the prevention of contraception, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Alora; Watson Pharmaceuticals;
                    Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals;
                    Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Forteo (teriparatide); Eli Lilly;
                    For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Vivelle-Dot (estradiol transdermal system); Novartis;
                    For the prevention of post-menopausal osteoporosis, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Zoloft (sertraline HCl); Pfizer;
                    Oral tablets for the treatment of premenstrual dysphoric mood disorder (PMDD), Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Bextra; Pharmacia, Pfizer;
                    Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Femara (letrozole); Novartis;
                    First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Monistat 3 (miconazole nitrate); Advanced Care Products;
                    Emulsion, cream for the treatment of vaginal yeast infections, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"NuvaRing; Organon;
                    Monthly vaginal ring for birth control, Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ortho Evra; Ortho-McNeil Pharmaceutical;
                    Transdermal patch for contraception, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Yasmin (drospirenone/ethinyl estradiol); Berlex Laboratories;
                    Oral contraceptive, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
                    Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cetrotide; Asta Medica;
                    For the prevention of premature ovulation in women undergoing controlled ovarian stimulation, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Mirena (levonorgestrel-releasing intrauterine system); Berlex Laboratories;
                    Hormone-releasing system for intrauterine contraception, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories;
                    For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Trivagizole 3 (clotrimazole) Vaginal Cream; Taro Pharmaceuticals;
                    For the treatment of vaginal yeast infections, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Vivelle (estradiol transdermal system); Novartis;
                    For the prevention of postmenopausal osteoporosis, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Aromasin Tablets; Pharmacia & Upjohn;
                    Exemestane Tablets, 25 mg, October 21, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cenestin; Duramed Pharmaceuticals;
                    Treatment for relief of vasomotor symptoms due to menopause, Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cenestin; Duramed Pharmaceuticals;
                    Treatment for symptoms associated with menopause, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
                    Treatment for bacterial vaginosis, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Climara; Berlex Laboratories;
                    For the prevention of postmenopausal osteoporosis (loss of bone mass), Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Doxil (doxorubicin HCl liposome injection); Alza;
                    Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ellence; Pharmacia & Upjohn;
                    epirubicin hydrochloride, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estradiol Transdermal System; Wyeth;
                    Transdermal patch system for the treatement of vulvar vaginal atrophy and vasomotor symptoms., Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Osteoporosis treatment, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Femhrt Tablets; Parke-Davis;
                    Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals;
                    Treatment for endometriosis and uterine fibroids, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ortho-Prefest; Ortho-McNeil Pharmaceutical, RW Johnson;
                    17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Tequin; Bristol-Myers Squibb;
                    Tequin (Injectable and Tablet), December, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Cleocin (clindamycin phosphate); Pharmacia & Upjohn;
                    Treatment for bacterial vaginosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Esclim; Fournier Research;
                    Treatment for symptoms associated to Menopause, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estratab (.3 mg ); Solvay Pharmaceuticals;
                    Treatment for the prevention of osteoporosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Herceptin (trastuzumab); Genentech;
                    For the treatment of metastatic breast cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Inform HER-2/neu breast cancer test; Oncor;
                    Treatment for breast cancer prediction, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Micardis (telmisartan); Boehringer Ingelheim;
                    Treatment for Hypertension, Approved November 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Mircette; Organon;
                    Oral contraceptive, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Prempro; Wyeth;
                    Treatment for hormone replacement therapy, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"PREVEN ; Emergency Contraceptive Kit; Gynetics;
                    Emergency Contraceptive Pills, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Prometrium; Schering-Plough;
                    Treatment for Endometrial Hyperplasia, Approved December 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Prometrium; Solvay Pharmaceuticals;
                    Treatment for amenorrhea (abnormal cessation of menses), Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Xeloda; Roche;
                    Treatment for advanced breast cancer tumors, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets); Wyeth;
                    Treatment for the prevention of pregnancy, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Crinone 8% (progesterone gel); Wyeth;
                    Treatment for infertile women with pregestone deficiency, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estradiol tablets; Barr Laboratories;
                    Generic equivalent of Estrace, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estradiol tablets; Duramed Pharmaceuticals;
                    Generic equivalent of Estrace tablets, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estrostep (norethindrone acetate and ethinyl estradiol); Warner-Lambert;
                    Treatment for oral contraception, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Evista (raloxifene hydrochloride); Eli Lilly;
                    Treatment for the prevention of osteoporosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Femara (letrozole); Novartis;
                    Treatment for breast cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"FEMSTAT One; Roche;
                    Treatment for vaginal yeast infections, Approved Februrary 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Flagyl ER; Searle;
                    Treatment for bacterial vaginosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Floxin Tablets (ofloxacin tablets); Ortho-McNeil Pharmaceutical;
                    Treatment for pelvic inflammatory disease (PID), Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Follistim (TM) (follitropin beta for injection); Organon;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Gonal-F (follitropin alfa for injection); Serono Laboratories;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Miraluma test; DuPont Merck Pharmaceutical Company;
                    Test for breast cancer, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol); Ortho-McNeil Pharmaceutical;
                    Treatment for acne in women seeking contraception, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Trivora-21 and Trivora-28; Watson Pharmaceuticals;
                    Generic equivalents of levonorgestrel and ethinyl estradiol, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Aredia (pamidronate disodium for injection); Chiron;
                    Treatment for osteolytic bone metastases of breast cancer, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Arimidex (anastrozole); AstraZeneca;
                    Treatment for advanced breast cancer in postmenopausal women, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Estrostep (norethindrone acetate and ethinyl estradiol); Parke-Davis;
                    Treatment for birth control, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"FemPatch; Parke-Davis;
                    Treatment for menopausal symptoms, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Fertinex (urofollitropin for injection, purified); Serono Laboratories;
                    Treatment for patients undergoing infertility treatments, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Hycamtin (topotecan hydrochloride); SmithKline Beecham;
                    Treatment for metastatic ovarian cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Monistat 3 (miconazole nitrate); Johnson & Johnson;
                    Over the counter treatment for vaginal yeast infections, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Seprafilm; Genzyme;
                    Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Taxotere (Docetaxel); Rhone Poulenc Rorer;
                    Treatment for locally advanced or metastatic breast cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Vivelle (estradiol transdermal system); Ciba Pharmaceuticals;
                    Treatment for moderate and severe vasomotor menopausal symptoms, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Ethyol (amifostine); Alza;
                    Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Femstat 3 (butoconazole nitrate 2%); Procter & Gamble, Roche;
                    Over the counter treatment for vaginal yeast infections, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Fosamax (alendronate sodium); Merck;
                    Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
                    Treatment for post-menopausal osteoporosis, Approved on August 17, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
                    Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/11/obstetrics-gynecology-womens-health,"Self-examination breast pad; Inventive Products;
                    Self-examination breast pad, Approved on December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme;
                    For the treatment of HER2-overexpressing breast cancer, Approved February 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tecentriq (atezolizumab); Genentech/Roche;
                    For the treatment of extensive-stage small cell lung cancer , Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tecentriq (atezolizumab); Genentech/Roche;
                    For the treatment of triple negative breast cancer, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Asparlas (calaspargase pegol-mknl ); Servier;
                    For the treatment of acute lymphoblastic leukemia in pediatrics and young adults, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Braftovi (encorafenib) + Mektovi (binimetinib); Array BioPharma;
                    For the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Copiktra (duvelisib); Verastem;
                    For the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or follicular lymphoma, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Daurismo (glasdegib); Pfizer;
                    For the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Elzonris (tagraxofusp-erzs); Stemline Therapeutics;
                    For the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatrics, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Erleada (apalutamide); Janssen Oncology;
                    For the treatment of prostate cancer, Approved February 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of recurrent or metastatic cervical cancer , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of primary mediastinal B-cell lymphoma, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of Merkel cell carcinoma, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of hepatocellular carcinoma, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lenvima (lenvatinib); Eisai;
                    For the treatment of unresectable hepatocellular carcinoma, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals;
                    For the treatment of cutaneous squamous cell carcinoma, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lorbrena (lorlatinib); Pfizer;
                    For the treatment of ALK-positive metastatic non-small cell lung cancer , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lumoxiti (moxetumomab pasudotox-tdf); AstraZeneca;
                    For the treatment of  relapsed or refractory hairy cell leukemia, Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications;
                    For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of advanced small cell lung cancer, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of MSI-H or dMMR metastatic colorectal cancer , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Poteligeo (mogamulizumab-kpkc); Kyowa Kirin;
                    For the treatment of mycosis fungoides or SÃ©zary syndrome , Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Talzenna (talazoparib); Pfizer;
                    For the treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tibsovo (ivosidenib); Agios Pharmaceuticals;
                    For the treatment of acute myeloid leukemia with a susceptible IDH1 mutation, Approved July 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vitrakvi (larotrectinib); Loxo Oncology;
                    For the treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vizimpro (dacomitinib); Pfizer;
                    For the treatment of metastatic non-small cell lung cancer , Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xospata (gilteritinib) ; Astellas;
                    For the treatment of acute myeloid leukemia with a FLT3 mutation, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Aliqopa (copanlisib); Bayer;
                    For the treatment of follicular lymphoma , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Alunbrig (brigatinib); Ariad Pharmaceuticals;
                    For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Bavencio (avelumab) ; EMD Serono/Pfizer;
                    For the treatment of  Merkel cell carcinoma , Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Besponsa (inotuzumab ozogamicin); Pfizer;
                    For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Calquence (acalabrutinib); Acerta Pharmaceuticals;
                    For the treatment of mantle cell lymphoma , Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"IDHIFA (enasidenib); Celgene;
                    For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of marginal zone lymphoma, Approved January 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imfinzi (durvalumab); AstraZeneca;
                    For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of urothelial carcinoma (bladder cancer), Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of classical Hodgkin Lymphoma, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of PD-L1 expressing gastric or gastroesophageal junction adenocarcinoma, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kisqali (ribociclib); Novartis;
                    For the treatment of breast cancer, Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kymriah (tisagenlecleucel); Novartis;
                    For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Nerlynx (neratinib); Puma Biotech;
                    For the treatment of HER2 breast cancer, Approved July 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of hepatocellular carcinoma , Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of metastatic urothelial carcinoma , Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Rydapt (midostaurin); Novartis;
                    For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Verzenio (abemaciclib); Eli Lilly;
                    For the treatment of HR+, HER2- breast cancer, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma;
                    For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xermelo (telotristat ethyl); Lexicon Pharmaceuticals;
                    For the treatment of carcinoid syndrome diarrhea, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals;
                    For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zejula (niraparib); Tesaro;
                    For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Cabometyx (cabozantinib); Exelixis;
                    For the treatment of advanced renal cell carcinoma, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of head and neck squamous cell cancer , Approved August 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lartruvo (olaratumab) ; Eli Lilly;
                    For the treatment of soft tissue sarcoma, Approved October 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lenvima (lenvatinib); Eisai;
                    For the treatment of advanced renal cell carcinoma, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of classical Hodgkin lymphoma, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, Approved November 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Rubraca (rucaparib); Clovis Oncology;
                    For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sustol (granisetron); Heron Therapeutics;
                    For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Syndros (dronabinol oral solution); Insys Therapeutics;
                    For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tecentriq (atezolizumab); Genentech;
                    For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Venclexta (venetoclax); AbbVie;
                    For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Alecensa (alectinib); Roche;
                    For the treatment of ALK-positive, metastatic non-small cell lung cancer , Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Cotellic (cobimetinib) ; Genentech;
                    For the treatment of BRAF V600E or V600K melanoma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Darzalex (daratumumab); Janssen Biotech;
                    For the treatment of multiple myeloma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Empliciti (elotuzumab); Bristol-Myers Squibb;
                    For the treatment of patients with multiple myeloma who have received prior therapies, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Farydak (panobinostat); Novartis;
                    For the treatment of multiple myeloma, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ibrance (palbociclib); Pfizer;
                    For the treatment of HR-positive, HER2-negative breast cancer, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of WaldenstrÃ¶mâ€™s macroglobulinemia, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imlygic (talimogene laherparepvec) ; Amgen;
                    For the treatment of unresectable recurrent melanoma, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of PD-L1 positive advanced non-small cell lung cancer, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lenvima (lenvatinib); Eisai;
                    For the treatment of thyroid cancer, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lonsurf (trifluridine and tipiracil); Taiho Oncology;
                    For the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ninlaro (ixazomib); Millennium Pharmaceuticals;
                    For the treatment of multiple myeloma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Odomzo (sonidegib); Novartis;
                    For the treatment of locally advanced basal cell carcinoma, July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Onivyde (irinotecan liposome injection); Merrimack;
                    For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of advanced renal cell carcinoma, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Portrazza (necitumumab) ; Eli Lilly;
                    For the treatment of metastatic squamous non-small cell lung cancer, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tagrisso (osimertinib); AstraZeneca;
                    For the treatment of EGFR T790M mutation positive non-small cell lung cancer , Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Unituxin (dinutuximab); United Therapeutics;
                    For the treatment of pediatrics with high-risk neuroblastoma, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Varubi (rolapitant); Tesaro;
                    For the prevention of delayed nausea and vomiting associated with chemotherapy, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vistogard (uridine triacetate); Wellstat Therapeutics;
                    For the emergency treatment of patients with a fluorouracil or capecitabine overdose, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Yondelis (trabectedin); Janssen;
                    For the treatment of liposarcoma or leiomyosarcoma, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Akynzeo (netupitant and palonosetron); Helsinn;
                    For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of persistent, recurrent, or metastatic cervical cancer, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved November 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Beleodaq (belinostat); Spectrum Pharmaceuticals;
                    For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Blincyto (blinatumomab); Amgen;
                    For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Cyramza (ramucirumab); Eli Lilly;
                    For the treatment of gastric cancer, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of unresectable or metastatic melanoma, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lynparza (olaparib); AstraZeneca;
                    For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of unresectable or metastatic melanoma, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zydelig (idelalisib); Gilead;
                    For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zykadia (ceritinib); Novartis;
                    For the treatment of ALK+ metastatic non-small cell lung cancer, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gazyva (obinutuzumab); Genentech;
                    For the treatment of previously untreated chronic lymphocytic leukemia, Approved October of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gilotrif (afatinib); Boehringer Ingelheim;
                    For the treatment of metastatic non-small cell lung cancer with EGFR mutations, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Imbruvica (ibrutinib); Pharmacyclics;
                    For the treatment of mantle cell lymphoma, Approved November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kadcyla (ado-trastuzumab emtansine); Genentech;
                    For the treatment of HER2-positive metastatic breast cancer, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Mekinist (trametinib); GlaxoSmithKline;
                    For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, Approved May of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Pomalyst (pomalidomide); Celgene;
                    For the treatment of relapsed and refractory multiple myeloma, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Revlimid (lenalidomide); Celgene;
                    For the treatment of mantle cell lymphoma, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Stivarga (regorafenib); Bayer;
                    For the treatment of gastrointestinal stromal tumor, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tafinlar (dabrafenib); GlaxoSmithKline;
                    For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Valchlor (mechlorethamine) gel; Ceptaris Therapeutics;
                    For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xgeva (denosumab); Amgen;
                    For the treatment of giant cell tumor of bone, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xofigo (radium Ra 223 dichloride); Bayer Healthcare Pharmaceuticals;
                    For the treatment of prostate cancer with bone metastases, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene;
                    For the treatment of non-small cell lung cancer, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Afinitor (everolimus); Novartis;
                    For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Afinitor (everolimus); Novartis;
                    For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Bosulif (bosutinib); Pfizer;
                    For the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Cometriq (cabozantinib); Exelixis;
                    For the treatment of metastatic medullary thyroid cancer, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Erivedge (vismodegib); Genentech;
                    For the treatment of basal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Iclusig (ponatinib); Ariad Pharmaceuticals;
                    For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Inlyta (axitinib); Pfizer;
                    For the treatment of advanced renal cell carcinoma, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kyprolis (carfilzomib); Onyx Pharmaceuticals;
                    For the treatment of multiple myeloma, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics;
                    For the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Neutroval (tbo-filgrastim); Teva Pharmaceutical;
                    For the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Perjeta (pertuzumab); Genentech;
                    For the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Picato (ingenol mebutate) gel; LEO Pharma;
                    For the treatment of actinic keratosis, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals;
                    For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Subsys (fentanyl sublingual spray); Insys Therapeutics;
                    For the treatment of breakthrough cancer pain, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Synribo (omacetaxine mepesuccinate); Teva Pharmaceutical;
                    For the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of soft tissue sarcoma, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xtandi (enzalutamide); Medivation;
                    For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zaltrap (ziv-aflibercept); Sanofi-aventis;
                    For the treatment of metastatic colorectal cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Abstral (fentanyl sublingual tablets); ProStrakan;
                    For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Adcetris (brentuximab vedotin); Seattle Genetics;
                    For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, Approved August 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Afinitor (everolimus); Novartis;
                    For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Erwinaze (asparaginase Erwinia chrysanthemi); Eusa Pharma;
                    For the treatment of acute lymphoblastic leukemia, Approved November of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lazanda (fentanyl citrate) nasal spray; Archimedes;
                    For the management of breakthrough cancer pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sutent (sunitinib malate); Pfizer;
                    For the treatment of pancreatic neuroendocrine tumors, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sylatron (peginterferon alfa-2b); Merck;
                    For the treatment of melanoma, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vandetanib (vandetanib); AstraZeneca;
                    For the treatment of thyroid cancer, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xalkori (crizotinib); Pfizer;
                    For the treatment of ALK+ non-small cell lung cancer, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Yervoy (ipilimumab); Bristol-Myers Squibb;
                    For the treatment of metastatic melanoma, Approved March 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zelboraf (vemurafenib); Roche;
                    For the treatment of  BRAF + melanoma, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zytiga (abiraterone acetate); Centocor Ortho Biotech;
                    For the treatment of prostate cancer, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Halaven (eribulin mesylate); Eisai;
                    For the treatment of metastatic breast cancer, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Herceptin (trastuzumab); Genentech;
                    For the treatment of gastric cancer, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Jevtana (cabazitaxel); sanofi aventis;
                    For the treatment of prostate cancer, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Provenge (sipuleucel-T); Dendreon;
                    For the treatment of hormone refractory prostate cancer, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of chronic lymphocytic leukemia, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xgeva (denosumab); Amgen;
                    For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals;
                    For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Afinitor (everolimus); Novartis;
                    For the treatment of renal cell carcinoma, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Arzerra (ofatumumab); GlaxoSmithKline;
                    For the treatment of chronic lymphocytic leukemia, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of renal cell carcinoma, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of recurrent glioblastoma in adults, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
                    For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Elitek (rasburicase); sanofi-aventis;
                    For the management of plasma uric acid levels in adults with malignancies, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Folotyn (pralatrexate injection); Allos Therapeutics;
                    For the treatment of peripheral T-cell lymphoma, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Istodax (romidepsin); Gloucester Pharmaceuticals;
                    For the treatment of cutaneous T-cell lymphoma, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Onsolis (fentanyl buccal); BioDelivery Sciences;
                    For the management of breakthrough cancer pain, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Votrient (pazopanib); GlaxoSmithKline;
                    For the treatment of renal cell carcinoma, Approved October of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Alimta  (pemetrexed for injection); Eli Lilly;
                    For the treatment of non-small cell lung cancer, Approved September 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Degarelix (degarelix for injection); Ferring Pharmaceuticals;
                    For the treatment of prostate cancer, Approved December of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Fusilev (levoleucovorin); Spectrum Pharmaceuticals;
                    For rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate, Approved March of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Mozobil (plerixafor injection); Genzyme;
                    For the treatment of non-Hodgkinâ€™s lymphoma and multiple myeloma, Approved December 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sancuso (granisetron); ProStrakan;
                    For the treatment of chemotherapy-induced nausea and vomiting, Approved September 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Treanda (bendamustine hydrochloride); Cephalon;
                    For the treatment of Chronic lymphocytic leukemia and B-cell non-Hodgkinâ€™s lymphoma, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Evista (raloxifene hydrochloride); Eli Lilly;
                    For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Hycamtin (topotecan hydrochloride); GlaxoSmithKline;
                    For the treatment of small cell lung cancer, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ixempra (ixabepilone); Bristol-Myers Squibb;
                    For the treatment of breast cancer, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tasigna (nilotinib hydrochloride monohydrate); Novartis;
                    For the treatment of chronic myelogenous leukemia, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Torisel (temsirolimus); Wyeth;
                    For the treatment of renal cell carcinoma, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tykerb (lapatinib); GlaxoSmithKline;
                    For the treatment of breast cancer, Approved March 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of nonâ€“squamous nonâ€“small cell lung cancer, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck;
                    For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sprycel (dasatinib); Bristol-Myers Squibb;
                    For the treatment of imatinib-resistant chronic myeloid leukemia, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sutent (sunitinib); Pfizer;
                    For the treatment of kidney cancer and gastrointestinal stromal tumors, Approved January 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Vectibix (panitumumab); Amgen;
                    For the treatment of colorectal cancer, Approved September 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Arranon (nelarabine); GlaxoSmithKline;
                    For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, Approved October 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Nexavar (sorafenib); Bayer/Onyx;
                    For the Treatment of Renal Cell Carcinoma, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Alimta (pemetrexed for injection); Eli Lilly;
                    For the treatment of malignant pleural mesothelioma, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Avastin (bevacizumab); Genentech;
                    For the treatment of metastatic carcinoma of the colon or rectum, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Clolar (clofarabine); Genzyme;
                    For the treatment of acute lymphoblastic leukemia in pediatric patients, Approved December, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Erbitux (cetuximab); Imclone, Bristol-Myers Squibb;
                    For the treatment of EGFR-expressing, metastatic colorectal cancer, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sensipar (cinacalcet); Amgen;
                    For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients, Approved March 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Tarceva (erlotinib, OSI 774); Genentech, OSI Pharmaceuticals;
                    For the treatment of advanced refractory metastatic non-small cell lung cancer, Approved November, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Aloxi (palonosetron); MGI Pharma, Helsinn Healthcare;
                    For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, Approved August 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Bexxar; Corixa;
                    For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved  June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Emend (aprepitant); Merck;
                    For the treatment of nausea and vomiting associated with chemotherapy, Approved March 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Iressa (gefitinib); AstraZeneca;
                    For the second-line treatment of non-small-cell lung cancer, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals;
                    For treatment of advanced prostate cancer, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Premarin (conjugated estrogens); Wyeth;
                    For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis;
                    For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Velcade (bortezomib); Millennium Pharmaceuticals;
                    Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Eligard (leuprolide acetate); Atrix Laboratories;
                    For the palliative treatment of advanced prostate cancer, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); Sanofi-aventis;
                    For the treatment of colon or rectum carcinomas, Approved August 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Faslodex (fulvestrant); AstraZeneca;
                    For the treatment of hormone receptor positive metastatic breast cancer, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gleevec (imatinib mesylate); Novartis;
                    For the treatment of gastrointestinal stromal tumors (GISTs), Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Neulasta; Amgen;
                    Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"SecreFlo (secretin); Repligen;
                    To aid in the diagnosis of pancreatic dysfunction and gastrinoma, Approved April 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zevalin (ibritumomab tiuxetan); Biogen IDEC;
                    For the treatment of non-Hodgkin's lymphoma, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zometa (zoledronic acid); Novartis;
                    For the treatment of multiple myeloma and bone metastases from solid tumors, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Campath; Berlex Laboratories;
                    Injectable treatment of B-cell chronic lymphocytic leukemia, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Femara (letrozole); Novartis;
                    First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gleevec (imatinib mesylate); Novartis;
                    Oral therapy for the treatment of chronic myeloid leukemia, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kytril (granisetron) solution; Roche;
                    For the prevention of nausea and vomiting associated with cancer therapy, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Trelstar LA (triptorelin pamoate); Debiopharm;
                    Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xeloda; Roche;
                    Oral chemotherapy for the treatment of metastatic colorectal cancer, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zometa (zoledronic acid); Novartis;
                    For the treatment of hypercalcemia of malignancy, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Mylotarg (gemtuzumab ozogamicin); Wyeth;
                    For the treatment of CD33 positive acute myeloid leukemia (AML), Approved May 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
                    For the palliative treatment of advanced prostate cancer, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Trisenox (arsenic trioxide); Cell Therapeutics;
                    For the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Viadur (leuprolide acetate implant); Alza;
                    For pain relief in men with advanced prostate cancer, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Aromasin Tablets; Pharmacia & Upjohn;
                    Exemestane Tablets, 25 mg, October 21, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Busulflex; Orphan Medical;
                    For use in combination for the treatment of leukemia, Approved February 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Doxil (doxorubicin HCl liposome injection); Alza;
                    Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ellence; Pharmacia & Upjohn;
                    epirubicin hydrochloride, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ethyol (amifostine); US Bioscience, Alza;
                    Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Temodar; Schering-Plough;
                    Treatment for refractory anaplastic astrocytoma, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"UVADEX Sterile Solution; Therakos;
                    Treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL), Approved February 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zofran; GlaxoSmithKline;
                    Treatment for the prevention of chemotherapy and radiation-induced nausea, Approved January 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Actiq; Anesta Corporation;
                    Treatment for Cancer Pain, Approved November 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Anzemet; Hoechst Marion Roussel;
                    Treatment for the prevention of nausea and vomiting associated with chemotherapy and surgery, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Camptosar; Pharmacia & Upjohn;
                    Treatment for Colon or Rectal Cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for Lung Cancer, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Herceptin (trastuzumab); Genentech;
                    For the treatment of metastatic breast cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Inform HER-2/neu breast cancer test; Oncor;
                    Treatment for breast cancer prediction, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Neupogen; Amgen;
                    Treatment for slow white blood cell recovery following chemotherapy, Approval April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Nolvadex; AstraZeneca;
                    Treatment for Breast Cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Photofrin; QLT;
                    Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Proleukin; Chiron;
                    Treatment for metastatic melanoma, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Sclerosol Intrapleural Aerosol; Bryan Corporation;
                    Treatment for malignant pleural effusions, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Valstar; Anthra Pharmaceuticals;
                    Treatment for Bladder Cancer, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Xeloda; Roche;
                    Treatment for advanced breast cancer tumors, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zofran; GlaxoSmithKline;
                    Treatment for postoperative vomiting and nausea in adults, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Anzemet; Hoechst Marion Roussel;
                    Treatment for emesis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Bromfenac; Duract, Wyeth-Ayerst Laboratories;
                    Management of acute pain, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Femara (letrozole); Novartis;
                    Treatment for breast cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals;
                    Treatment for brain cancer, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Intron A (interferon alfa-2b, recombinant); Schering-Plough;
                    Treatment for non-Hodgkin's lymphoma, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kytril (granisetron) tablets; SmithKline Beecham;
                    Prevention of nausea and vomiting associated with chemotherapy, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals;
                    Treatment for prostate cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Miraluma test; DuPont Merck Pharmaceutical Company;
                    Test for breast cancer, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Neumega; Genetics Institute;
                    Treatment for thrombocytopenia, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Quadramet (Samarium Sm 153 Lexidronam Injection); DuPont Merck Pharmaceutical Company;
                    Treatment for pain associated with bone cancer, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Rituxan (rituximab) ; Biogen IDEC, Genentech;
                    For the treatment of Non-Hodgkin's lymphoma, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Taxol; Bristol-Myers Squibb;
                    Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Anexsia; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Aredia (pamidronate disodium for injection); Chiron;
                    Treatment for osteolytic bone metastases of breast cancer, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Arimidex (anastrozole); AstraZeneca;
                    Treatment for advanced breast cancer in postmenopausal women, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Campostar; Pharmacia & Upjohn;
                    Treatment for metastatic colorectal cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"CEA-Scan; Immunomedics;
                    Diagnostic imaging product for colorectal cancer, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection); Orphan Medical;
                    Treatment of meningeal leukemia or lymphocytic lymphoma, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Eulexin (flutamide); Schering-Plough;
                    Treatment for prostate cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Feridex I.V.; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of liver lesions, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"GastroMARK; Advanced Magnetics;
                    Contrast agent for magnetic resonance imaging of the gastrointestinal tract, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Gemzar (gemcitabine HCL); Eli Lilly;
                    Treatment for pancreatic cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Hycamtin (topotecan hydrochloride); SmithKline Beecham;
                    Treatment for metastatic ovarian cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Kadian; Purepac Pharmaceutical;
                    Treatment for chronic moderate to severe pain, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for the replenishment of white blood cells, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Photodynamic Therapy; Sanofi-aventis;
                    Photodynamic therapy device for the treatment of esophageal cancer, Approved January, 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Taxotere (Docetaxel); Rhone Poulenc Rorer;
                    Treatment for locally advanced or metastatic breast cancer, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"UltraJect; Mallinckrodt Group;
                    Treatment for chronic pain, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Ethyol (amifostine); Alza;
                    Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Intron A (Interferon alfa-2b, recombinant); Schering-Plough;
                    An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Leukine (sargramostim); Partner Therapeutics;
                    Treatment for mobilizing peripheral blood progenitor cells for use after transplantation., Approved on November 24, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology,"Self-examination breast pad; Inventive Products;
                    Self-examination breast pad, Approved on December 22, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Rocklatan (netarsudil and latanoprost ophthalmic solution); Aerie Pharmaceuticals;
                    For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Oxervate (cenegermin-bkbj) ; Dompe Pharmaceuticals;
                    For the treatment of neurotrophic keratitis, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Luxturna (voretigene neparvovec); Spark Therapeutics;
                    For the treatment of vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Rhopressa (netarsudil ophthalmic solution) ; Aerie Pharmaceuticals;
                    For the treatment of glaucoma or ocular hypertension, Approved December 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Vyzulta (latanoprostene bunod ophthalmic solution); Bausch & Lomb;
                    For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Zerviate (cetirizine ophthalmic solution 0.24%); NicOx;
                    For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Humira (adalimumab); Abbvie;
                    For the treatment of uveitis, Approved July 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Xiidra (lifitegrast); Shire;
                    For the treatment of dry eye disease, Approved July 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of diabetic retinopathy in patients with diabetic macular edema, Approved March 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of diabetic macular edema, Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Hetlioz (tasimelteon); Vanda Pharmaceuticals;
                    For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Omidria (phenylephrine and ketorolac injection); Omeros;
                    For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals;
                    For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of macular edema following retinal vein occlusion, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Jetrea (ocriplasmin); Thrombogenics;
                    For the treatment of symptomatic vitreomacular adhesion, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Lucentis (ranibizumab injection); Genentech;
                    For the treatment of diabetic macular edema, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Zioptan (tafluprost ophthalmic solution); Merck;
                    For the treatment of elevated intraocular pressure, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Eylea (aflibercept); Regeneron Pharmaceuticals;
                    For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Zymaxid (gatifloxacin ophthalmic solution); Allergan;
                    For the treatment of bacterial conjunctivitis, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Acuvail (ketorolac tromethamine); Allergan;
                    For the treatment of pain and inflammation following cataract surgery., Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals;
                    For the treatment of itching associated with allergic conjunctivitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb;
                    For the treatment of bacterial conjunctivitis, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Ozurdex (dexamethasone); Allergan;
                    For the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics;
                    For the treatment of acute herpetic keratitis, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Akten (lidocaine hydrochloride); Akorn;
                    For anesthesia during ophthalmologic procedures, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Durezol (difluprednate); Sirion Therapeutics;
                    For the treatment of inflammation and pain associated with ocular surgery, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"AzaSite (azithromycin); InSite Vision;
                    For the treatment of bacterial conjunctivitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Lucentis (ranibizumab); Genentech;
                    For the treatment of neovascular (wet) age related macular degeneration, Approved June 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Macugen (pegaptanib); Pfizer / Eyetech Pharmaceuticals;
                    For the treatment of wet age-related macular degeneration., Approved December 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Restasis (cyclosporine ophthalmic emulsion); Allergan;
                    For the treatment of low tear production., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Lumigan (bimatoprost ophthalmic solution); Allergan;
                    For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Travatan (travoprost ophthalmic solution); Alcon;
                    For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Valcyte (valganciclovir HCl); Roche;
                    For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Betaxon; Alcon;
                    For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Quixin (levofloxacin); Santen;
                    For treatment of bacterial conjunctivitis, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Rescula (unoprostone isopropyl ophthalmic solution) 0.15%; Ciba Vision;
                    For the treatment of open-angle glaucoma or ocular hypertension, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Visudyne (verteporfin for injection); QLT;
                    For the treatment of wet age-related macular degeneration (wet AMD), Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Alamast; Santen;
                    pemirolast potassium ophthalmic solution, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"ZADITOR; Ciba Vision;
                    Treatment for the prevention of itching of the eye, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Alrex; Bausch & Lomb,  Pharmos;
                    Treatment for seasonal allergic conjunctivitis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Cosopt; Merck;
                    Treatment for glaucoma or ocular hypertension, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Lotemax; Bausch & Lomb,  Pharmos;
                    Treatment for post-operative eye inflammation, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Salagen Tablets; MGI Pharma;
                    Treatment for Sjogren's Syndrome, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Viroptic; King Pharmaceuticals;
                    Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Vitravene Injection; Isis Pharmaceuticals;
                    Treatment for CMV in AIDS patients, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan;
                    Treatment for postoperative inflammation in patients who have undergone cataract extraction, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan;
                    Treatment for post-surgical inflammation following cataract extraction, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"BSS Sterile Irrigating Solution; Alcon;
                    Treatment during ocular surgical procedures, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"AK-Con-A (naphazoline ophthalmic); Akorn;
                    Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Alphagan (brimonidine); Allergan;
                    Treatment for open-angle glaucoma and ocular hypertension, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Ocuflox (ofloxacin opthalmic solution) 0.3%; Allergan;
                    Treatment for corneal ulcers, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"OcuHist; Pfizer;
                    Over-the-counter antihistamine eye drop, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Vistide (cidofovir); Gilead;
                    Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/13/ophthalmology,"Vitrasert Implant; Chiron;
                    Drug delivery system for the treatment of cytomegalovirus, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Strensiq (asfotase alfa); Alexion;
                    For the treatment of hypophosphatasia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Otezla (apremilast); Celgene;
                    For the treatment of adults with active psoriatic arthritis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Xgeva (denosumab); Amgen;
                    For the treatment of giant cell tumor of bone, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Prolia (denosumab); Amgen;
                    For the treatment of osteoporosis and bone loss in men and women, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/28/orthopedics-orthopedic-surgery,"Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
                    For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Otiprio (ciprofloxacin otic suspension); Otonomy;
                    For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Grastek (Timothy Grass Pollen Allergen Extract); Merck;
                    For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Ragwitek (Short Ragweed Pollen Allergen Extract); Merck;
                    For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Xtoro (finafloxacin otic suspension) 0.3%; Alcon;
                    For the treatment of acute otitis externa, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc;
                    For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Vandetanib (vandetanib); AstraZeneca;
                    For the treatment of thyroid cancer, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Oravig (miconazole); Strativa Pharmaceuticals;
                    oropharyngeal candidiasis, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals;
                    For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Patanase (olopatadine hydrochloride); Alcon;
                    For the treatment of seasonal allergic rhinitis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Veramyst (fluticasone furoate); GlaxoSmithKline;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Depakote ER (divalproex sodium); Abbott Laboratories;
                    For the prophylaxis (prevention) of migraine headaches in adults, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth;
                    For treatment of erosive esophagitis, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
                    For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Ethyol (amifostine); US Bioscience, Alza;
                    Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Rocephin; Roche;
                    Treatment for pediatric otitis media, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Floxin otic; Daiichi Sankyo;
                    Treatment for otitis media, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Bactroban Nasal 2% (mupirocin calcium ointment); SmithKline Beecham;
                    Treatment for nasal bacteria, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/14/otolaryngology-ear-nose-throat,"Cedax (ceftibuten); Schering-Plough;
                    Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Asparlas (calaspargase pegol-mknl ); Servier;
                    For the treatment of acute lymphoblastic leukemia in pediatrics and young adults, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Diacomit (stiripentol) ; Biocodex;
                    For the treatment of seizures associated with Dravet syndrome, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Dupixent (dupilumab); Regeneron Pharmaceuticals;
                    For the treatment of moderate-to-severe asthma , Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Elzonris (tagraxofusp-erzs); Stemline Therapeutics;
                    For the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatrics, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Epidiolex (cannabidiol); GW Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Vaxelis (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b); Merck;
                    For the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b, Approved December 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Brineura (cerliponase alfa); BioMarin;
                    For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Emflaza (deflazacort); Marathon Pharmaceuticals;
                    For the treatment of Duchenne muscular dystrophy, Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Hemlibra (emicizumab-kxwh); Genentech;
                    For the prevention or reduction of bleeding episodes in patients with or without FVIII inhibitors, Approved November 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk;
                    For the treatment of  hemophilia B, Approved June 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Briviact (brivaracetam); UCB;
                    For the treatment of partial onset seizures related to epilepsy, Approved February 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Exondys 51 (eteplirsen); Sarepta Therapeutics;
                    For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ;
                    For the treatment of hemophillia A, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Spinraza (nusinersen); Biogen;
                    For the treatment of spinal muscular atrophy, Approved December 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Bexsero (Meningococcal Group B Vaccine); Novartis;
                    For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Cholbam (cholic acid); Asklepion Pharmaceuticals;
                    For the treatment of bile acid synthesis and peroxisomal disorders, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kanuma (sebelipase alfa); Alexion;
                    For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Orkambi (lumacaftor and ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Otiprio (ciprofloxacin otic suspension); Otonomy;
                    For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Strensiq (asfotase alfa); Alexion;
                    For the treatment of hypophosphatasia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Unituxin (dinutuximab); United Therapeutics;
                    For the treatment of pediatrics with high-risk neuroblastoma, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec;
                    For the treatment of hemophilia B, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline;
                    For the treatment of asthma, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Qudexy XR (topiramate); Upsher-Smith Laboratories;
                    For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Vimizim (elosulfase alfa); BioMarin;
                    For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Actemra (ocilizumab); Genentech;
                    For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Ilaris (canakinumab); Novartis;
                    For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kineret, anakinra; Swedish Orphan Biovitrum;
                    For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kynamro (mipomersen sodium); Genzyme;
                    For the treatment of homozygous familial hypercholesterolemia, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics;
                    For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tivicay (dolutegravir); ViiV HealthCare;
                    For the treatment of HIV-1 in adults and children over 12 years of age, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Trokendi XR (topiramate); Supernus Pharmaceuticals;
                    For the treatment of partial onset, tonic-clonic and Lennox-Gastaut Syndrome seizures, Approved August 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Fycompa (perampanel); Eisai;
                    For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Oxtellar XR (oxcarbazepine extended release); Supernus Pharmaceuticals;
                    For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Quillivant XR (methylphenidate hydrochloride); NextWave Pharmaceuticals;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Sklice (ivermectin) lotion; Sanofi Pasteur;
                    For the treatment of head lice, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Surfaxin (lucinactant); Discovery Laboratories;
                    For the treatment of respiratory distress syndrome in premature infants, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Actemra (tocilizumab); Genentech;
                    For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Daliresp (roflumilast); Forest Pharmaceuticals;
                    For the treatment of chronic obstructive pulmonary disease, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Onfi (clobazam); Lundbeck;
                    For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Approved October 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Cuvposa (glycopyrrolate); Shionogi;
                    For the treatment of chronic severe drooling in pediatrics with neurologic conditions, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Dulera (mometasone furoate + formoterol fumarate dihydrate); Merck;
                    For the treatment of asthma, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kapvay (clonidine hydrochloride); Shionogi;
                    For the treatment of attention deficit hyperactivity disorder, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Veltin (clindamycin phosphate and tretinoin); Stiefel;
                    For the treatment of acne vulgaris, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Berinert (C1 Esterase Inhibitor (Human)); CSL Behring;
                    For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Colcrys (colchicine); Mutual Pharmaceuticals;
                    For gout flares and familial Mediterranean fever, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline;
                    For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Ilaris (canakinumab); Novartis;
                    For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved June 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Intuniv (guanfacine extended-release); Shire Pharmaceuticals;
                    For the treatment of ADHD in children and adolescents, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Sabril (vigabatrin); Lundbeck;
                    For the treatment of infantile spasms and complex partial seizures, Approved August 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Accretropin (somatropin rDNA Original); Cangene;
                    For the treatment of growth failure in pediatrics, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Alvesco (ciclesonide); Nycomed;
                    For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Aptivus (tipranavir); Boehringer Ingelheim;
                    For the treatment of HIV, Approved June 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Banzel (rufinamide); Elan Pharmaceuticals;
                    For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Cinryze (C1 Inhibitor (Human)); Lev Pharmaceuticals;
                    For the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals;
                    For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Orencia (abatacept); Bristol-Myers Squibb;
                    For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Patanase (olopatadine hydrochloride); Alcon;
                    For the treatment of seasonal allergic rhinitis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Rotarix (Rotavirus Vaccine, Live, Oral); GlaxoSmithKline;
                    For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Altabax (retapamulin); GlaxoSmithKline;
                    For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Supprelin LA (histrelin acetate); Indevus Pharmaceuticals;
                    For the treatment of central precocious puberty, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Veramyst (fluticasone furoate); GlaxoSmithKline;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Vyvanse (Lisdexamfetamine Dimesylate); New River;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Zingo (lidocaine hydrochloride monohydrate); Powder Pharmaceuticals;
                    For local analgesia prior to venipuncture or peripheral intravenous cannulation, Approved August 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Desonate (desonide); Dow Pharm;
                    For the treatment of atopic dermatitis, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Elaprase (idursulfase); Shire Pharmaceuticals;
                    For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Myozyme (alglucosidase alfa); Genzyme;
                    For the treatment of Pompe disease (glycogen storage disease type II), Approved April 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Aldurazyme (laronidase); Genzyme;
                    For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Alinia (nitazoxanide); Romark Laboratories;
                    For the treatment Diarrhea caused by Cryptosporidium and Giardia in children., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Daptacel; Sanofi Pasteur;
                    Pediatric vaccine for immunization against diptheria, tetanus and pertussis, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Fluzone Preservative-free; Sanofi Pasteur;
                    Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Orfadin (nitisinone); Orphan Pharmaceuticals;
                    Capsules for the treatment of hereditary tyrosinemia type I, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Pediarix Vaccine; GlaxoSmithKline;
                    For the prevention of diphtheria, tetanus, pertussi, polio and  hepatitis  B in children 6 weeks to 7 years old., Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Qvar (beclomethasone dipropionate); Ivax;
                    For the treatment of asthma, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Ritalin LA (methylphenidate HCl); Novartis;
                    Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Strattera (atomoxetine HCl); Eli Lilly;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Adderall XR; Shire Pharmaceuticals;
                    Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Focalin (dexmethylphenidate HCl); Celgene;
                    For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Genotropin (somatropin) injection; Pharmacia & Upjohn;
                    For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Metadate CD; Celltech Pharmaceuticals;
                    Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"NasalCrom Nasal Spray; Pharmacia & Upjohn;
                    Over-the-counter nasal spray for treatment of all nasal allergy symptoms, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Kogenate FS (Antihemophilic Factor Recombinant); Bayer;
                    For the treatment of hemophilia A, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
                    For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Neurontin (gabapentin) oral solution; Parke-Davis;
                    For the treatment of partial seizures in pediatric patients three years of age and older, Approved October 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Trileptal (oxcarbazepine) Tablets; Novartis;
                    Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Amoxil (amoxicillin); SmithKline Beecham;
                    Treatment (antibiotic) for common bacteria, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Topamax (topiramate); Ortho-McNeil Pharmaceutical;
                    Treatment for epilepsy in pediatric patients, Approved July 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Curosurf; Dey Laboratories;
                    Treatment for respiratory distress syndrome in premature infants., Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Cylert; Abbott Laboratories;
                    Treatment for Attention Deficit Disorder, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Desmopressin Acetate (DDAVP); Rhone Poulenc Rorer;
                    Treatment for nocturnal enuresis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Infasurf; ONY;
                    For the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants, Approved July 1998."
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Rocephin; Roche;
                    Treatment for pediatric otitis media, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Singulair; Merck;
                    Treatment for asthma, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Timentin; SmithKline Beecham;
                    Treatment for wide range of infections in children, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Viroptic; King Pharmaceuticals;
                    Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology," INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham;
                    Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"AneuVysion Assay; Vysis;
                    Genetic test for birth defects, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Antizol Injection; Orphan Medical;
                    Treatment for ethylene glycol poisoning, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Flovent Rotadisk; GlaxoSmithKline;
                    Treatment of asthma in patients four and older, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Floxin otic; Daiichi Sankyo;
                    Treatment for otitis media, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Geref (sermorelin acetate for injection); Serono Laboratories;
                    Treatment for pedicatric growth disorder, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Norditropin  (somatropin (rDNA origin) for injection); Novo Nordisk;
                    Treatment of children who have growth failure, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Norvir (ritonavir); Abbott Laboratories;
                    Treatment for HIV infection, Approved March 1996/March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for mild-to-moderate bronchial asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Timentin; SmithKline Beecham;
                    Treatment for septicemia, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tobi; PathoGenesis;
                    Treatment for cystic fibrosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"VERSED (midazolam HCI); Roche;
                    Treatment for sedating children who must undergo painful surgery, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals;
                    Treatment for HIV infection in adults and children, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Zerit (stavudine); Bristol-Myers Squibb;
                    Treatment for infants and children infected with HIV, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Zoloft (sertraline HCl); Pfizer;
                    Treatment of panic disorder in children ages 6-17, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Adderall (mixed salts of a single-entity amphetamine); Richwood Pharmaceutical;
                    Treatment for attention-deficit/hyperactivity disorder, Supplemental NDA Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Children's Advil (pediatric ibuprofen); Whitehall-Robins Healthcare;
                    Treatment of fever and minor aches and pains, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Claritin Syrup (loratadine); Schering-Plough;
                    Treatment for children with seasonal allergies, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Havrix; SmithKline Beecham;
                    Treatment for hepatitis A, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Merrem I.V. (meropenem); AstraZeneca;
                    Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
                    Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tegretol (carbamazepine); Ciba Pharmaceuticals;
                    Treatment for young children with epilepsy, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology,"Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed); Connaught Laboratories;
                    Treatment for whooping cough, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola Pharmaceuticals;
                    for the reversal of factor Xa inhibitors, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Lucemyra (lofexidine); US Worldmeds;
                    For the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Actemra (tocilizumab) injection; Genentech;
                    For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Gocovri (amantadine) ; Adamas Pharmaceuticals;
                    For the treatment of Parkinson's disease dyskinesia, Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Sustol (granisetron); Heron Therapeutics;
                    For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Bridion (sugammadex); Merck;
                    For the reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery, Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Akynzeo (netupitant and palonosetron); Helsinn;
                    For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Bunavail (buprenorphine and naloxone); BioDelivery Sciences;
                    For the maintenance treatment of opioid dependence, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Movantik (naloxegol); AstraZeneca;
                    For the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Myalept (metreleptin for injection); Bristol-Myers Squibb;
                    For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Kcentra (Prothrombin Complex Concentrate); CSL Behring;
                    For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Voraxaze (glucarpidase); BTG International;
                    For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function, Approved January 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Oxecta (oxycodone HCl); Pfizer;
                    For the management of acute and chronic moderate to severe pain, Approved June 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Egrifta (tesamorelin for injection); Theratechnologies;
                    For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals;
                    For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Akten (lidocaine hydrochloride); Akorn;
                    For anesthesia during ophthalmologic procedures, Approved October 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Fusilev (levoleucovorin); Spectrum Pharmaceuticals;
                    For rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate, Approved March of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Sancuso (granisetron); ProStrakan;
                    For the treatment of chemotherapy-induced nausea and vomiting, Approved September 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Campral (acamprosate calcium); Forest Laboratories;
                    For the treatment of alcohol dependence and the maintenance of alcohol abstinence, Approved August, 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Mesnex; Bristol-Myers Squibb, Baxter Healthcare;
                    Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex (ifosfamide), Approved March 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Subutex/Suboxone (buprenorphine/naloxone); Reckitt Benckiser;
                    Oral tablets for the treatment of opiate dependence, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Raplon; Organon;
                    Adjunct to general anesthesia during surgical procedures, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"AneuVysion Assay; Vysis;
                    Genetic test for birth defects, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Antizol Injection; Orphan Medical;
                    Treatment for ethylene glycol poisoning, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Galzin (zinc acetate); Teva Pharmaceutical;
                    Treatment for Wilsonâ€™s disease, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Kytril (granisetron) tablets; SmithKline Beecham;
                    Prevention of nausea and vomiting associated with chemotherapy, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Oxycodone with Acetaminophen 5mg/325mg; Watson Pharmaceuticals;
                    Generic equivalent of Percocet and Tylox, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Trovan; Pfizer;
                    Treatment for bacterial infections, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Iontocaine; Iomed;
                    Needle-free anesthetic, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals;
                    Treatment for nail fungal infections, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/16/pharmacology-toxicology,"Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
                    Treatment for vitamin B-12 deficiency, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals;
                    For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Veregen (kunecatechins); Medigene;
                    For the treatment of external genital and perianal warts, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis;
                    For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough;
                    For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Aldara (imiquimod); 3M Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals;
                    Treatment for external genital and perianal warts, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"Mentax (1% butenafine HCl cream); Penederm;
                    Treatment for athlete's foot, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/30/podiatry,"REGRANEX (becaplermin) Gel; RW Johnson;
                    Treatment for diabetic foot ulcers, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Spravato (esketamine) nasal spray; Janssen Pharmaceuticals;
                    For the treatment of treatment-resistant depression in adults, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zulresso (brexanolone); Sage Therapeutics;
                    For the treatment of postpartum depression, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Nuplazid (pimavanserin); Acadia Pharmaceuticals;
                    For the treatment of hallucinations and delusions associated with Parkinsonâ€™s disease psychosis, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Aristada (aripiprazole lauroxil) extended-release injectable; Alkermes;
                    For the treatment of schizophrenia, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Rexulti (brexpiprazole); Otsuka;
                    For the treatment of depression and schizophrenia, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Vraylar (cariprazine); Allergan;
                    For the treatment of schizophrenia and bipolar disorder, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Bunavail (buprenorphine and naloxone); BioDelivery Sciences;
                    For the maintenance treatment of opioid dependence, Approved June 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Brintellix (vortioxetine); Takeda Pharmaceuticals USA;
                    For the treatment of Major Depressive Disorder, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Fetzima (levomilnacipran); Forest Laboratories;
                    For the treatment of major depressive disorder, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zubsolv (buprenorphine and naloxone); Orexo AB;
                    For the maintenance treatment of opioid dependence, Approved July 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Qsymia (phentermine + topiramate extended-release); Vivus;
                    For the treatment of chronic weight management, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Quillivant XR (methylphenidate hydrochloride); NextWave Pharmaceuticals;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals;
                    For the treatment of insomnia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Viibryd (vilazodone hydrochloride); Clinical Data;
                    For the treatment of major depressive disorder, Approved January 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Latuda (lurasidone); Sunovion;
                    For the treatment of schizophrenia, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Oleptro (trazodone hydrochloride); Labopharm;
                    For the treatment of major depressive disorder, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the prevention of relapse to opioid dependence, Approved October 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Edluar (zolpidem tartrate); Orexo;
                    For the treatment of insomnia, Approved March 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Fanapt (iloperidone); Vanda;
                    For the treatment of schizophrenia, Approved May of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Intuniv (guanfacine extended-release); Shire Pharmaceuticals;
                    For the treatment of ADHD in children and adolescents, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Saphris (asenapine); Schering-Plough;
                    For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Aplenzin (bupropion hydrobromide); Biovail Laboratories;
                    For the treatment of major depressive disorder, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Stavzor (valproic acid delayed release); Banner Pharmacaps;
                    For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Vyvanse (Lisdexamfetamine Dimesylate); New River;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Chantix (varenicline); Pfizer;
                    For the treatment of nicotine addiction, Approved May 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Invega (paliperidone); Janssen Pharmaceuticals;
                    For the treatment of schizophrenia, Approved December 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
                    For the treatment of alcohol dependence, Approved April 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Cymbalta (duloxetine); Eli Lilly;
                    For the treatment of major depressive disorder, Approved August 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Abilify (aripiprazole); Bristol-Myers Squibb, Otsuka America Pharmaceutical;
                    Oral drug for the treatment of schizophrenia, Approved November 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Geodon (ziprasidone mesylate); Pfizer;
                    To control agitated behavior and psychotic symptoms in schizophrenia patients, Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Lexapro (escitalopram oxalate); Forest Laboratories;
                    An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder, Approved August 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Paxil CR (paroxetine hydrochloride); GlaxoSmithKline;
                    Oral tablet for the treatment of depression and panic disorder, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Ritalin LA (methylphenidate HCl); Novartis;
                    Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Strattera (atomoxetine HCl); Eli Lilly;
                    For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Subutex/Suboxone (buprenorphine/naloxone); Reckitt Benckiser;
                    Oral tablets for the treatment of opiate dependence, Approved October 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zoloft (sertraline HCl); Pfizer;
                    Oral tablets for the treatment of premenstrual dysphoric mood disorder (PMDD), Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Adderall XR; Shire Pharmaceuticals;
                    Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Focalin (dexmethylphenidate HCl); Celgene;
                    For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Metadate CD; Celltech Pharmaceuticals;
                    Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Prozac Weekly (fluoxetine HCl); Eli Lilly;
                    For the treatment of depression, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Remeron SolTab (mirtazapine); Organon;
                    Orally disintegrating tablet for the treatment of depression, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Ziprasidone (ziprasidone hydrochloride); Pfizer;
                    Oral capsule for the treatment of schizophrenia, Approved February 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Concerta; Alza;
                    For the treatment of Attention Deficit Hyperactivity Disorder, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Effexor (venlafaxin HCL); Wyeth;
                    Treatment for generalized anxiety disorder, Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Paxil CR (paroxetine hydrochloride); SmithKline Beecham;
                    Treatment for depression, Approved March 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Sonata; American Home Products;
                    Treatment fo insomnia, Approved August 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Celexa; Forest Laboratories;
                    Treatment for depression, Approved July 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Clomipramine hydrochloride; Mylan Laboratories;
                    Generic equivalent of Anafranil, Approved April 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Cylert; Abbott Laboratories;
                    Treatment for Attention Deficit Disorder, Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Marplan Tablets; Roche;
                    Treatment of Depression, Approved August 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Naltrexone Hydrochloride Tablets; Barr Laboratories;
                    Generic equivalent of Revia, Approved May 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Prochlorperazine; IVAX;
                    Generic equivalent of SmithKline Beecham's Compazine, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Effexor XR (venlafaxin HCI); Wyeth;
                    Treatment of depression, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Generic Transdermal Nicotine Patch; Sano;
                    Generic equivalent of Habitrol, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"LUVOX  (fluvoxamine maleate); Solvay Pharmaceuticals, Pharmacia & Upjohn;
                    Treatment for obsessive compulsive disorder (OCD) in children and adolescents, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Seroquel (R)  (quetiapine fumarate) Tablets; AstraZeneca;
                    Treatment for schizophrenia, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Trazadone 150mg; Teva Pharmaceutical;
                    Generic equivalent of Desyrel 7, Approved  May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zoloft (sertraline HCl); Pfizer;
                    Treatment for panic disorder, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zoloft (sertraline HCl); Pfizer;
                    Treatment of panic disorder in children ages 6-17, Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zyban Sustained-Release Tablets; GlaxoSmithKline;
                    Treatment for smoking cessation, Approved May 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Adderall (mixed salts of a single-entity amphetamine); Richwood Pharmaceutical;
                    Treatment for attention-deficit/hyperactivity disorder, Supplemental NDA Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"ARICEPT (donepezil hydrochloride); Eisai;
                    Treatment for Alzheimer's Disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Depakote (divalproex sodium); Abbott Laboratories;
                    Treatment for migraine headaches, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Lithobid (Lithium Carbonate); Solvay Pharmaceuticals;
                    Treatment for manic depression, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"NicoDerm CQ; SmithKline Beecham, Hoechst Marion Roussel, Alza;
                    Treatment for smoking cessation, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Nicorette (nicotine polacrilex); SmithKline Beecham;
                    Over-the-counter aid in smoking cessation, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Nicotrol nasal spray; Pharmacia & Upjohn;
                    Treatment for nicotine addiction, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Nicotrol transdermal patch; McNeil Consumer Products;
                    Treatment for smoking cessation, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Paxil (paroxetine hydrochloride); SmithKline Beecham;
                    Treatment for panic disorder, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Redux (dexfenfluramine hydrochloride); Wyeth;
                    Treatment for obesity, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Remeron (Mirtazapine); Organon;
                    Treatment for depression, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Risperdal Oral Formulation; Janssen Pharmaceuticals;
                    Treatment for schizophrenia, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology,"Zyprexa; Eli Lilly;
                    Treatment of the symptoms of psychotic disorders, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Sunosi (solriamfetol) ; Jazz Pharmaceuticals;
                    For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tecentriq (atezolizumab); Genentech/Roche;
                    For the treatment of extensive-stage small cell lung cancer , Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Dupixent (dupilumab); Regeneron Pharmaceuticals;
                    For the treatment of moderate-to-severe asthma , Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Lorbrena (lorlatinib); Pfizer;
                    For the treatment of ALK-positive metastatic non-small cell lung cancer , Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Nuzyra (omadacycline) ; Paratek Pharmaceuticals;
                    For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, Approved October 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of advanced small cell lung cancer, Approved August 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Symdeko (tezacaftor/ivacaftor) ; Vertex;
                    For the treatment of cystic fibrosis , Approved February 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Vizimpro (dacomitinib); Pfizer;
                    For the treatment of metastatic non-small cell lung cancer , Approved September 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Yupelri (revefenacin); Theravance Biopharma;
                    For the maintenance treatment of chronic obstructive pulmonary disease, Approved November 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Imfinzi (durvalumab); AstraZeneca;
                    For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca;
                    For the treatment of chronic obstructive pulmonary disease, Approved April 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cinqair (reslizumab); Teva Pharmaceuticals;
                    For the treatment of severe asthma, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tecentriq (atezolizumab); Genentech;
                    For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Alecensa (alectinib); Roche;
                    For the treatment of ALK-positive, metastatic non-small cell lung cancer , Approved December 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Keytruda (pembrolizumab); Merck;
                    For the treatment of PD-L1 positive advanced non-small cell lung cancer, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Nucala (mepolizumab); GlaxoSmithKline;
                    For the treatment of severe asthma with an eosinophilic phenotype, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015 "
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Orkambi (lumacaftor and ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis, Approved July 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Portrazza (necitumumab) ; Eli Lilly;
                    For the treatment of metastatic squamous non-small cell lung cancer, Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Stiolto Respimat (tiotropium bromide and olodaterol) ; Boehringer Ingelheim;
                    For the maintenance of  chronic obstructive pulmonary disease, Approved May 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tagrisso (osimertinib); AstraZeneca;
                    For the treatment of EGFR T790M mutation positive non-small cell lung cancer , Approved November 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Utibron Neohaler (indacaterol and glycopyrrolate); Novartis;
                    For the long term, maintenance treatment of airflow obstruction in patients with COPD, Approved October 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline;
                    For the treatment of asthma, Approved August 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Esbriet (pirfenidone); InterMune;
                    For the treatment of idiopathic pulmonary  fibrosis , Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Grastek (Timothy Grass Pollen Allergen Extract); Merck;
                    For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Incruse Ellipta (umeclidinium inhalation powder); GlaxoSmithKline;
                    For the treatment of chronic obstructive pulmonary disease, Approved May 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Ofev (nintedanib); Boehringer Ingelheim;
                    For the treatment of idiopathic pulmonary  fibrosis , Approved October 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs;
                    For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Ragwitek (Short Ragweed Pollen Allergen Extract); Merck;
                    For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Striverdi Respimat (olodaterol); Boehringer Ingelheim;
                    For the treatment of chronic obstructive pulmonary  disease , Approved July 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zykadia (ceritinib); Novartis;
                    For the treatment of ALK+ metastatic non-small cell lung cancer, Approved April 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Adempas (riociguat); Bayer Healthcare Pharmaceuticals;
                    For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Anoro Ellipta (umeclidinium and vilanterol inhalation powder); GlaxoSmithKline;
                    For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline;
                    For the treatment of chronic obstructive pulmonary disease, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Opsumit (macitentan); Actelion Pharmaceuticals;
                    For the treatment of pulmonary arterial hypertension, Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Vibativ (telavancin); Theravance;
                    For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus, Approved June 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene;
                    For the treatment of non-small cell lung cancer, Approved October 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc;
                    For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Kalydeco (ivacaftor); Vertex Pharmaceuticals;
                    For the treatment of cystic fibrosis with the G551D mutation in the CFTR gene, Approved January of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical;
                    For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Sirturo (bedaquiline); Janssen Therapeutics;
                    For the treatment of multi-drug resistant tuberculosis, Approved December 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Surfaxin (lucinactant); Discovery Laboratories;
                    For the treatment of respiratory distress syndrome in premature infants, Approved March 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories;
                    For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Arcapta (indacaterol maleate inhalation powder); Novartis;
                    For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease, Approved July 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Daliresp (roflumilast); Forest Pharmaceuticals;
                    For the treatment of chronic obstructive pulmonary disease, Approved February 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Xalkori (crizotinib); Pfizer;
                    For the treatment of ALK+ non-small cell lung cancer, Approved August of 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cayston (aztreonam for inhalation solution); Gilead;
                    For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Dulera (mometasone furoate + formoterol fumarate dihydrate); Merck;
                    For the treatment of asthma, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Adcirca (tadalafil); Eli Lilly;
                    For the treatment of pulmonary arterial hypertension, Approved May 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tyvaso (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension, Approved July 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Alimta  (pemetrexed for injection); Eli Lilly;
                    For the treatment of non-small cell lung cancer, Approved September 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Alvesco (ciclesonide); Nycomed;
                    For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents, Approved January 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Patanase (olopatadine hydrochloride); Alcon;
                    For the treatment of seasonal allergic rhinitis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Letairis (ambrisentan); Gilead;
                    For the treatment of pulmonary arterial hypertension, Approved June 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Xyzal (levocetirizine dihydrochloride); UCB;
                    For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Avastin (bevacizumab); Genentech;
                    For the treatment of nonâ€“squamous nonâ€“small cell lung cancer, Approved October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Brovana (arformoterol tartrate); Sepracor;
                    For the treatment of Chronic Obstructive Pulmonary Disease, Approved in October 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tygacil (tigecycline); Wyeth;
                    For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Ketek (telithromycin); Sanofi-aventis;
                    For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia., Approved April 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Spiriva HandiHaler (tiotropium bromide); Boehringer Ingelheim;
                    For the treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved February 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Aldurazyme (laronidase); Genzyme;
                    For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Iressa (gefitinib); AstraZeneca;
                    For the second-line treatment of non-small-cell lung cancer, Approved May 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Xolair (omalizumab); Genentech;
                    For the treatment of asthma, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
                    For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Clarinex; Schering-Plough;
                    Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Qvar (beclomethasone dipropionate); Ivax;
                    For the treatment of asthma, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Remodulin (treprostinil); United Therapeutics;
                    For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Xopenex; Sepracor;
                    Inhaled solution for treatment of reversible obstructive airway disease, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Avelox I.V. (moxifloxacin hydrochloride); Bayer;
                    For adults with susceptible strains of bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"DuoNeb (albuterol sulfate and ipratropium bromide); Dey Laboratories;
                    For the treatment of bronchospasm associated with COPD, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Foradil Aerolizer (formoterol fumarate inhalation powder); Novartis;
                    Bronchodilator for COPD, asthma and bronchospasm, Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"NasalCrom Nasal Spray; Pharmacia & Upjohn;
                    Over-the-counter nasal spray for treatment of all nasal allergy symptoms, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tavist (clemastine fumarate); Novartis;
                    Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tracleer (bosentan); Actelion;
                    For the treatment of pulmonary arterial hypertension, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Ventolin HFA (albuterol sulfate inhalation aerosol); GlaxoSmithKline;
                    For the treatment or prevention of bronchospasm, Approved April 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Advair (fluticasone propionate and salmeterol); GlaxoSmithKline;
                    For the treatment of asthma and chronic obstructive pulmonary disease , Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories;
                    For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
                    For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Accolate; AstraZeneca;
                    zafirlukast, 10 mg and 20 mg tablets., Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cafcit Injection; Roxane Laboratories;
                    For the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age., Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Proventil HFA Inhalation Aerosol; 3M Pharmaceuticals;
                    Treatment or prevention of bronchospasm, Approved June 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Rhinocort Aqua Nasal Spray; AstraZeneca;
                    A nasal spray containing budesonide, Approved October 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tequin; Bristol-Myers Squibb;
                    Tequin (Injectable and Tablet), December, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tikosyn Capsules; Pfizer;
                    Capsules of dofetilide, Approved October 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Allegra-D; Hoechst Marion Roussel;
                    Treatment for nasal congestion due to seasonal allergy, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Clemastine fumarate syrup; Morton Grove Pharmaceuticals;
                    Generic equivalent of Tavist Syrup, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Curosurf; Dey Laboratories;
                    Treatment for respiratory distress syndrome in premature infants., Approved October 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Dynabac; Sanofi-aventis;
                    Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Infasurf; ONY;
                    For the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants, Approved July 1998."
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Priftin; Hoechst Marion Roussel;
                    Treatment for pulmonary tuberculosis, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Sclerosol Intrapleural Aerosol; Bryan Corporation;
                    Treatment for malignant pleural effusions, Approved January 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Singulair; Merck;
                    Treatment for asthma, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Synagis; MedImmune;
                    Treatment for the prevention of serious lower respiratory tract disease in infants, Approved June 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Ceftin (cefuroxime axetil); GlaxoSmithKline;
                    Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cipro (ciprofloxacin HCl); Bayer;
                    Treatment for acute sinusitis, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet); Schering-Plough;
                    Treatment for seasonal allergy symptoms, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Flonase Nasal Spray; GlaxoSmithKline;
                    Treatment for seasonal and perennial allergic rhinitis, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Flovent Rotadisk; GlaxoSmithKline;
                    Treatment of asthma in patients four and older, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Metaprotereol Sulfate Inhalation Solution, 5%; Morton Grove Pharmaceuticals;
                    Generic equivalent of Alupentr Inhalation Solution, 5%, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Raxar (grepafloxacin); GlaxoSmithKline;
                    Treatment for chronic bronchitis, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Serevent; GlaxoSmithKline;
                    Treatment of asthma, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for mild-to-moderate bronchial asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for asthma, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tilade (nedocromil sodium); Rhone Poulenc Rorer;
                    Treatment for mild to moderate asthma, Approved November 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tobi; PathoGenesis;
                    Treatment for cystic fibrosis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Vanceril 84 mcg Double Strength (beclomethasone dipropionate, 84 mcg) Inhalation Aerosol; Schering-Plough;
                    Treatment for asthma, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zagam (sparfloxacin) tablets; Rhone Poulenc Rorer;
                    Treatment for community-acquired pneumonia (CAP) and chronic bronchitis, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zyflo (Zileuton); Abbott Laboratories;
                    Treatment for asthma in patients 12 years and older, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Accolate; AstraZeneca;
                    Treatment for asthma, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Allegra (fexofenadine hydrochloride); Hoechst Marion Roussel;
                    Treatment for seasonal allergy symptoms, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Astelin nasal spray; Wallace Laboratories;
                    Treatment for seasonal allergic rhinitis, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Atrovent (ipratropium bromide); Boehringer Ingelheim;
                    Treatment for runny nose due to allergies and the common cold, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Augmentin (amoxicillin/clavulanate); SmithKline Beecham;
                    Treatment for infections involving drug-resistant bacteria, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Azmacort (triamcinolone acetonide) Inhalation Aerosol; Rhone Poulenc Rorer;
                    Treatment for asthma, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Breathe Right; CNS;
                    Treatment for breathing difficulties due to deviated nasal septum, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Claritin Syrup (loratadine); Schering-Plough;
                    Treatment for children with seasonal allergies, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate); Schering-Plough;
                    Treatment for nasal congestion, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Covera-HS (verapamil); GD Searle, Alza;
                    Treatment for hypertension and angina, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Nasacort AQ (triamcinolone acetonide) Nasal Spray; Rhone Poulenc Rorer;
                    Treatment for allergic rhinitis, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"OcuHist; Pfizer;
                    Over-the-counter antihistamine eye drop, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Pulmozyme (dornase alfa); Genentech;
                    Treatment for cystic fibrosis patients with advanced disease, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
                    Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tavist (clemastine fumarate); Sandoz Pharmaceuticals;
                    Treatment for cold symptoms, Approved November 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed); Connaught Laboratories;
                    Treatment for whooping cough, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Vancenase AQ 84 mcg Double Strength; Schering-Plough;
                    Treatment for allergic and non-allergic rhinitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Visipaque (iodixanol); Nycomed;
                    Diagnostic contrast agent, Approved April 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zosyn (sterile piperacillin sodium/tazobactam sodium); Wyeth;
                    Treatment for hospital-acquired pneumonia, Approved May 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Cedax (ceftibuten); Schering-Plough;
                    Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/18/pulmonary-respiratory-diseases,"Zyrtec (cetirizine HCl); Pfizer;
                    Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/35/rare-diseases-and-disorders,"Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline;
                    For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/35/rare-diseases-and-disorders,"Carbatrol; Elan Pharmaceuticals;
                    Treatment for epileptic seizures and trigeminal neuralgia, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Olumiant (baricitinib); Eli Lilly;
                    For the treatment of moderate to severe rheumatoid arthritis with inadequete response to TNF antagonist therapies, Approved May 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Duzallo (lesinurad and allopurinol) ; Ardea Biosciences;
                    For the treatment of hyperuricemia associated with gout , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Kevzara (sarilumab); Sanofi ;
                    For the treatment of active rheumatoid arthritis, Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics;
                    For the treatment of osteoarthritis knee pain, Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Taltz (ixekizumab); Eli Lilly;
                    For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Otezla (apremilast); Celgene;
                    For the treatment of adults with active psoriatic arthritis, Approved March 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Actemra (ocilizumab); Genentech;
                    For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active psoriatic arthritis, Approved September 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of active ankylosing spondylitis , Approved October 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Ilaris (canakinumab); Novartis;
                    For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Rayos (prednisone) delayed-release tablets; Horizon Pharma;
                    For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and  psoriatic conditions, Approved July of 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Stendra (avanafil); Vivus;
                    For the treatment of erectile dysfunction, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Xeljanz (tofacitinib); Pfizer;
                    For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Actemra (tocilizumab); Genentech;
                    For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Duexis (ibuprofen and famotidine); Horizon Pharma;
                    For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Actemra (tocilizumab); Genentech;
                    For the treatment of rheumatoid arthritis, Approved January 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Krystexxa (pegloticase); Savient Pharma;
                    For the treatment of chronic gout (hyperuricemia), Approved September 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Vimovo (naproxen + esomeprazole); AstraZeneca;
                    For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Cimzia (certolizumab pegol); UCB;
                    For the treatment of rheumatoid arthritis, Approved May of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Colcrys (colchicine); Mutual Pharmaceuticals;
                    For gout flares and familial Mediterranean fever, Approved October 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Pennsaid (diclofenac sodium topical solution); Nuvo Research;
                    For the treatment of osteoarthritis of the knee, Approved November 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Simponi (golimumab); Centocor Ortho Biotech;
                    For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Stelara (ustekinumab); Janssen Biotech;
                    For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease, Approved September 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Uloric (febuxostat); Takeda;
                    For the treatment of chronic hyperuricemia in patients with gout, Approved February 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Orencia (abatacept); Bristol-Myers Squibb;
                    For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Elaprase (idursulfase); Shire Pharmaceuticals;
                    For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Rituxan (rituximab); Biogen IDEC, Genentech;
                    For the treatment of moderately-to severely-active rheumatoid arthritis, Approved February 2006"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Orencia (abatacept); Bristol-Myers Squibb;
                    For the Treatment of Rheumatoid Arthritis, Approved December 2005"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Vioxx (rofecoxib); Merck;
                    For the treatment of rheumatoid arthritis, Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Enbrel (etanercept); Immunex;
                    For the treatment of psoriatic arthritis, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Humira (adalimumab); Abbott Laboratories;
                    For the treatment of moderately to severely active rheumatoid arthritis, Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Remicade (infliximab); Centocor Ortho Biotech;
                    Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Bextra; Pharmacia, Pfizer;
                    Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Kineret; Amgen;
                    Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Remicade (infliximab); Centocor Ortho Biotech;
                    For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Supartz; Smith & Nephew Orthopaedics;
                    Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Mobic (meloxicam) Tablets; Boehringer Ingelheim;
                    For relief of the signs and symptoms of osteoarthritis, Approved April 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Vivelle (estradiol transdermal system); Novartis;
                    For the prevention of postmenopausal osteoporosis, Approved August 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Lodine XL (etodolac); Wyeth;
                    Treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis, Approved May 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Arava; Hoechst Marion Roussel;
                    Treatment for Rheumatoid Arthritis, Approved September 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Lodine XL (etodolac); Wyeth;
                    Treatment for arthritis, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Salagen Tablets; MGI Pharma;
                    Treatment for Sjogren's Syndrome, Approved February 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Arthrotec; Searle;
                    Treatment for arthritis, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Etodolac; Royce Laboratories;
                    Generic equivalent of Lodine, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Etodolac; Royce Laboratories;
                    Generic equivalent of  Lodine, Approved April 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Ketoprofen; Schein Pharmaceutical;
                    Generic equivalent or Oruvail, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Synvisc, Synvisc-One (Hylan GF 20); Genzyme;
                    For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Tolmetin Sodium; Teva Pharmaceutical;
                    Treatment for arthritis, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn;
                    Treatment for rheumatoid arthritis, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Lodine (etodolac); Wyeth;
                    Treatment for rheumatoid arthritis, Approved July 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology,"Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
                    Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/31/sleep,"Hetlioz (tasimelteon); Vanda Pharmaceuticals;
                    For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/31/sleep,"Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals;
                    For the treatment of insomnia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/31/sleep,"Silenor (doxepin); Somaxon Pharma;
                    For the treatment of insomnia, Approved March 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Kcentra (Prothrombin Complex Concentrate); CSL Behring;
                    For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Lyrica (pregabalin); Pfizer;
                    For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Exparel (bupivacaine liposome injectable suspension); Pacira Pharmaceuticals;
                    For postsurgical analgesia, Approved November 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals;
                    For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
                    For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human); Octapharma;
                    For the treatment of von Willebrand disease, Approved December of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"Iamin; ProCyte;
                    Gel wound dressing, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/20/trauma-emergency-injury-surgery,"OsmoCyte Pillow Wound Dressing; ProCyte;
                    Treatment for chronic and acute wounds, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Jatenzo (testosterone undecanoate); Clarus Therapeutics;
                    For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Erleada (apalutamide); Janssen Oncology;
                    For the treatment of prostate cancer, Approved February 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Nocdurna (desmopressin acetate); Ferring Pharmaceuticals;
                    For the treatment of nocturia due to nocturnal polyuria , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Zemdri (plazomicin); Achaogen;
                    For the treatment of complicated urinary tract infections , Approved June 2018"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Imfinzi (durvalumab); AstraZeneca;
                    For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Keytruda (pembrolizumab); Merck;
                    For the treatment of urothelial carcinoma (bladder cancer), Approved May 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Opdivo (nivolumab); Bristol-Myers Squibb;
                    For the treatment of metastatic urothelial carcinoma , Approved February 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Vabomere (meropenem and vaborbactam); The Medicines Company;
                    For the treatment of complicated urinary tract infections , Approved August 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Tecentriq (atezolizumab); Genentech;
                    For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Avycaz  (ceftazidime-avibactam); Actavis;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Xuriden (uridine triacetate); Wellstat Therapeutics;
                    For the treatment of hereditary orotic aciduria, Approved September 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals;
                    For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Xiaflex (collagenase clostridium histolyticum); Auxilium;
                    For the treatment of Peyronie's disease, Approved December of 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Xofigo (radium Ra 223 dichloride); Bayer Healthcare Pharmaceuticals;
                    For the treatment of prostate cancer with bone metastases, Approved May 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Bio-T-Gel (testosterone gel); Teva Pharmaceutical;
                    For the treatment of hypogonadism, Approved February 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Myrbetriq (mirabegron); Astellas Pharma US, Inc;
                    For the treatment of overactive bladder, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Stendra (avanafil); Vivus;
                    For the treatment of erectile dysfunction, Approved April 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Xtandi (enzalutamide); Medivation;
                    For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Anturol (oxybutynin) Gel; Antares Pharma;
                    For the treatment of overactive bladder, Approved December 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Zytiga (abiraterone acetate); Centocor Ortho Biotech;
                    For the treatment of prostate cancer, Approved May 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Jalyn (dutasteride + tamsulosin); GlaxoSmithKline;
                    For the treatment of benign prostatic hyperplasia, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Jevtana (cabazitaxel); sanofi aventis;
                    For the treatment of prostate cancer, Approved June 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Provenge (sipuleucel-T); Dendreon;
                    For the treatment of hormone refractory prostate cancer, Approved May 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Degarelix (degarelix for injection); Ferring Pharmaceuticals;
                    For the treatment of prostate cancer, Approved December of 2008"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Doribax (doripenem); Johnson & Johnson;
                    For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Cialis (tadalafil); Eli Lilly;
                    Oral agent for the treatment for erectile dysfunction, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Levitra (vardenafil); Bayer, GlaxoSmithKline;
                    For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals;
                    For treatment of advanced prostate cancer, Approved December 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis;
                    For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals;
                    Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Eligard (leuprolide acetate); Atrix Laboratories;
                    For the palliative treatment of advanced prostate cancer, Approved January 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Dutasteride; GlaxoSmithKline;
                    For the treatment of symptomatic benign prostatic hyperplasia, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Trelstar LA (triptorelin pamoate); Debiopharm;
                    Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories;
                    For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
                    For the palliative treatment of advanced prostate cancer, Approved June 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Viadur (leuprolide acetate implant); Alza;
                    For pain relief in men with advanced prostate cancer, Approved March 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Viagra; Pfizer;
                    Treatment for impotence, Approved March 1998"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology," INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham;
                    Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"EDEX; Schwarz Pharma;
                    Treatment for erectile dysfunction, Approved June 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"FEMSTAT One; Roche;
                    Treatment for vaginal yeast infections, Approved Februrary 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"FLOMAX; Boehringer Ingelheim;
                    Treatment for benign prostatic hypertrophy (BPH), Approved October 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Follistim (TM) (follitropin beta for injection); Organon;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Gonal-F (follitropin alfa for injection); Serono Laboratories;
                    Treatment for infertility, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Interstim Continence Control Therapy; Medtronic;
                    Treatment for incontinence, Approved September 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals;
                    Treatment for prostate cancer, Approved July 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
                    Generic equivalent of Pergonal, Approved February 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"SPORANOX (itraconazole); Janssen Pharmaceuticals;
                    Treatment for oral thrush, Approved March 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Eulexin (flutamide); Schering-Plough;
                    Treatment for prostate cancer, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Fertinex (urofollitropin for injection, purified); Serono Laboratories;
                    Treatment for patients undergoing infertility treatments, Approved September 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Monurol; Forest Laboratories;
                    Treatment for uncomplicated urinary tract infection, Approved December 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Muse; Vivus;
                    Treatment for impotence, Approved October 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
                    Treatment for advanced prostate cancer, Approved January 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/32/urology,"Caverject (alprostadil); Upjohn;
                    Treatment for impotence, Approved on July 6, 1995"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline;
                    For the prevention of herpes zoster (shingles), Approved October 2017"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
                    For active immunization against Cholera, Approved June 2016"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Bexsero (Meningococcal Group B Vaccine); Novartis;
                    For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Flublok (seasonal influenza vaccine); Protein Sciences;
                    For the active immunization against influenza virus subtypes A and type B, Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"VariZIG, Varicella Zoster Immune Globulin (Human); Cangene;
                    For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Flucelvax, Influenza Virus Vaccine; Novartis;
                    For the treatment of influenza virus subtypes A and type B, Approved November 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of postherpetic neuralgia, Approved June 2012"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Horizant (gabapentin enacarbil); GlaxoSmithKline;
                    For the treatment of restless legs syndrome, Approved April 2011"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Menveo (meningitis vaccine); Novartis;
                    For the active immunization to prevent invasive meningococcal disease, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine); Wyeth;
                    For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae, Approved February 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Teflaro (ceftaroline fosamil); Cerexa;
                    For the treatment of bacterial skin infections and bacterial pneumonia, November 2010"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline;
                    For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"FluMist ( Influenza Virus Vaccine); MedImmune;
                    For the prevention of disease caused by influenza A and B viruses, Approved June 2003"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Fluzone Preservative-free; Sanofi Pasteur;
                    Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Neurontin (gabapentin); Pfizer;
                    Oral treatment for the management of post-herpetic neuralgia (PHN), Approved May 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Pediarix Vaccine; GlaxoSmithKline;
                    For the prevention of diphtheria, tetanus, pertussi, polio and  hepatitis  B in children 6 weeks to 7 years old., Approved December 2002"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Avelox I.V. (moxifloxacin hydrochloride); Bayer;
                    For adults with susceptible strains of bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Invanz; Merck;
                    Once-daily injectable treatment for bacterial infections, Approved November 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Spectracef; TAP Pharmaceuticals;
                    Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Twinrix; GlaxoSmithKline;
                    For the prevention of hepatitis A and B, Approved May 2001"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Cefazolin and Dextrose USP; B Braun Medical;
                    Respiratory tract infections, Approved July 2000"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Synercid I.V.; Rhone Poulenc Rorer;
                    quinupristin and dalfopristin for injection, Approved September 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Tamiflu  capsule; Roche;
                    Oseltamivir phosphate capsule, October 27, 1999"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Omnicef; Warner-Lambert;
                    Treatment against various bacterias, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Trovan; Pfizer;
                    Treatment for bacterial infections, Approved December 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Zagam (sparfloxacin) tablets; Rhone Poulenc Rorer;
                    Treatment for community-acquired pneumonia (CAP) and chronic bronchitis, Approved January 1997"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Augmentin (amoxicillin/clavulanate); SmithKline Beecham;
                    Treatment for infections involving drug-resistant bacteria, Approved February 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Havrix; SmithKline Beecham;
                    Treatment for hepatitis A, Approved March 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Merrem I.V. (meropenem); AstraZeneca;
                    Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed); Connaught Laboratories;
                    Treatment for whooping cough, Approved August 1996"
https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/33/vaccines,"Zosyn (sterile piperacillin sodium/tazobactam sodium); Wyeth;
                    Treatment for hospital-acquired pneumonia, Approved May 1996"
